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ABSTRACT 
 
Okihiro, Alexandra M. M.S., Purdue University, May 2013. Isolation and 
Characterization of Active Elderberry Fractions that Inhibit Melanoma Growth in vitro 
and in vivo. Major Professor: Elliott J. Blumenthal. 
 
 
 
The incidence rates of melanoma continue to rise annually despite recent 
progression in cancer treatments. Cancer is the most prevalent amongst elderly 
individuals, where immunosenescence has compromised some immune function, and 
therefore decreased certain tumor detection abilities. Current tumor removal strategies 
include radiation, chemotherapy and surgical excision: treatments that aim to lower 
cancer cells, but may also affect normal cells in the process.  In the case of 
chemotherapy, which targets and kills rapidly dividing cells, many immune cells are 
lowered as a side effect, leaving many patients immune-suppressed and more susceptible 
to infection.  There is a need for naturopathic treatments capable of decreasing tumor cell 
proliferation without compromising the body’s normal immune function. Extracts from 
elderberry (Sambucus nigra) may be able to satisfy this need. Previous reports suggest 
that phytochemicals, such as the ones present in elderberry, may stimulate the immune 
response by secretion of cytokines, provide antioxidant protection to prevent cellular 
damage, and inhibit tumor growth directly.
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Our primary goal was to separate the active components of elderberry and assess 
their inhibitory effects on the growth of multiple cancerous and transformed cell lines, as 
well as characterize their effects on stimulation of T lymphocyte proliferation and IL-2 
secretion in vitro. Murine melanoma model experiments were also performed with crude 
elderberry and elderberry fractions to analyze the tumor-suppressive activity of 
elderberry treatments in vivo.   Spleen cell proliferation and in vivo experiments were also 
performed with different aged groups of mice to uncover the tumor –inhibiting and 
immune-inducing effects of elderberry and active elderberry fractions on aged mice. 
Active elderberry fractions were then preliminarily identified.   
All separated elderberry fractions were able to significantly suppress the growth 
of B16-F10 murine melanoma and SH-SY5Y human neuroblastoma cells in vitro. 
Several separated fractions also inhibited growth of a human melanoma cell line, MeWo, 
and a transformed non-cancerous line, CHO-K1. When incubated with concanavalin A 
(Con A, a known mitogen) and spleen cells from a middle aged and old mouse, separated 
fractions of elderberry did not increase proliferation above the positive control (cells 
incubated with con A only) , however, they induced a larger proliferation response in the 
older mouse spleen cells. Three active fractions induced secretion of IL-2 from spleen 
cells above the positive control. In general, mice induced to produce tumors developed 
smaller, localized tumors when treated with crude elderberry compared to mice treated 
with water, whose tumors were larger and metastatic.  The active elderberry fractions 
were too potent to be successfully implemented in an in vivo experiment, and need to be 
diluted for future mouse model experiments. Of the four primary anthocyanins in 
elderberry, cyanidin 3-sambubioside and cyanidin 3-glucoside were identified as the 
xv 
 
major tumor-inhibiting, immune-inducing components in different active fractions 
separated from elderberry.  
The positive benefits of active fractions on tumor suppression and potentially on 
modulation of immune-inducing mechanisms provide further support for the use of 
bioactive phytochemicals in preventative cancer treatment. 
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INTRODUCTION 
 
Melanoma 
Cancer is a disease characterized by the uncontrolled growth and decreased 
regulation of cell function, resulting in abnormal and atypical cell behavior. Often, these 
abnormal cells invade adjacent tissues or even migrate to other organs in a process known 
as metastasis, which can greatly increase the severity of the disease. In 2010, it was 
predicted that 1,500 individuals in the United States would die each day from cancerous 
diseases. Currently, cancer claims the second highest number of lives in America each 
year, exceeded only by heart disease. However, the trend in comparably developed 
countries, such as England and Canada, suggest that cancer will soon overtake heart 
disease as the number one cause of fatalities in the United States. The lifetime risk of 
developing cancer is slightly less than 50% in men, and slightly above 1 in 3 in women. 
Cancer is most often diagnosed in individuals who are middle aged or older. 
Approximately 77% of cancers are found in individuals aged 55 or older (American 
Cancer Society, 2013). The natural process of aging brings about changes to the immune 
system known as immunosenescence: a catch-all term describing the general decline of 
immune efficiency that correlates with maturation, which makes elderly people an at-risk 
population for many illnesses, including cancer. Genetically, cancer arises from DNA 
mutations that cause malfunction in important cell growth, division and modulation 
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processes. Skin, being the body’s largest organ, has a high incidence rate of cancer. Basal 
cell and squamous cell cancers (nonmelanoma cancers) make up the majority of skin 
cancer diagnoses; an estimated 3.5 million cases were diagnosed in the United States in 
2006. Basal cell and squamous cell cancers are often highly curable and do not account 
for many cancer fatalities, especially when detected in early stages of the disease.  
Melanoma (or cutaneous melanoma, or malignant melanoma) is far less common, 
however it is the skin cancer type that claims the most lives compared to all other forms 
of skin cancer. It is estimated that melanoma causes 71-80% of skin cancer deaths 
(Brozyna et al., 2007). Melanoma begins in the melanin pigment forming cells 
(melanocytes) found in the deepest layer of the epidermis. The normal function of 
melanocytes is to increase melanin production in a protective response against ultra violet 
(UV) radiation. Melanin is also responsible for skin color phenotype.  Faulty repair of 
DNA damage in melanocytes ultimately leads to aberrant cell function, which can lead to 
transformation of cells into cancerous ones. According to the American Cancer Society, 
incidence rates of melanoma have been increasing over the past 30 years and mortality 
due to melanoma increases approximately 0.4% annually (Linos et. al, 2009). In 2000, 
the lifetime risk of developing malignant melanoma was 1 in 74, and the trend has been 
steadily increasing since 1935 (Rigel & Carucci, 2000) despite advances in cancer 
treatments and declining incidence rates of other cancers.  
 
Etiology of Melanoma Development 
Certain induction agents, such as chemical carcinogens, viruses, and radiation, 
have been shown to increase cancer risk. The most well known risk for melanoma 
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development is chronic UV radiation exposure. Substantial buildup of reactive oxygen 
species (ROS) consequent of UV radiation can cause oxidative stress in active 
melanocytes, increasing creation of free radicals capable of damaging DNA and 
increasing the likelihood of a DNA-repair error mutation, which may lead to aberrant cell 
function.  The DNA mutations consequent of UV exposure in spontaneous melanoma 
cases can cause mutations in the important cell cycle tumor suppressor protein p53 and 
proteins from the Cyclin-dependent kinase inhibitor 2A gene (CDKN2A), a gene 
important in familial melanoma and some sporadic melanoma cases as well.  The p53 
protein, encoded by the TP53 gene on the short arm of chromosome 17, has a variety of 
normal functions, including initiation of apoptosis (programmed cell death) and induction 
of DNA repair in genetically damaged cells. It is one of the key proteins in a cell that 
maintains genomic stability. In melanoma, abnormal p53 function causes the melanocyte 
to proceed through a cell cycle ‘check-point’, even if DNA has been damaged, resulting 
in survival of the genetically abnormal cell. The CDKN2A gene (Cyclin-dependent 
kinase inhibitor 2A) is located on the short arm of chromosome 9 and has two reading 
frames, producing proteins p16INK4 and p14ARF. Both proteins function to inhibit cyclin-
dependent kinases, enzymes that promote cellular growth and progression within the cell 
cycle by binding to their respective cyclin counterparts. P16INK4 inhibits cyclin-dependent 
kinase 4 by causing a conformational change to the kinases’ active site, thus decreasing 
its phosphorylating ability and overall function. P14ARF functions by inhibiting murine 
double minute (MDM2), a negative regulator of p53, thus freeing p53 to maintain cellular 
integrity of the melanocyte (Brozyna et al., 2007). Therefore mutation in the CDKN2A 
gene increases the risk of improper cell cycle regulation that may lead to cancer. 
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Melanoma can also be the result of genetic disposition. Approximately 10% of 
melanoma cases are familial (Tung, 2011). A rare genetic disorder (autosomal recessive) 
called xeroderma pigmentosum (XP) affects an individual’s ability to repair damaged 
DNA consequent of UV exposure, greatly increasing lifetime likelihood of melanoma 
development.  Approximately 90% of XP patients have mutations in p53, which greatly 
increases the risk of melanoma, as well as other skin cancers (Brozyna, et al., 2007).  
Many familial melanoma cases involve mutations in p16, the tumor suppressor gene 
essential in cell-cycle arrest encoded by the CDKN2A gene.  
Over 50% of melanomas can be traced back to a DNA mutation in the V-raf 
murine sarcoma virus oncogene homolog B1 (BRAF) gene, located on the long arm of 
chromosome 7 in humans.  A common mutation in this gene protein is the point mutation 
of valine to glutamine at amino acid codon 600 (BRAFV600E).  This mutation has been 
found in other cancers (such as papillary thyroid carcinomas); however it is the most 
common in melanoma.  In normal melanocytes, BRAF functions as a modulator of the 
Mek/Erk pathway. The Mek/Erk pathway begins when a ligand binds a cellular receptor, 
activating Ras protein, which creates a cascade of phosphorylation events, ultimately 
leading to increased cellular proliferation. The point mutation in BRAF causes 
continuous kinase activation (phosphorylation at the active site) which results in Ras-
independent activation of the Mek/Erk pathway with the end result being continuous cell 
division and avoidance of apoptosis (Brozyna et al., 2007).  It is currently unclear 
whether or not UV exposure directly contributes to the acquisition of BRAF mutations, as 
a correlation between the two is uncommon.  
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Individuals with a certain skin phenotype have an increased lifetime risk for 
melanoma development. Individuals with fair skin (less melanin), possession of multiple 
nevi and freckles, and individuals prone to sunburning are more likely to develop 
melanoma.  Increased age is also a factor in assessing lifetime risk of melanoma. 
Alterations to the immune system consequent of immunosenescence in elderly 
individuals may decrease immunosurveillance against cancerous cells, which contributes 
to tumor development. Immunosuppressed individuals, such as recent organ transplant 
patients, also exhibit increased risk of cancers including melanoma, suggesting that a 
functional immune system may play a vital role in suppressing the onset of cancer 
(Kubica & Brewer, 2012). 
 
Components of the Immune System 
The immune system is a highly adaptable, dynamic network of cells and 
molecules specialized in identifying and eliminating foreign pathogens from the body. 
There are two systems of immunity that function together to provide this protection.  
Innate immunity is the body’s first line of defense consisting of physical, chemical, and 
cellular barriers present before the onset of infection, such as skin, mucosal membrane 
enzymes, and stomach acidity.  Beyond these barriers are a number of nonspecific 
leukocyte host cells ready to engulf, neutralize and kill any foreign invaders who breach 
the immunological barriers, such as macrophages, neutrophils, dendritic cells and natural 
killer (NK) cells. Certain molecular patterns on invaders may activate the nonspecific 
complement system, which promotes opsonization of foreign agents and recruitment of 
phagocytic cells by inflammation (Goldsby et al., 2003). Generation of cytokines such as 
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interferon, tumor necrosis factor and interleukin is also the result of innate immunity. 
Cytokines are proteins or glycoproteins that bind to specific membrane receptors and 
induce a cascade of events via signal-transduction, ultimately resulting in gene expression 
alteration in specific cells. Cytokines secreted by injured cells or nonspecific leukocytes 
act in an antigen-nonspecific manner to promote cell proliferation and differentiation, 
regulate inflammation, and influence adaptive immunity, the second, and more specific, 
line of immune defense (Goldsby et al., 2003). 
Adaptive immunity serves as a specific responsive against foreign pathogens that 
are able to evade the innate immunity mechanisms, and is therefore activated after onset 
of the infection. Whereas innate immunity recognizes large-scale molecular patterns on 
foreign invaders, adaptive immunity recognizes small immunologically active substances 
on pathogens known as “antigens”. B lymphocytes (white blood cells that mature in the 
bone marrow) and T lymphocytes (white blood cells that mature in the thymus) are the 
main cellular components of adaptive immunity.  B lymphocytes play a large role in 
humoral immunity: immunity by non-cellular substances, such as antibodies, present in 
humours (body fluids).   Antibodies are able to activate complement, promote antigen 
phagocytosis and induce death in antibody-bound foreign target cells. When an antigen 
binds the surface antibody of a naïve B lymphocyte, the cell undergoes clonal expansion 
and differentiation into effector plasma cells (which secrete antibodies) and long-lived 
memory cells. Following a secondary response to an identical or similar antigen, memory 
cells secrete high affinity antibodies to bind and clear the antigen quickly and effectively.  
T lymphocytes are the major cell type involved in attacking cancer cells and play 
a large role in cell-mediated immunity. They function by interacting with other host cells 
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by binding antigenic peptides and major histocompatibility complex (MHC) presented by 
designated antigen-presented cells (APCs), which have phagocytized the foreign 
pathogen and displayed it on their surface. During maturation in the thymus, T 
lymphocytes are permitted to survive only if their T-cell receptor (TCR) can recognize 
self-major histocompatibility complex (MHC) and react to it at an appropriate affinity 
(Goldsby et al., 2003). If recognition of self-MHC is too strong, the T lymphocyte will be 
killed. Presence of MHC is necessary for a T lymphocyte to be activated. Two important 
subsets of mature T lymphocytes are CD4+ T-helper cells (TH) and CD8+ T-cytotoxic 
cells (TC). TH cells bind MHC class II, which is frequently found on the surface of 
dendrites, macrophages and other specialized phagocytic APCs. Once bound, the TH cell 
induces multiple intracellular signals, including release of IL-2, which causes autocrine 
and paracrine proliferation of TH cells, which ultimately leads to differentiation into 
effector, regulatory, and memory TH cells, secretion of multiple other cytokines and 
recruitment of helpful B lymphocytes and TC cells. TC cells bind MHC class I, which is 
present on all nucleated cells, and is able to directly kill a target cell expressing a foreign 
antigen, such as a host cell infected by a virus. The TC cell killing process can occur by 
many mechanisms, including receptor-ligand binding of the FAS death receptor 
molecules which induces programmed steps to cell death and exocytosis of perforin, 
granzymes, and other lytic proteins leading to necrosis or apoptosis of the target cell by 
activation of caspases (Groscurth & Filgueira, 1998). Once activated, TC cells also 
proliferate and differentiate in response to cytokine signals to increase the immune 
response.  The major difficulty in attacking cancerous cells is that, although they function 
abnormally, they are self-cells. 
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Tumor Suppressive Function of the Immune System 
Of the multiple components of the immune system, the most important functional 
component is the systems’ ability to provide self-nonself discrimination, effectively 
distinguishing the body’s own cells from foreign agents and altered host cells, therefore 
being especially important in detection and elimination of cancerous cells. Evidence of 
tumor immunology is rapidly accumulating; however the basic concepts and mechanisms 
are continuously being debated and revised (Weinberg, 2007). Cancer cells may possess 
two different types of antigen, differentiating them from host cells. The first is a tumor-
specific transplantation antigen (TSTA), which is an antigen unique to the tumor cell due 
to a genetic event such as a mutation. TC cells can recognize these novel proteins if 
present in conjunction with MHC class I and are able to mount a cell-mediated immune 
response and effectively kill the tumor cell.   The second tumor antigen type is a tumor-
associated transplantation antigen (TATA) and occurs more frequently than TSTAs. 
TATAs are not unique to the tumor cell; rather they are proteins expressed by normal 
cells, but at much higher levels in tumor cells, which can also be identified and targeted 
by TC cells. Nonspecific immune system components such as macrophages, NK cells and 
cytokines also play a prominent role in the immune response to tumors.  Both activated 
macrophages and NK cells are able to act against tumor cells in an MHC-independent 
mechanism, and are observed to surround tumor cells and mediate antibody-dependent 
cell-mediated cytotoxicity (Goldsby et al., 2003).  NK cells in particular are important in 
recognizing cancer cells that are only slightly aberrant, sometimes by lacking only a 
single MHC-I allele, and can induce cytotoxicity rapidly due to their constitutively 
expressed lytic machinery (Zamai et al., 2007). IL-2 is a cytokine of particular interest for 
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cancer immunotherapy due to its ability to cause proliferation, recruitment, activation and 
differentiation of several key immunological cells, including tumor-specific TC cells, 
capable of recognizing tumor cells.  The presence of tumor-specific antibodies and T 
lymphocytes, as well as abundance of macrophages, in patients with tumors also confirms 
the immune systems active response to aberrant cells. Therefore, it is convincing that 
both innate and adaptive immunity components are important in maintaining cell 
integrity and suppressing tumor cell growth.   
Despite the vast array of protective mechanisms contributed by the immune 
system against tumors, some cancer cells use strategies of immunoevasion to remain 
undetected. If continuous expression of a TATA or TSTA is not essential to neoplastic 
growth, the simplest way for a cancer cell to avoid immune detection is to stop displaying 
the antigen.  Antigen-negative variants of the cancer cell would therefore be more 
successful in evading immune reactivity (Weinberg, 2007). If continuous expression of 
tumor-antigens is required for tumor proliferation, cancer cells are able to escape immune 
response by other mechanisms, such as down-regulation of MHC class I, increased 
resistance to caspase and Fas-ligand (FASL) mediated apoptosis, and secretion of 
immunosuppressive chemokines such as CCL22, which increases the number of T-
regulatory cells, a line of T-lymphocytes that directly inhibit or kill TC and TH cells, 
(Weinberg, 2007). Melanoma cells in particular demonstrate many ways to evade 
suppression by the immune system. By secreting large amounts of transforming growth 
factor-beta (TGF-β), melanoma cells are able to transform CD4+CD25- T cells into T-
regulatory cells (Liu et al., 2007).  The BRAFV600E mutation seen in the majority of 
melanoma tumors causes secretion of immunosuppressive vascular endothelial growth 
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factor (VEGF), IL-10 and IL-6, as well as a decreased production of inflammatory 
cytokines IL-12 and tumor necrosis factor-alpha (TNF-α) (Sumimoto et al., 2006). 
 
Current Treatments of Melanoma 
Current treatments available for melanoma include surgical excision of cancerous 
tumors, radiation therapy and chemotherapy, all invasive procedures that affect both 
cancerous and noncancerous cells. Surgical excision remains the primary treatment for 
melanoma tumor removal. During this procedure, the cancerous mass and surrounding 
healthy tissue, and in some cases adjacent lymph nodes, are removed from the body, 
often leading to scarring and possible bleeding or infection around the excision site. This 
treatment does not guarantee permanent removal of the cancer, as local recurrence and 
distant metastasis are both possible following surgical treatment. Therefore, surgical 
excision is most effective before the cancerous cells have metastasized to other locations. 
Radiation therapy of melanoma uses high doses of radiation to reduce tumor size, which 
often leads to damage of normal surrounding cells, causing nausea and potential 
abdominal region problems.   Another treatment for melanoma that can be administered 
primarily, or in conjunction with other treatments, is chemotherapy. Chemotherapy in the 
form of anticancer drugs, such as Dacarbazine, act by targeting DNA replication in 
rapidly proliferating cells. The toxicity of anticancer drugs cause apoptosis of cancerous 
cells, but may also kill healthy cells. Undesirable side effects of chemotherapy include, 
but are not limited to, fatigue, vomiting, stomatitis and diarrhea in the patient. Recently, 
two new drugs have been FDA approved for use to treat melanoma in conjunction with 
chemotherapy. The first is Zelboraf (vemurafenib), a small molecular inhibitor of the 
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active site of BRAF protein that contains the V600E mutation, a mutation commonly 
seen in melanoma patients. Zelboraf binds the active site with greater affinity than ATP, 
which inhibits the kinase’s ability to phosphorylate other substrates in the Mek/Erk 
pathway (Davis & Schlessinger, 2012). Zelboraf has also shown inhibitory activity on 
BRAF mutations that are V600K substitutions, a mutation that occurs in 5% of BRAF 
mutations (Chapman, 2012).   The second drug recently FDA-approved for the treatment 
of metastatic melanoma is Ipilimumab (Yervoy), an anti-CTLA-4 monoclonal antibody.  
CTLA-4 stands for cytotoxic T lymphocyte antigen 4, and it is a negative modulator of T-
cell response, which can decrease the immune response to a tumor. By blocking this 
antigen, which is present on T-cells, antitumor activity of T lymphocytes is not inhibited 
by cancer cell mechanisms (Weber, 2007). Adverse effects of these new drugs include 
fatigue, rash, inflamed intestines (colitis) and a higher rate of serious side effects in 
patients versus treatment with radiation and chemotherapy alone. Using monoclonal 
antibodies to bind target cells and stimulate a cytotoxic reaction is not uncommon in the 
discussion of cancer therapies; however there are limits to their effectiveness. Some 
TSTAs cannot be purified for monoclonal antibody preparation, and if they can be, it is 
likely that the monoclonal antibody would target only syngeneic tumor cells with high 
affinity.  
 
Bioactive Components of Berries 
The use of bioactive food components in naturopathic therapies is a growing field 
of interest.  Utilization of extracts from dark-pigmented berries, such as chokeberry, 
blueberry, bilberry and elderberry, is one of the areas receiving considerable attention due 
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to their diverse positive health benefits, global availability and attainability. For example, 
recent studies link increased consumption active berry extracts with decreased neuronal 
and behavioral changes related to aging, decreased risk of hypertension and 
cardiovascular disease, and increased protection against viral and bacterial infection  
(Joseph et al., 2009) (Zafra-Stone et al., 2007).  Several berry extracts also show promise 
as a preventative strategy against human cancer cell growth, angiogenesis and metastasis 
(Zafra-Stone et al., 2007) (Matchett et al., 2005). One of the most important physiological 
functions of active berry extracts is their antioxidant activity.  Cells can incur oxidative 
stress from environmental pollutants as well as through cellular processes, potentially 
causing oxidative damage to DNA, lipids, and proteins (Trachootham et al., 2009). 
Reactive oxygen species (ROS) activate essential components of the immune system by 
stimulating release of cytokines and mediating the inflammatory response; therefore, a 
small quantity of ROS is necessary in sustaining functional biological systems. Moderate 
increases in ROS are capable of modulating cell growth and cell differentiation by 
influencing important cell growth signal transduction pathways, which can play a role in 
eliminating foreign pathogens (Trachootham et al., 2009). Certain cellular antioxidants, 
such as superoxide dismutase (SOD) function to maintain a homeostasis of ROS. 
Excessive increases in ROS may offset the biological equilibrium and cause permanent 
damage to important cellular molecules, including DNA, which may cause apoptosis of 
the cell, or a mutation that leads to cell transformation. The latter may be a precursor 
event to the onset of cancer.   
Over the past 20 years, anticancer researchers have been studying minimally 
invasive cancer treatments to address the severity of the many current treatment side 
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effects. A proposed treatment in the forefront is utilization of dark-pigmented berry 
extracts that are able to selectively target and suppress cancer cell growth (Katsube et al., 
2003). The anticancer potential of dark-pigmented berries comes from the phytochemical 
properties of their extracts, most of which are phenolic components (Seeram, 2008). 
Flavanoids, including classes such as flavanols, flavonols and anthocyanins, act via 
multiple cellular mechanisms to modulate events associated with cancer cell development 
(Kanadaswami et al., 2005). Anthocyanins in particular have been the sub group of 
flavonoids most widely studied for their suppression of human cancer cell growth. 
Proposed mechanisms of cancer cell growth inhibition by anthocyanins include initiating 
apoptotic pathways, initiating cell cycle arrest, and inhibiting expression of tumor-
associated enzymes in human cancer cells (Seeram, 2008). There are hundreds of 
different anthocyanins distributed throughout the plant kingdom, with the most abundant 
being cyanidin, delphinidin, malvidin, petunidin, peonidin and pelargonidin derivatives. 
Anthocyanins are water-soluble pigments responsible for the bright coloring of berries, 
ranging from orange and scarlet to blue and purple. All anthocyanins share the same 
basic 3-ring molecular skeleton (Figure 1), and are commonly glycosylated at position C-
3. Naturally occurring anthocyanins are always glycosylated at position C-3. 
Glycosylation at position C-5 also occurs, and glycosylation at position C-7 is rare. The 
aglycone of an anthocyanin is referred to as an anthocyanidin. 
14 
 
 
Aglycone R1 Substitution R2 Substitution 
Cyanidin -OH -H 
Delphinidin -OH -OH 
Malvidin - OCH3 - OCH3 
Petunidin -OCH3 -OH 
Peonidin -OCH3 -H 
Pelargonidin -H -H 
 
Figure 1. The structure of common anthocyanidins. 
 
 
 
In many in vitro and recently in vivo studies, it has been found that certain 
anthocyanins exhibit significant anticancer benefits, and are proposed to function by 
affecting a broad range of cellular mechanisms. Anthocyanins block cancer cell 
proliferation during various stages of the cell cycle, effecting important regulator proteins 
such as p53 and cyclin A, and have also been shown to induce apoptosis in cancerous 
cells via caspase activation or modulation of FAS and FASL expression on cancer cells 
(Wang & Stoner, 2008). Some anthocyanins are able to inhibit aberrant increases of 
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nuclear factor-kappa B (NF-κB) and cyclooxygenase-2 (COX-2), two proteins commonly 
up-regulated in cancers (Wang & Stoner, 2008). There have also been reports suggesting 
that anthocyanins are capable of decreasing metastatic risk and angiogenesis of cancer 
cells by inhibiting extracellular matrix degradation by matrix metalloproteinases (MMPs) 
and VEGF receptor and ligand expression on endothelial cells (Wang & Stoner, 2008). 
The antioxidant nature of anthocyanins is extremely important as a chemopreventative 
strategy to reduce risk of cancer, and it is also suggested that anthocyanins can induce 
ROS-mediated mitochondrial caspase-independent pathways, leading to tumor cell death 
(Wang & Stoner, 2008). The multiple number of anticancer benefits resultant of 
anthocyanin treatment and the increasing body of evidence supporting their activity 
warrants further study in this discipline. 
 
European Black Elder (Sambucus nigra) 
Sambucus is a genus consisting of approximately 20 different fruit-bearing small 
trees and shrubs, with European black elder (Sambucus nigra L) being the most common 
species of elder, a flowering plant in the Adoxaceae family, used in complementary and 
alternative medicine (Atkinson & Atkinson, 2002). Although native to Europe, Africa 
and Asia, European black elder has become widespread and commercially grown in the 
United States, found in the form of syrups, wines and jams. The elder tree native to North 
America (Sambucus canadensis) is closely related to the European black elder; however 
the medicinal benefits of this particular species are not yet well-defined. Future mention 
of ‘elderberry’ in this thesis should be assumed to be the berry product of European black 
elder unless otherwise notified. 
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Elderberry has been used previously in traditional and folk medicine for the 
treatment of multiple viral infections, including the common cold (acute viral 
nasopharyngitis), influenza, and herpes virus. Recent studies confirm the benefits of 
elderberry as an antiviral. In a 2009 randomized, double-blind, placebo-controlled pilot 
clinical study, it was concluded that elderberry extract given in the form of a slow-
dissolve lozenge was able to significantly relieve multiple influenza symptoms within 24 
hours of treatment compared to the placebo (Kong, 2009). In the same year, flavonoids 
isolated from elderberry proved to inhibit Human influenza A (H1N1) infection in vitro 
by binding directly to H1N1 virions, effectively blocking their ability to bind and enter 
host cells (Roschek et al., 2009). Multiple current studies now support the use of 
elderberry extracts for treatment of not only flu-like symptoms, but for treatment and 
prevention of diabetes, cardiovascular disease, open wounds, and cancers. Studies 
indicate that active components present in elderberry are capable of stimulating and 
modulating immune response, as well as providing anti-oxidant protection against 
cellular damage (Roxas & Jurenka, 2007). Sambucol, an elderberry extract product, has 
been shown to increase production of inflammatory cytokines IL-1b, TNF-α, IL-6 and 
IL-8, thereby stimulating a number of immune effector cells (Barak et al., 2001). 
Elderberry anthocyanins can be incorporated into vascular endothelial cells and exhibit 
significant oxidative protection against a number of oxidative stressors, thereby 
maintaining cellular integrity and preventing DNA mutation (Youdim et al., 2000). The 
benefits previously reported of elderberry extracts, and in particular of elderberry 
anthocyanins, are promising as a naturopathic treatment for many infections and diseases.    
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The anticancer potential of certain anthocyanins in vitro is now widely accepted 
(Wang & Stoner, 2008); however, anticancer studies of specific elderberry anthocyanins 
in vitro and in vivo have been limited. Elderberry contains four primary anthocyanins: 
cyanidin 3-sambubioside-5-glucoside, cyanidin 3,5-diglucoside, cyanidin 3-
sambubioside, and cyanidin 3-glucoside, all of which are 100% nonacylated with 
minimal glycosylation (Youdim et al., 2000) (Jing et al., 2008).  It was found that 
nonacylated monoglycosylated anthocyanins have a great effect on inhibition of colon 
cancer cell growth in vitro (Jing et al., 2008). Cyanidin 3-glucoside in particular has a 
strong inhibitory effect on the cellular growth of metastatic breast cancer in vivo (Chen et 
al., 2005). It has also recently been shown that the glycosylated structures of 
anthocyanins in elderberry can be absorbed in humans, despite previous claims that 
anthocyanin form is changed prior to absorption (Cao et al., 2001)(Milbury et al., 2002). 
One study showed that certain elderberry fractions demonstrate inhibition of COX-2 
(anticancer function) and induction of quinone reductase (antioxidant function) in vitro. 
Based on these findings, it is reasonable to assume that elderberry anthocyanins may be 
able to prevent the onset of cancer by antioxidant activity, and also modulate a variety of 
cellular mechanisms capable of inducing cancer cell death.   
 
Aim 
The goal of this research endeavor is to obtain evidence that further supports the 
use of natural berry extracts in a therapeutic manner to help treat and prevent incidence of 
melanoma. This research aims to separate and identify the individual components of 
elderberry by column chromatography and examine their effects on human melanoma 
18 
 
tumor cell growth in vitro.  Active elderberry fractions will be pooled and assessed for 
suppressive activity against many cell lines, including human and murine melanoma 
lines, a human neuroblastoma line, void of caspase-8 (a pro-apoptotic protein), and a non-
cancerous transformed cell line derived from the ovary of a Chinese hamster. 
Additionally, pooled active column fractions will be evaluated for stimulatory activity of 
spleen cells from young and old mice, as well as induction of cytokine IL-2. Pooled 
active fractions that demonstrate increased immune response in elderly 
(immunosenescent) mice and significant tumor suppressive ability will be used in a 
murine melanoma model to evaluate tumor suppressive ability in vivo. Final 
identification of active fraction components will be achieved through high-performance 
liquid chromatography (HPLC). Proper identification of melanoma-suppressing, 
immune-inducing elderberry fractions may lead to diet-based strategies for natural 
prevention and suppression of melanoma. 
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METHODS 
 
Elderberry 
The elderberry preparation used for experimentation was 13% standardized 
Sambucus nigra elderberry powder, generously provided by Artemis International, Inc. 
(Fort Wayne, IN). To prepare the powder, pure elderberry was concentrated by a physical 
process without solvent, then spray dried onto an excipient (Artemis International, Inc., 
2005). Anthocyanin and polyphenol contents were expressed as a minimum 13g/100g 
and 17g-29g/100g, respectively (Artemis International, Inc., 2005).  When not in use, the 
elderberry powder was stored in a cool, dry area to avoid moisture absorption and to 
maintain the integrity of the chemicals. 10 mg/mL and 1mg/mL crude elderberry stocks 
were prepared, filter-sterilized using a 0.2µm Nalgene filter, and stored at 4oC until use. 
 
Extraction of Elderberry Samples 
Gravity column chromatography was used to separate the components of 
Sambucus nigra elderberry powder. In this procedure, elderberry powder components are 
eluted through a solid polyamide stationary phase by a series of liquid mobile phases. 
Polarity of the components, polarity of the stationary phase, polarity of the mobile phases 
and hydrostatic pressure due to gravity are the driving forces behind the elution.  It is 
well established that phenolic compounds, such as the ones present in berries, can be well  
20 
 
resolved using polyvinylpyrrolidone (PVP) as the stationary phase and varying 
concentrations of water-methanol mobile phases for gradient elution (Strack & Mansell, 
1975). The retention times for the different components are generally determined by the 
difference in between the polarity of the stationary phase and mobile phases. By running 
mobile phases in order of decreasing polarity by gradient elution, strongly retained (late-
eluting) components will elute from the column at a reasonable retention time. 
The protocol used for gravity column chromatography was taken from Rizvi 
(2012); an adaptation from the protocol first published by Strack & Mansell (1975).   A 
250-mL Kimex® chromatography column (Internal Diameter ~2.5 cm) was used for the 
first extraction. Following addition of a sterile cotton ball (Diameter ~2.5 cm) placed at 
the base of the column, 25 g of dry PVP was added to fill the column to an approximate 
height of 18.4 cm. Suitable elderberry solute for extraction was prepared by adding 2 g 
13% standardized elderberry powder to 4 mL of 0.01N hydrochloric acid (HCl). The 
elderberry powder-HCl preparation was added to the column on top of the stationary 
phase. Gradient elution was carried out using mobile phases of sterile deionized water, 
methanol, and a consistent amount of 0.01 N HCL (Figure 2a). The first solvent was 
100% sterile deionized water with 15 mL 0.01 N HCL, and 10 other mobile phases were 
added sequentially in order of decreasing polarity after the preceding mobile phase was 
eluted. See Appendix for a complete list of mobile phases.  
14.5 mL increments of elderberry samples were sequentially collected from the 
column into 15 mL sterile vials (Figure 2) and stored at -18oC to preserve elutant 
chemical integrity. After collection of elutants was complete, the majority of the mobile 
phase solvent was evaporated from each individual samples by Buchi rotary evaporator 
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(Figure 2b). The samples were concentrated down to 1-1.5 mL volumes on medium water 
bath heat (40-50oC) and collected into autoclaved 1.5 mL microcentrifuge tubes. To fully 
eliminate the presence of all methanol solvent, the elderberry samples in 1.5 mL 
microcentrifuge tubes were evaporated dry using a vacuum centrifuge on medium (36oC) 
heat (Figure 2c). Each sample was first covered with parafilm, and small holes were 
poked through the parafilm using a sterile needle to allow evaporated solvent escape. 
Once fractions were completely dry, they were re-dissolved in 0.5 mL filter-sterile 
phosphate buffered saline (PBS), agitated until homogenous, and stored at -18oC until 
further use.   
22 
 
   
 
Figure 2. Separation and solvent removal techniques. (a) Column chromatography, (b) 
rotary evaporation and (c) vacuum centrifugation. 
 
 
 
Two additional 250-mL columns (Internal Diameter ~2.5 cm) were purchased 
from C-Tech Glassware (New Jersey; Item #: CL-0009-016) to collect large quantities of 
elderberry samples for analysis. Following the same gravity column chromatography 
protocol previously described, 23 additional columns were run using the 250-mL 
b 
c 
a 
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Kimax® chromatography column and the two 250-mL chromatography columns from C-
Tech Glassware. The PVP stationary phase reached an approximate height of 16.2 cm in 
the C-Tech Glassware columns. Column elution for Columns #3-24 was ended after 
completion of the 20% Water/80% Methanol mobile phase, because samples of interest 
for future experiments elute before addition of the 10% Water/90% Methanol and 0% 
Water/100% Methanol mobile phases.  14.5 mL increments of elderberry samples were 
sequentially collected from the columns into 15 mL sterile vials and stored at -18oC to 
preserve chemical integrity. After collection of elutants was complete, the mobile phase 
solvent was evaporated from each individual samples by Buchi rotary evaporator on 
medium water bath heat (40-50oC). The fractions were evaporated dry in 100-mL round 
bottom flasks, re-dissolved in 0.5 mL PBS, and collected into autoclaved 1.5 mL 
microcentrifuge tubes, which were stored at -18oC until further use. This method of 
completely removing methanol from the samples can be validated by Escribano-Bailón et 
al. who also used a combination of column chromatography and rotary evaporation to 
achieve organic solvent-free samples for further analysis (2006).   
 
Cell Lines 
Multiple cells lines were used over the course of this study. The human melanoma 
line, MeWo, used to measure individual sample tumor suppressive ability was obtained 
from Dr. Robert Visalli (IPFW, Department of Biology, IN) and was maintained in Eagle 
minimum essential media (MEM) supplemented with 10% fetal bovine serum (FBA) and 
1% NEAA nutrient mixture. MeWo cells were kept in 75 cm3 flasks in a 7.5% CO2 
incubator at a constant temperature of 37.5oC, and were sub-cultured every 3-4 days 
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based on confluence. The murine melanoma line, B16-F10, was obtained from ATCC 
(Manassas, VA; #CRL-6475) and selected for its’ well-established use in murine 
melanoma models. B16-F10 cells are syngeneic to C57BL/6J mice. The B16-F10 cells 
were maintained in RPMI-1640 media supplemented with 10% FBS and 1% Penicillin-
Streptomycin-Amphotericin, and were sub-cultured every 2-3 days based on confluence. 
The B16-F10 lines were also used to determine tumor suppressive ability of elderberry 
fractions, and were kept in 75 cm3 flasks in a 7.5% CO2 incubator at a constant 
temperature of 37.5oC. Chinese hamster ovary (CHO-K1) cells, a commonly cell line 
derived from a line of transformed cells taken from a Chinese hamster ovary, were 
obtained from ATCC (Manassas, VA; #CCL-61) for use in a noncancerous, transformed 
cell proliferation assay with active elderberry fractions. The CHO-K1 cells were 
maintained in RPMI-1640 media supplemented with 10% FBS and 1% Penicillin-
Streptomycin-Amphotericin, incubated in 75 cm3 flasks at 37.5oC and 7.5% CO2, and 
were sub-cultured every 1-2 days based on confluence. To determine whether active 
fractions also suppressed tumor growth of another cancer line, SH-SY5Y neuroblastoma 
cells were generously provided by Dr. Robert Ross (Fordham University, Department of 
Neurobiology, NY) for use in this assay. SH-SY5Y cells lack caspase-8, and are therefore 
resistant to apoptosis induction through caspase-8 pathways. The SH-SY5Y cells were 
maintained in RPMI-1640 media supplemented with 10% FBS and 1% Penicillin-
Streptomycin-Amphotericin, incubated in 75 cm3 flasks at 37.5oC and 7.5% CO2, and 
were sub-cultured every 4-5 days based on confluence. To assess immunological 
response induced by active fractions, spleen cells were obtained from BALB/c male mice 
or C57BL/6J male mice. The C57BL/6J mouse strain was used when comparing the 
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immunological response of young and old mice. When it was possible, having two 
different cell lines in the CO2 incubator was avoided to reduce the risk of cross-
contamination. If two or more cell lines were being used in different experiments 
simultaneously, the flasks were kept on different levels of the CO2 incubator. When cell 
lines were not in use, they were appropriately prepared for cryopreservation in 1.5 mL 
cryovials, and were quickly transferred into a liquid nitrogen tank after 1-2 days of slow 
cooling at -80oC. Biocidal ZFTM disinfectant and AquaClean microbiocidal additive for 
heating bath fluids from ConTaFree Liquids was generously provided by Dr. Shree 
Dhawale (IPFW, Department of Biology, IN) for cleaning of the CO2 incubator.  
 
Preparation of Spleen Cells 
BALB/c male mice or C57BL/6J male mice were used to prepare spleen cells for 
proliferative assays.  Mice were sacrificed through cervical dislocation, and laid ventral 
side up in a dissecting pan. A few drops of 70% ethanol were used to wet the fur and 
eliminate interference during dissection. Using heat-sterilized scissors and heat-sterilized 
forceps, a small left paramedical incision was made in the abdominal region to expose the 
parietal peritoneum. A second careful incision through the parietal peritoneum exposes 
the abdominal organs contained within the mesenteries, including the spleen. The spleen 
was dissected out of the abdominal cavity with heat-sterilized forceps, and any additional 
visceral peritoneum and fatty tissue was removed. The spleen was placed into a sterile 
petri dish on top of a heat-sterilized mesh screen. 1 mL of RPMI-1640 media 
supplemented with 10% FBS and 1% Penicillin-Streptomycin-Amphotericin was pipetted 
over the spleen into the petri dish. Using the plunger from a 1 mL syringe, the spleen was 
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gently massaged into the mesh screen, creating a single cell suspension. A 26 gauge 
needle was used to collect the cell suspension. The spleen cells were immediately used in 
experimental assays.  
 
Cell Harvesting and Liquid Scintillation Counting 
  Cell harvesting was accomplished with a Brandel (Model# M-24) cell harvester 
(Figure 3a). Due to their adherent ability, tumor cells and transformed cells in 96-well 
tissue culture plates were treated with 2 µL trypsin EDTA, 1X 5 minutes prior to cell 
harvest, to release the cells from the plate and increase accuracy of cell counting. 
Preliminary studies with MeWo cells and trypsin EDTA, 1X identified 2 µL as the 
optimal volume for increasing the release of cancer cells (Appendix, Figure B1). Trypsin 
EDTA, 1X was not added prior to spleen cell harvesting. To harvest, the cells were 
washed 25-30 times with PBS and precipitated onto WhatmanTM filter paper sheets with 
10% trichloroacetic acid (TCA).  After drying (approximately 30 minutes after 
harvesting) the filter paper discs were placed into individual 6 mL vials, filled with 3 mL 
EcolumeTM scintillation cocktail, and were tightly capped. Tritiated thymidine is not 
strong enough to be counted by a Geiger counter. Addition of scintillation cocktail, which 
contains fluors, allows the radioisotope-containing nuclei to be counted by scintillation 
counter in counts per minute (CPM). A Beckman CoulterTM LS 6500 Multi-Purpose 
Scintillation Counter was used for all cell counting assays (Figure 3b).  
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Figure 3. Cell harvesting and counting techniques. (a) Cell harvester and (b) WhatmanTM 
filter paper collection and scintillation counter. 
 
 
 
Mouse Habitat Conditions and Handling 
BALB/c male mice and C57BL/6J mice were housed in cages and fed a dry pellet 
diet and water ad libitum. A 12-hour light/dark cycle was maintained for the duration of 
all experiments. Certain C57BL/6J mice exude social dominance by removing pelage and 
whiskers from other mice that share the same habitat in a behavior known as barbering.  
Any C57BL/6J mice seen barbering or fighting other mice were placed in their own 
separate cage, to eliminate possible speculation that physical pelage abnormalities was 
caused by experimental treatment.  Prior to any experimentation, mice were acclimatized 
 
 b 
a 
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for no less than three weeks in this environment. When working with the mice, hands 
were washed before and after handling, and gloves and a lab coat were worn at all times 
for sanitary purposes. 
 
Tumor Cell Proliferation Assays with Separated Elderberry Samples  
To assess the tumor suppressing ability of elderberry samples from Column #1, an 
assay was set up to measure percent proliferation of MeWo cells following elderberry 
treatment in a 72-hour thymidine uptake assay in vitro.  MeWo cells were collected from 
culture flasks, counted using a hemocytometer, and diluted with Eagle MEM X media 
supplemented with 10% FBS and 1% NEAA to a final concentration of 5 x 105 cells/mL.  
In a MICROTESTTM  96-well tissue culture plate, each experimental well was filled with 
100 µL MeWo cell dilution and 100 µL additional Eagle MEM X media supplemented 
with 10%FBS and 1% NEAA, bringing the final cell concentration of each well to 5 x 
104 cells/200 µL supplemented media. After 24 hours of incubation at 37.5oC and 7.5% 
CO2, 10 µL of crude 10mg/mL elderberry, crude 1mg/mL elderberry, or elderberry 
fraction was added to the appropriate wells and incubated for another 24 hours. At 48 
hours, each well was given 1 mCi/mL tritiated thymidine and incubated for an additional 
24 hours. This radioisotope is incorporated into DNA replication events of dividing 
cellular nuclei. At 72 hours, the cells were harvested and counted. This experiment was 
repeated three times validate results. 
To assess the tumor-suppressing ability of the individual fractions collected from 
columns #2-24, a B16-F10 cell proliferation assay was performed for the fractions of 
each column. Since the separated fractions of interest were between the approximate 
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range of sample 45-90, only samples 45-90 were used in the column #23 and column #24 
B16-F10 cell proliferation assays. B16-F10 cells were diluted with RPMI-1640 media 
supplemented with 10% FBS and 1% Penicillin-Streptomycin-Amphotericin to a final 
concentration of 5 x 105 cells/mL.  In a MICROTESTTM  96-well tissue culture plate, 
each experimental well was filled with 100 µL B16-F10 cell dilution and 100 µL 
additional RPMI-1640 media supplemented with 10% FBS and 1% Penicillin-
Streptomycin-Amphotericin, bringing the final cell concentration of each well to 5 x 104 
cells/200 µL supplemented media. After 24 hours of incubation at 37.5oC and 7.5% CO2, 
10 µL of crude 10mg/mL elderberry 10 µL of separated elderberry fraction was added to 
the appropriate plate wells and incubated for another 24 hours. At 48 hours, each well 
was given 1 mCi/mL tritiated thymidine and incubated for an additional 24 hours. At 72 
hours, the cells were harvested and counted. This experiment was performed once for 
each column. 
 
Pooling of Assumed Active Elderberry Samples  
Individual elderberry samples from Column #1 that showed similar MeWo cell 
proliferation inhibition were pooled together in equal concentrations to make pooled 
fractions. 
Three pooled fractions from column #1 were chosen as active pooled fractions of 
interest for future analysis, due to their high tumor-suppressive activity and stimulation of 
immune response. Using the results from the MeWo cell proliferation assay with 
separated fractions from column #1 as a guide, separated fractions from column 2-24 
were appropriately pooled with neighboring active fractions to create pools with the same 
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activity pattern as the pooled fractions from column #1. The pools from column #2-24 
that matched the activity of the pools of interest from column #1 were stored at -18oC 
until further use. The recreated pooled fractions 16, 24, and 29 were renamed P16, P24, 
and P29 respectively to avoid confusion with the terms “pool 16”, “pool 24”, and “pool 
29”, which refer exclusively to the fractions pooled from column #1. 
  
MeWo Cell Proliferation Assay with Pooled Elderberry Fractions 
To assess the tumor suppressing ability of pooled fractions from Column #1, an 
assay was set up to measure percent proliferation of MeWo cells following pooled 
elderberry treatment in a 72-hour thymidine uptake assay in vitro.  MeWo cells were 
diluted with Eagle MEM X media supplemented with 10%FBS and 1% NEAA to a final 
concentration of 5 x 105 cells/mL.  In a MICROTESTTM  96-well tissue culture plate, 
each experimental well was filled with 100 µL MeWo cell dilution and 100 µL additional 
Eagle MEM X media supplemented with 10%FBS and 1% NEAA, bringing the final cell 
concentration of each well to 5 x 104 cells/200 µL supplemented media. After 24 hours of 
incubation at 37.5oC and 7.5% CO2, 10 µL of crude 10mg/mL elderberry, 10 µL of crude 
1mg/mL elderberry, or 10 µL of pooled elderberry fraction was added to the appropriate 
plate wells and incubated for another 24 hours. At 48 hours, each well was given 1 
mCi/mL tritiated thymidine and incubated for an additional 24 hours. At 72 hours, the 
cells were harvested and counted. This experiment was repeated twice. 
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B16-F10 Cell Proliferation Assay with Pooled Elderberry Fractions 
Similar to the MeWo cell proliferation assay with pooled elderberry fractions 
from Column #1, this assay implements the same method using B16-F10 melanoma cells 
as the target cells. B16-F10 cells were diluted with RPMI-1640 media supplemented with 
10% FBS and 1% Penicillin-Streptomycin-Amphotericin to a final concentration of 5 x 
105 cells/mL.  In a MICROTESTTM  96-well tissue culture plate, each experimental well 
was filled with 100 µL B16-F10 cell dilution and 100 µL additional RPMI-1640 media 
supplemented with 10% FBS and 1% Penicillin-Streptomycin-Amphotericin, bringing 
the final cell concentration of each well to 5 x 104 cells/200 µL supplemented media. 
After 24 hours of incubation at 37.5oC and 7.5% CO2, 10 µL of crude 10mg/mL 
elderberry, 10 µL of crude 1mg/mL elderberry, or 10 µL of pooled elderberry fraction 
was added to the appropriate plate wells and incubated for another 24 hours. At 48 hours, 
each well was given 1 mCi/mL tritiated thymidine and incubated for an additional 24 
hours. At 72 hours, the cells were harvested and counted. The experiment was performed 
three times for validation. 
 
SH-SY5Y Cell Proliferation Assay with Pooled Elderberry Fractions 
Similar to the B16-F10 cell proliferation assay with pooled elderberry fractions 
from Column #1, this assay implements the same method using SH-SY5Y neuroblastoma 
cells as the target cells. SH-SY5Y cells were diluted with RPMI-1640 media 
supplemented with 10% FBS and 1% Penicillin-Streptomycin-Amphotericin to a final 
concentration of 5 x 105 cells/mL.  In a MICROTESTTM  96-well tissue culture plate, 
each experimental well was filled with 100 µL B16-F10 cell dilution and 100 µL 
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additional RPMI-1640 media supplemented with 10% FBS and 1% Penicillin-
Streptomycin-Amphotericin, bringing the final cell concentration of each well to 5 x 104 
cells/200 µL supplemented media. After 24 hours of incubation at 37.5oC and 7.5% CO2, 
10 µL of crude 10mg/mL elderberry, 10 µL of crude 1mg/mL elderberry, or 10 µL of 
pooled elderberry fraction was added to the appropriate plate wells and incubated for 
another 24 hours. At 48 hours, each well was given 1 mCi/mL tritiated thymidine and 
incubated for an additional 24 hours. At 72 hours, the cells were harvested and counted. 
The experiment was performed three times for validation. 
 
CHO-K1 Cell Proliferation Assay with Pooled Elderberry Fractions 
This assay implements the same method as the SH-SY5Y neuroblastoma and 
B16-F10 melanoma cell proliferation assay with pooled fractions using CHO-K1 cells as 
the target cells to determine the effect of pooled fractions from Column #1 on the growth 
of a noncancerous transformed cell line. CHO-K1 cells were diluted with RPMI-1640 
media supplemented with 10% FBS and 1% Penicillin-Streptomycin-Amphotericin to a 
final concentration of 5 x 105 cells/mL.  In a MICROTESTTM  96-well tissue culture 
plate, each experimental well was filled with 100 µL B16-F10 cell dilution and 100 µL 
additional RPMI-1640 media supplemented with 10% FBS and 1% Penicillin-
Streptomycin-Amphotericin, bringing the final cell concentration of each well to 5 x 104 
cells/200 µL supplemented media. After 24 hours of incubation at 37.5oC and 7.5% CO2, 
10 µL of crude 10mg/mL elderberry, 10 µL of crude 1mg/mL elderberry, or 10 µL of 
pooled elderberry fraction was added to the appropriate plate wells in triplicate and 
incubated for another 24 hours. At 48 hours, each well was given 1 mCi/mL tritiated 
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thymidine and incubated for an additional 24 hours. At 72 hours, the cells were harvested 
and counted. The experiment was performed three times. 
 
Middle Aged Mouse Spleen Cell Proliferation Assay with Pooled Elderberry Fractions 
 
To assess the immune-inducing effects of the pooled elderberry fractions, a spleen 
cell proliferation assay was performed. Spleen cells were incubated with and without 
concanavalin A (Con A), a known mitogen to induce proliferation of T lymphocytes. 
Rizvi (2012) showed that Con A addition was essential to demonstrate the immune-
inducing effect of elderberry fractions. Optimal Con A concentration, 2.5 µL of 50 
µg/mL Con A (equivalent to 0.125 µg/mL Con A), was determined in a preliminary study 
using the spleen from a BALB/c male mouse (Appendix, Figure B2). Spleen cells for this 
assay were prepared from a C57BL/6J male mouse (11 months old), and diluted with 
RPMI-1640 media supplemented with 10%FBS and 1% Penicillin-Streptomycin-
Amphotericin to a final concentration of 10 x 106 cells/mL.  In a MICROTESTTM  96-
well tissue culture plate, each experimental well was filled with 100 µL spleen cell 
dilution and 100 µL additional RPMI-1640 media supplemented with 10%FBS and 1% 
Penicillin-Streptomycin-Amphotericin, bringing the final cell concentration of each well 
to 1 x 106 cells/200 µL supplemented media. 2.5 µL of 50µg/mL con A was added to all 
wells, except for control wells, which remained spleen cells in supplemented media only. 
After 24 hours of incubation at 37.5oC and 7.5% CO2, 10 µL pooled elderberry fractions 
were added to wells containing con A in duplicate, and were incubated for another 24 
hours. The control and spleen cells + con A only wells were plated in triplicate. At 48 
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hours, each well was given 1 mCi/mL tritiated thymidine and incubated for an additional 
24 hours. At 72 hours, the cells were harvested and counted.  
 
Young and Old Mouse Comparative Spleen Cell Proliferation Assay with Pooled 
Elderberry Fractions 
 
To compare the immunological effect of pooled elderberry fractions on spleen 
cell proliferation from a young and old mouse, a comparative spleen cell proliferation 
assay was performed.  A young mouse (5 months old) and an old mouse (retired breeder, 
18 months old)  were sacrificed, and their spleens were appropriately prepared and 
diluted with RPMI-1640 media supplemented with 10%FBS and 1% Penicillin-
Streptomycin-Amphotericin to a final concentration of 10 x 106 cells/mL.  In two 
MICROTESTTM  96-well tissue culture plates, each experimental well was filled with 
100 µL of either young or old spleen cell dilution and 100 µL additional RPMI-1640 
media supplemented with 10%FBS and 1% Penicillin-Streptomycin-Amphotericin, 
bringing the final cell concentration of each well to 1 x 106 cells/200 µL supplemented 
media. 2.5 µL of 50µg/mL Con A was added to all wells, except for control wells. After 
24 hours of incubation at 37.5oC and 7.5% CO2, 10 µL of crude 10mg/mL elderberry, 10 
µL of crude 1mg/mL elderberry, or 10 µL of pooled elderberry fractions were added to 
wells containing Con A in duplicate, for both young and old spleen cell plates, and were 
incubated for another 24 hours. At 48 hours, each well was given 1 mCi/mL tritiated 
thymidine and incubated for an additional 24 hours. At 72 hours, the cells were harvested 
and counted. 
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Modulation of Cytokine IL-2 by Pooled Elderberry Fractions 
To assess the production of the immune modulating cytokine IL-2 by spleen cells 
treated with pooled fractions, a colorimetric assay was used. A Quantikine® ELISA 
(enzyme-linked immunosorbant assay) kit for mouse IL-2 was obtained from R&D 
Systems (Minneapolis, MN). This assay employs the quantitative sandwich enzyme 
immunoassay technique, where a polyclonal antibody specific for mouse IL-2 is 
immobilized in each well of a 96-well microtiter plate. To prepare the samples, a 
C57BL/6J mouse (4 months old) was sacrificed and a single cell suspension of spleen 
cells was obtained and diluted to 10 x 106 cells/mL. In 12-well costar® microtiter plates, 
600 µL RPMI-1640 media supplemented with 10% FBS and 1% Penicillin-
Streptomycin-Amphotericin and 400 µL of spleen cell dilution was added to each well. 
Excluding the negative control well and well designated for Con A only (+12.5 µl 
50µg/mL Con A), each well received an addition of 50 µl pooled fraction and 12.5 µl 
50µg/mL Con A. The 12-well microtiter plates were incubated for 24 hours at 37.5oC and 
7.5% CO2.  Following incubation, the contents of each well were gently centrifuged for 5 
minutes and the supernatant was removed for use in the assay. The assay was performed 
by the manufacturer’s instructions and treatments were plated in duplicate. A Packard 
SpectraCountTM was used to determine the optical density (O.D.) for each well at 405 
nm, 490 nm and 570 nm wavelengths. Subtraction of the 570 nm reading from the 
average of the 405 nm and 490 nm readings allows for correction of optical imperfections 
present the microtiter plate.  
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Old Mouse in vivo Murine Melanoma Assay with Crude Elderberry 
 
 To assess the tumor-suppressive and immune-inducing activity of crude 10mg/mL 
elderberry in old (senescent) mice, an in vivo murine melanoma model was used. Six 
C57BL/6J male retired breeders (20 months old) were randomly grouped into a water 
treatment (control) group and a 10mg/mL elderberry treatment group. Each mouse was 
weighed on day 1, day 36 (successful tumor cell injection) and prior to sacrifice. For 36 
consecutive days, each mouse received a daily i.p. injection of either 0.5 mL filter-
sterilized deionized water or 0.5 mL filter-sterilized crude 10mg/mL using a sterile 26 
gauge needle. On day 36, each mouse received a 0.1 mL subcutaneous (s.c.) injection of 
1 x 106 cells/mL B16-F10 cells. Therefore, each mouse received 1 x105 B16-F10 cells. 
All mice were given daily i.p. injection of either 0.5 mL filter-sterilized deionized water 
or 0.5 mL filter-sterilized crude 10mg/mL for an additional 7 days (day 37-43), then were  
left undisturbed for an additional 7 days (day 44-50), and were sacrificed via cervical 
dislocation after tumors were formed, but were not burdensome to the mice. Additionally, 
two old mice were given daily i.p. injection of 0.5 mL filter-sterilized crude 10mg/mL 
elderberry for 36 days, were not given a s.c. injection of B16-F10 cells, and were 
sacrificed via cervical dislocation. Initial and final weights were recorded. 
 Tumor weight was recorded and tumor size was measured using calipers for all 
tumor-bearing mice. Spleens from all mice were dissected and prepared for a spleen cell 
proliferation assay. Spleen cells were counted using a hemocytometer, and diluted with 
RPMI-1640 media supplemented with 10%FBS and 1% Penicillin-Streptomycin-
Amphotericin to a final concentration of 10 x 106 cells/mL.  In MICROTESTTM  96-well 
tissue culture plates, experimental wells were filled with 100 µL of spleen cell dilution 
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from each mouse and 100 µL additional RPMI-1640 media supplemented with 10%FBS 
and 1% Penicillin-Streptomycin-Amphotericin, bringing the final cell concentration of 
each well to 1 x 106 cells/200 µL supplemented media. Either 0 µL (control), 2.5 µL or 5 
µL of a stock 50µg/mL Con A were added in triplicate for each mouse cell dilution. After 
48 hours of incubation at 37.5oC and 7.5% CO2, each well was given 1 mCi/mL tritiated 
thymidine and incubated for an additional 24 hours. At 72 hours, the cells were harvested 
and counted. 
 
Young Mouse in vivo Murine Melanoma Assay with Crude Elderberry 
To assess the tumor preventative ability of crude 10mg/mL elderberry in young 
mice, an in vivo murine melanoma model was used. Nine C57BL/6J male young mice 
(1.5 months old) were randomly grouped into a water treatment (control) group, a 
10mg/mL elderberry treatment group, and a 10mg/mL group (no-cancer challenge). Each 
mouse was weighed on day 1, day 21 (tumor cell injection) and prior to sacrifice. From 
day 1 to day 7, each mouse received a daily i.p. injection of either 0.5 mL filter-sterilized 
deionized water or 0.5 mL filter-sterilized crude 10mg/mL using a 26 gauge sterile 
needle. On day 7, each mouse received 0.1 mL s.c. injection of 1 x 105 cells/mL B16-F10 
cells to the right flank. Therefore, each mouse received 1 x104 B16-F10 cells. All mice 
were given daily i.p. injection of either 0.5 mL filter-sterilized deionized water or 0.5 mL 
filter-sterilized crude 10mg/mL for an additional 7 days (day 8-14), then were  left 
undisturbed for an additional 7 days (day 15-21). On day 21, mice were re-injected with 
0.1 mL s.c. injection of 1 x 106 cells/mL B16-F10 cells. Therefore, each mouse received 
1 x105 B16-F10 cells. The reason for re-injection was due to the lack of tumor cell 
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observation in all mice. All mice were given daily i.p. injection of either 0.5 mL filter-
sterilized deionized water or 0.5 mL filter-sterilized crude 10mg/mL for an additional 7 
days (day 21-27), then were left undisturbed for an additional 5-6 days (day 28-33), and  
mice were sacrificed via cervical dislocation after tumors were formed, but were not 
burdensome to the mice.  
 Tumor weight was recorded and tumor size was measured using calipers for all 
tumor-bearing mice. Spleens from all mice were dissected and prepared for a spleen cell 
proliferation assay. Spleen cells were counted using a hemocytometer, and diluted with 
RPMI-1640 media supplemented with 10%FBS and 1% Penicillin-Streptomycin-
Amphotericin to a final concentration of 10 x 106 cells/mL.  In MICROTESTTM  96-well 
tissue culture plates, experimental wells were filled with 100 µL of spleen cell dilution 
from each mouse and 100 µL additional RPMI-1640 media supplemented with 10%FBS 
and 1% Penicillin-Streptomycin-Amphotericin, bringing the final cell concentration of 
each well to 1 x 106 cells/200 µL supplemented media. Either 0 µL (control), 2.5 µL or 5 
µL of 50µg/mL Con A were added in triplicate for each mouse cell dilution. After 48 
hours of incubation at 37.5oC and 7.5% CO2, each well was given 1 mCi/mL tritiated 
thymidine and incubated for an additional 24 hours. At 72 hours, the cells were harvested 
and counted. 
 
Middle Aged Mouse in vivo Murine Melanoma Assay with Active Pooled Elderberry 
Fractions 
 
To assess the tumor suppressive ability of active pooled fractions of interest in 
vivo, a murine melanoma model was used. Twenty C57BL/6J male mice (6 months old) 
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were randomly grouped into a water treatment (control) group, a 10mg/mL elderberry 
treatment group, a P16 group, a P24 group, and a P29 group. Each mouse was weighed 
on day 1. From day 1 to day 7, each mouse received a daily i.p. injection of either 0.5 mL 
filter-sterilized deionized water, 0.5 mL filter-sterilized crude 10mg/mL elderberry, or 0.5 
mL filter-sterilized pooled fraction using a 26 gauge sterile needle. On day 7, each mouse 
received 0.1 mL s.c. injection of 1 x 106 cells/mL B16-F10 cells to the right flank. 
Therefore, each mouse received 1 x105 B16-F10 cells. All mice were given daily 0.5 mL 
i.p. injections of their respective treatment for an additional 7 days (day 8-14), then were  
left undisturbed for an additional 7 days (day 15-21). Throughout the experiment, 
mortalities and behavioral cues, such as weakness, from the pooled fraction treated mice 
suggested that the pooled fractions were too potent and too concentrated to be used in the 
assay.  Remaining mice were sacrificed via cervical dislocation and the experiment was 
ended prematurely.  
 
Preliminary Identification of Active Pooled Elderberry Fractions by Heat-Induced 
Denaturation in a B16-F10 Cell Proliferation Assay 
 
Proteins can be denatured and rendered inactive or less active by changes in 
temperature and pH. To determine if the tumor suppressing ability in active elderberry 
fractions was due to a protein, certain active elderberry fractions were subject to heat 
treatment prior to B16-F10 cell addition in vitro.  B16-F10 cells were diluted with RPMI-
1640 media supplemented with 10% FBS and 1% Penicillin-Streptomycin-Amphotericin 
to a final concentration of 5 x 105 cells/mL.  In a MICROTESTTM  96-well tissue culture 
plate, each experimental well was filled with 100 µL B16-F10 cell dilution and 100 µL 
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additional RPMI-1640 media supplemented with 10% FBS and 1% Penicillin-
Streptomycin-Amphotericin, bringing the final cell concentration of each well to 5 x 104 
cells/200 µL supplemented media. After 24 hours of incubation at 37.5oC and 7.5% CO2, 
crude 10mg/mL elderberry, crude 1mg/mL elderberry, and select active pooled elderberry 
fractions were heated at 100oC for 5 minutes, and then were allowed to cool back to room 
temperature. 10 µL of heated and non-heated crude 10mg/mL elderberry, 10 µL of heated 
and non-heated crude 1mg/mL elderberry, and 10 µL of heated and non-heated pooled 
elderberry fraction were added to the appropriate plate wells in triplicate and incubated 
for another 24 hours. At 48 hours, each well was given 1 mCi/mL tritiated thymidine and 
incubated for an additional 24 hours. At 72 hours, the cells were harvested and counted. 
The experiment was performed twice.  
 
Preliminary Identification of Active Pooled Elderberry Fractions by Heat-Induced 
Denaturation in a Spleen Cell Proliferation Assay 
 
To determine if the immune inducing ability in active elderberry fractions was 
due to a protein, certain active elderberry fractions were subject to heat treatment prior to 
spleen cell addition in vitro.  Spleen cells for this assay were prepared from a C57BL/6J 
male mouse (16 months old), and diluted with RPMI-1640 media supplemented with 
10%FBS and 1% Penicillin-Streptomycin-Amphotericin to a final concentration of 10 x 
106 cells/mL.  In a MICROTESTTM  96-well tissue culture plate, each experimental well 
was filled with 100 µL spleen cell dilution and 100 µL additional RPMI-1640 media 
supplemented with 10%FBS and 1% Penicillin-Streptomycin-Amphotericin, bringing the 
final cell concentration of each well to 1 x 106 cells/200 µL supplemented media. 2.5 µL 
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of 50µg/mL Con A was added to all wells, except for control wells. After 24 hours of 
incubation at 37.5oC and 7.5% CO2, crude 10mg/mL elderberry, crude 1mg/mL 
elderberry, and select active pooled elderberry fractions were heated at 100oC for 5 
minutes, and then were allowed to cool back to room temperature. 10 µL of heated and 
non-heated crude 10mg/mL elderberry, 10 µL of heated and non-heated crude 1mg/mL 
elderberry, and 10 µL of heated and non-heated pooled elderberry fraction were added to 
the appropriate plate wells in triplicate and incubated for another 24 hours. At 48 hours, 
each well was given 1 mCi/mL tritiated thymidine and incubated for an additional 24 
hours. At 72 hours, the cells were harvested and counted. This experiment was performed 
twice. 
 
Identification of Active Pooled Elderberry Fractions by Reversed-Phase High-
Performance Liquid Chromatography (HPLC) 
 
The 4 major anthocyanins in Sambucus nigra were separated by reversed-phase 
HPLC using a Hewlett-Packard 1050 Model pump system (Hewlett-Packard, Palo Alto, 
CA) with a photo-diode array detector (model 1040A) at 520 nm. The system was 
equipped with a 4.6 x 250 mm 5 µm C8 column.  Anthocyanins were eluted using a 
gradient elution sequence adapted from von Baer et al. (2008).  Pooled fractions of 
interest were also eluted on this column to determine the primary anthocyanin(s) in the 
sample. The column was set to a flow rate of 0.8 mL/min and a 20 µL injection of 1 
mg/mL filter-sterilized crude elderberry was used for the elution. Milli Q water, formic 
acid and HPLC-grade acetonitrile were used to prepare the solvents for elution. The 
solvents for the elution were (A) water/formic acid/acetonitrile 87:10:3 (v/v/v) and (B) 
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water/formic acid/acetonitrile 40:10:50 (v/v/v). The gradient starts with 6% solvent B for 
1 minute, a linear gradient from 6% solvent B to 30% solvent B at 16 minutes, a linear 
gradient from 30% B to 50% B at 31 minutes, then back down to 6% B at 32 minutes. 
This gradient is followed by a 10 minute post run at 6% solvent B. The total time of the 
elution was 42 minutes. 
 Pooled fractions P16, P24, and P29 were diluted 1:50 and eluted based on the 
HPLC protocol developed for the crude elderberry elution.  
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RESULTS 
 
Extraction of Elderberry Samples 
Elderberry extraction of Column #1 by column chromatography yielded 111 
individual 14.5 mL solvent-containing samples. As the mobile phase decreased in 
polarity, the collection rate of eluting samples also decreased, eluting off of the column at 
a slower pace. The first mobile phase run through the column (100% water/0% methanol 
+ 0.01N HCl) resulted in the fastest collection time, with samples being eluted at a rate of 
0.37 mL/min. The final mobile phase run through the column (0% water/100% methanol 
+ 0.01N HCl) yielded the slowest fraction collection time at a rate of 0.12 mL/min (Table 
1).  Also, as the mobile phase decreased in polarity throughout the column elution, the 
colors of the samples changed in color and increased in color intensity. Collected samples 
in solvent varied from a pale yellow color to a dark and vibrant red.  Following removal 
of solvent by rotary evaporation and vacuum centrifugation, the samples were re-
dissolved in 0.5 mL PBS, an aqueous based solvent that does not affect cell proliferation 
(Rizvi, 2012).  Samples eluted with increased methanol solvent were evaporated to 1-
1.5mL by rotary evaporation quicker than samples eluted with high water solvent 
concentration (Table 2). The final sample colors ranged from pastel yellow to dark 
purple, including oranges, pinks, and reds in between.  
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Table 1. The collection times for elutants resolved by column chromatography using 
prepared standard elderberry powder (Column #1).  
 
Mobile Phase Composition Fraction Numbers Collection Rate (mL/min) 
100% water/0% Methanol 1-5 0.37 
90% water/10% Methanol 6-16 0.33 
80% water/20% Methanol 17-27 0.31 
70% water/30% Methanol 28-38 0.28 
60% water/40% Methanol 39-49 0.25 
50% water/50% Methanol 50-60 0.21 
40% water/60% Methanol 61-70 0.20 
30% water/70% Methanol 71-80 0.18 
20% water/80% Methanol 81-91 0.17 
10% water/90% Methanol 92-101 0.14 
0% water/100% Methanol 102-111 0.12 
 
 
 
Table 2. The evaporation times for elutants resolved from column chromatography to 1-
1.5 mL by rotary evaporator (Column #1). 
 
Mobile Phase Composition Fraction Numbers Evaporation Time  
to 1-1.5 mL (minutes) 
100% water/0% Methanol 1-5 21.50 
90% water/10% Methanol 6-16 20.50 
80% water/20% Methanol 17-27 19.00 
70% water/30% Methanol 28-38 18.25 
60% water/40% Methanol 39-49 16.00 
50% water/50% Methanol 50-60 15.50 
40% water/60% Methanol 61-70 15.00 
30% water/70% Methanol 71-80 13.00 
20% water/80% Methanol 81-91 12.25 
10% water/90% Methanol 92-101 10.50 
0% water/100% Methanol 102-111 9.25 
 
 
Column #2 yielded 115 individual 14.5 mL solvent-containing samples. Identical 
to Column #1, mobile phases with higher concentrations of methanol (less polar) 
decreased the collection rate of solvent-containing samples. The first mobile phase run 
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through the column (100% water/0% methanol + 0.01N HCl) resulted in the fastest 
collection time, with samples being eluted at a rate of 0.39 mL/min. The final mobile 
phase run through the column (0% water/100% methanol + 0.01N HCl) yielded the 
slowest sample collection time at a rate of 0.13 mL/min (Table 3).  The colors of the 
samples changed in color and increased in color intensity with decreasing polarity of 
mobile phases, similar to Column #1. Samples were eluted and completely dried using a 
rotary evaporator, and evaporation times increased as solvent methanol concentration 
increased (Table 4). The final sample colors followed the same range as those eluted and 
evaporated from Column #1.   
 
Table 3. The collection times for elutants resolved by column chromatography using 
prepared standard elderberry powder (Column #2).  
 
Mobile Phase Composition Fraction Numbers Collection Rate (mL/min) 
100% water/0% Methanol 1-6 0.39 
90% water/10% Methanol 7-17 0.36 
80% water/20% Methanol 18-28 0.34 
70% water/30% Methanol 29-39 0.31 
60% water/40% Methanol 40-50 0.28 
50% water/50% Methanol 51-61 0.27 
40% water/60% Methanol 62-72 0.24 
30% water/70% Methanol 73-83 0.21 
20% water/80% Methanol 84-94 0.17 
10% water/90% Methanol 95-105 0.13 
0% water/100% Methanol 106-115 0.13 
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Table 4. The complete evaporation times for elutants resolved from column 
chromatography by rotary evaporator (Column #2). 
 
Mobile Phase Composition Fraction Numbers Complete Evaporation  Time (minutes) 
100% water/0% Methanol 1-6 36.50 
90% water/10% Methanol 7-17 34.25 
80% water/20% Methanol 18-28 31.00 
70% water/30% Methanol 29-39 28.50 
60% water/40% Methanol 40-50 28.00 
50% water/50% Methanol 51-61 25.25 
40% water/60% Methanol 62-72 22.00 
30% water/70% Methanol 73-83 19.00 
20% water/80% Methanol 84-94 17.00 
10% water/90% Methanol 95-105 14.50 
0% water/100% Methanol 106-115 12.75 
 
 
 
Columns #3-24 were eluted following the same column chromatography protocol, 
and resulted in similar sample collection rates and evaporation times as Column #1 and 
Column #2. Columns #3-24 were concluded after addition of the 20% water/80% 
methanol + 0.01N HCl, because individual samples beyond elution by these mobile 
phases were not of interest for future study. Between 87 and 93 individual solvent-
containing samples were collected from each column. The collection rates and 
evaporation times for Columns #3-24 were averaged and recorded in Table 5 and 6.  
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Table 5. The average collection times for elutants resolved by column chromatography 
using prepared standard elderberry powder (Column #3-24).  
 
Mobile Phase Composition Collection Rate (mL/min) 
100% water/0% Methanol 0.46 
90% water/10% Methanol 0.41 
80% water/20% Methanol 0.38 
70% water/30% Methanol 0.35 
60% water/40% Methanol 0.33 
50% water/50% Methanol 0.31 
40% water/60% Methanol 0.30 
30% water/70% Methanol 0.30 
20% water/80% Methanol 0.28 
10% water/90% Methanol 0.25 
0% water/100% Methanol 0.24 
 
 
 
Table 6. The average complete evaporation times for elutants resolved from column 
chromatography by rotary evaporator (Column #3-24). 
 
Mobile Phase Composition Complete Evaporation  Time (minutes) 
100% water/0% Methanol 40.50 
90% water/10% Methanol 39.25 
80% water/20% Methanol 36.50 
70% water/30% Methanol 33.25 
60% water/40% Methanol 29.00 
50% water/50% Methanol 25.25 
40% water/60% Methanol 21.00 
30% water/70% Methanol 18.50 
20% water/80% Methanol 16.75 
10% water/90% Methanol 14.00 
0% water/100% Methanol 13.75 
 
 
 
Tumor Cell Proliferation Assays with Separated Elderberry Samples 
 
The MeWo cell proliferation assay with the samples isolated from column 
chromatography, rotary evaporation and vacuum centrifugation demonstrated that 
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individual components isolated from Column #1 have tumor-suppressive effects. The 
assay was repeated three times and the average of the trials revealed that all of the 
samples suppressed tumor growth by some degree. CPM measurements from the 
scintillation counter were analyzed, and the percent proliferation of elderberry treated 
cells was assessed based on the growth of control cells at 100%. When 10 µL additions 
were used, 102 of the 111 (91.9%)  individual samples decreased proliferation of the 
MeWo cell line by 40% or more compared to the untreated control. 88 of the 111 
individual fractions (79.2%) inhibited MeWo growth by 60% or more. The 10 mg/mL 
and 1 mg/mL crude elderberry treatments decreased MeWo cell proliferation by 41.8% 
and 8.3%, respectively from the control (Figure 4).  
 
 
Figure 4. MeWo cell suppression by individually separated elderberry samples (n=3).  
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A B16-F10 murine melanoma cell proliferation assay was performed for the 
separated samples from Columns #2-24. Appendix Tables A1-A23 show the results for 
the B16-F10 cell proliferation assays. Each assay produced a similar tumor cell 
suppression profile, facilitating subsequent pooling of active samples into pooled 
fractions. The B16-F10 cell proliferation assays for Column #23 and #24 start at sample 
45 because it was unnecessary to plate the preceding samples to develop pool 16, pool 24 
and pool 29. 
 
Pooling of Assumed Active Elderberry Samples 
Based on the results obtained from the MeWo cell proliferation assay with 
separated fractions from Column #1, neighboring fractions with similar tumor-
suppressive ability were pooled generating 39 pooled fractions (Appendix, Table A24). 
Assumed active fractions from Columns #2-24 were pooled together to recreate pooled 
fractions of interest from Column #1 (Pool 16, 24 and 29). A list of the individual 
fractions combined to recreate pooled fractions of interest for each column can be found 
in the appendix (Appendix, Table A25).  
 
MeWo Cell Proliferation Assay with Pooled Elderberry Fractions 
This assay was performed to assess the tumor-suppressive activity of Column #1 
pooled fractions on MeWo cell growth. CPM measurements from the scintillation counter 
were analyzed, and the percent proliferation of elderberry treated cells was assessed 
based on the growth of control cells at 100%. 20 of the 39 pooled fractions decreased 
MeWo cell proliferation by 40% or more. The 10 mg/mL and 1 mg/mL crude elderberry 
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treatments decreased MeWo cell proliferation by 42.5% and 37.6%, respectively from the 
control (Figure 5). This assay was performed twice. 
 
 
Figure 5. MeWo cell suppression by pooled elderberry fractions (n=2). 
 
B16-F10 Cell Proliferation Assay with Pooled Elderberry Fractions 
Similar to the MeWo cell proliferation assay with the Column #1 pooled 
fractions, this assay aimed to assess the tumor-suppressive activity of Column #1 pooled 
fractions on B16-F10 murine melanoma cells. CPM measurements from the scintillation 
counter were analyzed, and the percent proliferation of elderberry treated cells was 
assessed based on the growth of control cells at 100%. All 39 pooled fractions decreased 
B16-F10 cell proliferation by 40% or more (Figure 6). The assay was repeated three 
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times and the average of the trials revealed that the tumor-suppressive ability of the 
pooled fractions was significantly different than the control. The 10 mg/mL crude 
elderberry treatment significantly suppressed B16-F10 cell proliferation by 51.9% and 
the 1 mg/mL crude elderberry treatment decreased B16-F10 cell proliferation by 19.1%, 
although not significantly different from the control. Column #1 pooled fractions on 
average inhibit the growth of B16-F10 cells more compared to MeWo cells.  
Sample Identity
C
on
tro
l
10
 m
g/
m
l E
ld
er
be
rr
y
1 
m
g/
m
l E
ld
er
be
rr
y
Po
ol
 1
Po
ol
 2
Po
ol
 3
Po
ol
 4
Po
ol
 5
Po
ol
 6
Po
ol
 7
Po
ol
 8
Po
ol
 9
Po
ol
 1
0
Po
ol
 1
1
Po
ol
 1
2
Po
ol
 1
3
Po
ol
 1
4
Po
ol
 1
5
Po
ol
 1
6
Po
ol
 1
7
Po
ol
 1
8
Po
ol
 1
9
Po
ol
 2
0
Po
ol
 2
1
Po
ol
 2
2
Po
ol
 2
3
Po
ol
 2
4
Po
ol
 2
5
Po
ol
 2
6
Po
ol
 2
7
Po
ol
 2
8
Po
ol
 2
9
Po
ol
 3
0
Po
ol
 3
1
Po
ol
 3
2
Po
ol
 3
3
Po
ol
 3
4
Po
ol
 3
5
Po
ol
 3
6
Po
ol
 3
7
Po
ol
 3
8
Po
ol
 3
9
%
 P
ro
lif
er
at
io
n
[E
ld
er
be
rry
 T
re
at
ed
 C
el
ls
/C
on
tro
l C
el
ls
]
0
20
40
60
80
10
0
12
0
*
*
*
* * *
*
*
*
*
*
*
*
*
*
*
*
*
*
* *
*
* *
*
*
*
* *
* *
*
*
*
*
*
*
*
*
*
 
Figure 6. B16-F10 cell suppression by pooled elderberry fractions. Asterisks represent a 
significant proliferative difference vs. control cell growth (p<0.05) (n=3). 
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SH-SY5Y Cell Proliferation Assay with Pooled Elderberry Fractions 
To assess the ubiquity of pooled fraction tumor-suppressing activity, a tumor cell 
proliferation assay was performed to assess the tumor-inhibiting ability of Column #1 
pooled fractions on SH-SY5Y human neuroblastoma cells. CPM measurements from the 
scintillation counter were analyzed, and the percent proliferation of elderberry treated 
cells was assessed based on the growth of control cells at 100%. All 39 pooled fractions 
decreased SH-SY5Y cell proliferation by 20% or more (Figure 7). The assay was 
repeated three times and the average of the trials revealed that the tumor-suppressive 
ability of the pooled fractions was significantly different than the control. The 10 mg/mL 
crude elderberry treatment significantly suppressed SH-SY5Y cell proliferation by 27.3% 
and the 1 mg/mL crude elderberry treatment decreased SH-SY5Y cell proliferation by 
13.7%, although not significant from the control. 
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Figure 7. SH-SY5Y cell suppression by pooled elderberry fractions. Asterisks represent a 
significant proliferative difference vs. control cell growth (p<0.05) (n=3). 
 
 
 
CHO-K1 Cell Proliferation Assay with Pooled Elderberry Fractions 
To assess the growth suppressing activity of Column #1 pooled fractions on a 
noncancerous cell line, a cell proliferation assay was performed on CHO-K1 cells, a line 
of transformed noncancerous cells derived from the ovary of a Chinese hamster. CPM 
measurements from the scintillation counter were analyzed, and the percent proliferation 
of elderberry treated cells was assessed based on the growth of control cells at 100%. The 
assay was repeated three times and the average of the trials was graphed (Figure 8). 25 of 
the 39 pooled fractions decreased CHO-K1 cell proliferation by a statistically significant 
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percent. Pooled fractions 4, 5, 12, 18, 19, 25, 26, 27, 31, 32, 33, 38 and 39 did not 
decrease CHO-K1 cell proliferation significantly. Both the 10 mg/mL crude elderberry 
treatment and the 1 mg/mL crude elderberry treatment did not significantly decrease 
CHO-K1 cell proliferation significantly compared to the control cells, whereas the 10 
mg/mL crude elderberry did significantly suppress both B16-F10 and SH-SY5Y cells. In 
general, Column #1 pooled fractions that were exceptionally inhibitory in the B16-F10 
and SH-SY5Y cell proliferation assays also decreased cell proliferation of CHO-K1 cells. 
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Figure 8. CHO-K1 cell suppression by pooled elderberry fractions. Asterisks represent a 
significant proliferative difference vs. control cell growth (p<0.05) (n=3). 
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Middle Aged Mouse Spleen Cell Proliferation Assay with Pooled Elderberry Fractions 
 
 Column #1 pooled fractions were plated with spleen cells and Con A. Spleen cells 
plated with Con A in the absence of pooled fractions was designated as the positive 
control. The Column #1 pooled elderberry fractions incubated with con A did not induce 
spleen cell proliferation greater than the positive control when using 10 µL treatments. 
When compared amongst other pooled fractions, certain pooled fractions incubated with 
con A elicited great stimulation of spleen cells than others (Table 4). Pools 14, 16, 17, 19 
and 20 incubated with Con A were the top five pooled fractions that increased spleen cell 
proliferation compared to the other pooled fractions, but not more than the positive 
control. Each treatment was repeated in duplicate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
56 
 
Table 7. Average middle aged mouse spleen cell proliferation elicited by pooled fractions 
incubated with Con A. 
 
Sample Identity CPM (Average) Sample Identity CPM (Average) 
Control (resting) 166 20 + 2.5 µl Con A 5785 
2.5 µl Con A 14151 21 + 2.5 µl Con A 2974 
1 + 2.5 µl Con A 100 22 + 2.5 µl Con A 1892 
2 + 2.5 µl Con A 138 23 + 2.5 µl Con A 807 
3 + 2.5 µl Con A 141 24 + 2.5 µl Con A 2845 
4 + 2.5 µl Con A 72 25 + 2.5 µl Con A 1513 
5 + 2.5 µl Con A 885 26 + 2.5 µl Con A 71.5 
6 + 2.5 µl Con A 1374 27 + 2.5 µl Con A 1307 
7 + 2.5 µl Con A 1667 28 + 2.5 µl Con A 1882 
8 + 2.5 µl Con A 94 29 + 2.5 µl Con A 1644 
9 + 2.5 µl Con A 1370 30 + 2.5 µl Con A 1381 
10 + 2.5 µl Con A 442 31 + 2.5 µl Con A 1467 
11 + 2.5 µl Con A 895 32 + 2.5 µl Con A 262 
12 + 2.5 µl Con A 1753 33 + 2.5 µl Con A 137 
13 + 2.5 µl Con A 329 34 + 2.5 µl Con A 103 
14 + 2.5 µl Con A 4274 35 + 2.5 µl Con A 78 
15 + 2.5 µl Con A 1309 36 + 2.5 µl Con A 96 
16 + 2.5 µl Con A 5050 37 + 2.5 µl Con A 54 
17 + 2.5 µl Con A 5731 38 + 2.5 µl Con A 62 
18 + 2.5 µl Con A 2601 39 + 2.5 µl Con A 64 
19 + 2.5 µl Con A 5804 
   
 
Young and Old Mouse Comparative Spleen Cell Proliferation Assay with Pooled 
Elderberry Fractions 
 
Column #1 pooled fractions were plated with young and old mouse spleen cells 
and Con A. The percent proliferation of elderberry treated cells was assessed based on 
the growth of the positive control cells (addition of 2.5 µL Con A) at 100%. The pooled 
elderberry fractions incubated with Con A did not induce spleen cell proliferation greater 
than the positive control when using 10 µL treatments in either the young nor senescent 
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mouse spleen cells. Addition of crude elderberry treatments (10 mg/mL and 1 mg/mL) 
with Con A elicited a stronger proliferative response in young mouse spleen cells than in 
senescent mouse spleen cells. Addition of pooled fractions with Con A elicited a stronger 
proliferative response in senescent spleen cells compared to young mouse spleen cells for 
all 39 pooled fractions, and the range of relative increase was between 3% and 53% 
(Figure 9). Each treatment was repeated in duplicate. 
 
 
Figure 9. Senescent and young mouse spleen cell growth stimulation by pooled 
elderberry fractions.   
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
%
 P
ro
lif
er
at
io
n 
  
[E
ld
er
be
rr
y 
Tr
ea
te
d 
Ce
ll/
2.
5 
µL
 C
on
 A
 c
el
ls
] 
Sample Identity 
Young Mouse
Senescent Mouse
58 
 
Modulation of Cytokine IL-2 by Pooled Elderberry Fractions 
The spleen obtained for this assay was from a young 4 month old mouse. 
Standard optical densities (O.D.) measuring IL-2 protein concentration obtained from the 
ELISA were averaged and plotted to generate a linear standard curve for IL-2 protein 
concentration (Appendix, Figure B3).  Average O.D. readings of pooled fraction treated 
wells were converted into IL-2 concentrations based upon the linear formula generated 
from the IL-2 standard curve (R2 = 0.9967). Three column #1 pooled fractions incubated 
with Con A increased IL-2 concentration greater than the positive control. Pool 16, Pool 
26, and Pool 30 treated wells generated IL-2 concentrations of 269.86 pg/mL, 431.13 
pg/mL, and 270.50 pg/mL, respectively. The spleen cells incubated with 10 mg/mL 
elderberry + Con A stimulated IL-2 secretion greater that the spleen cells incubated with 
1 mg/mL elderberry + Con A (Figure 10). 
 
59 
 
 
Figure 10. Stimulation of IL-2 secretion from spleen cells treated with pooled elderberry 
fractions. 
 
 
Old Mouse in vivo Murine Melanoma Assay with Crude Elderberry 
 
 All mice were weighed at the start of the experiment, prior to s.c. injection of 
B16-F10 murine melanoma cells (or on the equivalent day) and prior to sacrifice. Over 
the course of the experiment the weight of each mouse did not change significantly. 
Senescent mouse weight averages for each group were not significantly different between 
each weighing day. Also, senescent mouse weight averages for all groups were not 
significantly different from each other (Figure 11).  
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Figure 11. Body weight results for old tumor-bearing mice given control and elderberry 
treatments. Senescent mice were weighed on day 1 (initial), day 36 (pre-tumor) and day 
50 (final).  
 
 
 
 Two senescent control mice and two senescent 10 mg/mL elderberry treated mice 
who were injected with B16-F10 cells, developed visible tumors which were removed 
after the mice were sacrificed. Elderberry treated mice developed smaller tumors in 
weight and volume compared to the control mice, although not significantly different. 
The average weight and tumor volume of the senescent control mice was 2.48g and 5.56 
61 
 
cm3, respectively. The average weight and tumor volume of the senescent elderberry 
treated mice was 1.67g and 2.16 cm3, respectively (Table 8). 
 
Table 8. Average tumor weight and volume for all tumor-bearing mice in the old mouse 
in vivo murine model assay with crude elderberry. 
 
Treatment 
Group 
Tumor 
Weight (g) 
Tumor Volume 
(cm3) 
Average Tumor  
Weight (g) 
Average Tumor  
Volume (cm3) 
Control 1 3.63 8.42 2.48 ± 1.15 5.56 ± 2.86 
Control 2 1.33 2.7 
Elderberry 1 1.85 2.25 1.67 ± 0.18 2.16 ± 0.09 
Elderberry 2 1.48 2.07 
 
 
 
 The spleens from all senescent mice were removed and prepared for a spleen cell 
proliferation assay with different concentrations of a known mitogen, Con A. The CPM 
measurements were averaged together amongst treatment groups and percent 
proliferation was determined based on the growth of resting (un-stimulated) control cells 
at 100%. For all treatment groups, there was a dose dependent increase in percent 
proliferation with increasing concentrations of mitogen up to 0.25 µg/mL Con A. There 
was no significant difference in percent proliferation induced by mitogen between all 
groups for senescent mice (Table 9).  
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Table 9. Senescent mouse spleen cell stimulation by Con A in the old mouse in vivo 
murine model assay with crude elderberry. 
 
Senescent Mouse Treatment Cell Treatment CPM % Proliferation 
Control (n=3) 
Resting 1823 100% 
0.125 µg/mL Con A 4153 265% 
0.25 µg/mL Con A 10534 816% 
Elderberry (n=3) 
Resting 3295 100% 
0.125 µg/mL Con A 4301 174% 
0.25 µg/mL Con A 7674 726% 
Elderberry-No Tumor (n=2) 
Resting 448 100% 
0.125 µg/mL Con A 646 149% 
0.25 µg/mL Con A 2262 510% 
 
 
 
Young Mouse in vivo Murine Melanoma Assay with Crude Elderberry 
 
All mice were weighed at the start of the experiment, prior to tumor injection (or 
on the equivalent day) and prior to sacrifice. 13 days following s.c. 1 x 104 B16-F10 cell 
injection to control and crude elderberry treated mice, no tumors were present. Mice were 
re-injected with 1 x 105 B16-F10 cells on the same flank to induce tumor growth. 
Injections of treatments (0.5 mL of water and 10 mg/mL elderberry) were continued 7 
days after the re-injection of cancer cells. 12 days following the re-injection of cancer 
cells, a control mouse succumbed to cancer. The tumor was removed for weighing and 
measuring. All other experimental mice were sacrificed the following day and tumors 
were removed for weighing and measuring. Spleens were also removed and prepared for 
a spleen cell proliferation assay.  Over the course of the experiment the weight of each 
young mouse gained weight, which is to be expected in young mice still growing.  Mouse 
weight averages for the elderberry treated and elderberry – no tumor group were not 
significantly different between each weighing day. Between the pre-tumor injection 
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weighing period and the final weighing period, the average control mouse weights were 
significantly different. Average control mouse weights increased significantly from 24.3 
grams to 27.0 grams between these two weighing periods (Figure 12).  
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Figure 12.  Body weight results for young tumor-bearing mice given control and 
elderberry treatments. Young mice were weighed on day 1 (initial), day 36 (pre-tumor) 
and day 50 (final). Asterisks represent a significant difference between two 
treatment/weighing period groups. 
 
 
 
 All six mice injected with B16-F10 cells developed tumors, which were removed 
after the mice were sacrificed. Two of the three control mouse tumors metastasized into 
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the peritoneal cavity, whereas all elderberry treated mouse tumors remained local. 
Elderberry treated tumor-bearing mice developed smaller tumors in weight and volume 
compared to the control mice, although not significantly different. The average weight 
and tumor volume of the control mice was 2.88g and 5.33 cm3, respectively. The average 
weight and tumor volume of the elderberry treated tumor-bearing mice was 0.54g and 
0.57 cm3, respectively (Table 10, Figure 13). 
 
Table 10. Average tumor weight and volume for all tumor-bearing mice in the young 
mouse in vivo murine model assay with crude elderberry. 
 
Treatment 
Group 
Tumor 
Weight (g) 
Tumor 
Volume (cm3) 
Average Tumor 
Weight (g) 
Average Tumor 
Volume (cm3) 
Control 1 0.02 0.02 
2.88 ± 1.46 5.33 ± 2.66 Control 2 4.83 8.18 
Control 3 3.78 7.79 
Elderberry 1 1.42 1.53 
0.54 ± 0.44 0.57 ± 0.48 Elderberry 2 0.14 0.17 
Elderberry 3 0.05 0.02 
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Figure 13. Tumor weight results for young tumor-bearing mice given control and 
elderberry treatments (n=3). 
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The spleens from all young mice were removed and prepared for a spleen cell 
proliferation assay with different concentrations of a known mitogen, Con A. The CPM 
measurements were averaged together amongst treatment groups and percent 
proliferation was determined based on the growth of resting (un-stimulated) control cells 
at 100%. For all treatment groups, there was a dose dependent increase in percent 
proliferation with increasing concentrations of mitogen up to 0.25 µg/mL Con A. There 
was no significant difference in percent proliferation induced by the different 
concentrations of mitogen between the groups (Table 11).  
 
 
Table 11. Young mouse spleen cell stimulation by Con A in the young mouse in vivo 
murine model assay with crude elderberry. 
. 
Young Mouse Treatment Cell Treatment CPM % Proliferation 
Control (n=3) 
Resting 1823 100% 
0.125 µg/mL Con A 4153 1023% 
0.25 µg/mL Con A 10534 2371% 
Elderberry (n=3) 
Resting 3295 100% 
0.125 µg/mL Con A 4301 458% 
0.25 µg/mL Con A 7674 834% 
Elderberry-No Tumor (n=3) 
Resting 448 100% 
0.125 µg/mL Con A 646 548% 
0.25 µg/mL Con A 2262 2209% 
 
 
 
Middle Aged Mouse in vivo Murine Melanoma Assay with Active Pooled Elderberry 
Fractions 
 
All mice were weighed at the start of the experiment, prior to s.c. injection of 
B16-F10 murine melanoma cells (or on the equivalent day) and prior to sacrifice. Mice 
from the 10 mg/mL crude elderberry treatment group started to show delayed reaction 
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time and weakness prior to tumor cell injection. Examination of the crude elderberry 
extract revealed a possible fungal contamination despite filter-sterilization. Mice from 
P16, P24, and P29 treatment groups also exhibited behavioral and physical changes post-
tumor cell injection, and were sacrificed prior to the end of the experiment. 
 
Preliminary Identification of Active Pooled Elderberry Fractions by Heat-Induced 
Denaturation in a B16-F10 Cell Proliferation Assay 
 
After examining the effect of pooled elderberry fractions on human and murine 
melanoma proliferation in vitro, as well as effect on T lymphocyte proliferation with 
optimal Con A in vitro, we identified Column #1 pooled fractions that were considered 
“active” in both tumor cell suppression and immune induction. Pool 7, 14, 16, and 29 
were chosen as active fractions in both tumor suppressive ability and immune modulating 
activity, and were subjected to boiling to denature the majority of the protein components 
of the pooled fractions. CPM measurements from the scintillation counter were analyzed, 
and the percent proliferation of elderberry treated cells was assessed based on the growth 
of the control cells at 100%. All treatments, excluding the 1 mg/mL crude unheated 
elderberry treatment, decreased B16-F10 cell proliferation significantly from the control. 
When the 10 mg/mL crude elderberry treatment was heated to induce denaturing of 
proteins, the proliferation of B16-F10 cells decreased significantly from 76.5% to 55.7%. 
The 1 mg/mL crude elderberry treatment also decreased proliferation of B16-F10 cells 
after heating from 90.1% proliferation to 77.7% proliferation, but the difference was not 
significant. Of the four chosen pooled fractions of interest, pool 14, pool 16 and pool 29 
showed a greater suppression of B16-F10 growth after being heated. Two of the Column 
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#1 pooled fractions decreased B16-F10 cell proliferation significantly after heating. 
When the pool 16 treatment was heated, the proliferation of B16-F10 cells decreased 
significantly from 29.6% to 12.7%. When the pool 29 treatment was heated, the 
proliferation of B16-F10 cells decreased significantly from 51.0% to 18.8% (Figure 14). 
Treatments were plated in triplicate and the experiment was repeated twice. 
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Figure 14. B16-F10 cell suppression by heated active pooled elderberry fractions. Single 
asterisks represent a significant proliferative difference vs. the control. Double asterisks 
represent a significant proliferative difference vs. the same elderberry fraction when 
heated (p<0.05) (n=2). 
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Preliminary Identification of Active Pooled Elderberry Fractions by Heat-Induced 
Denaturation in a Spleen Cell Proliferation Assay 
 
Heated treatments of Pool 7, 14, 16, and 29 were also used in a spleen cell 
proliferation assay to determine the effect of heated pooled fractions on senescent mouse 
spleen cell growth. CPM counts were analyzed, and the percent proliferation of 
elderberry treated cells was assessed based on the growth of the positive control cells 
(addition of 2.5 µL optimal Con A) at 100%. All treatments, with the exception of the 1 
mg/mL unheated crude elderberry treatment and the unheated pool 16 treatment, 
decreased spleen cell proliferation significantly from the positive control. When heated, 
the 10mg/mL and 1 mg/mL crude elderberry treatments did not elicit significant spleen 
cell proliferation differences compared to their respective unheated treatments.  Of all the 
pooled fractions investigated, only heated pooled fraction 16 differed significantly from 
its unheated treatment.  Heating pooled fraction 16 resulted in a decrease in spleen cell 
proliferation from 95.1% to 32.5% (Figure 12). Treatments were plated in triplicate and 
the experiment was repeated twice. 
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Figure 15. Senescent mouse spleen cell proliferation by heated active pooled elderberry 
fractions. Single asterisks represent a significant proliferative difference vs. the control. 
Double asterisks represent a significant proliferative difference vs. the same elderberry 
fraction when heated (p<0.05) (n=2). 
 
 
 
Identification of Active Pooled Elderberry Fractions by Reversed-Phase High-
Performance Liquid Chromatography (HPLC) 
 
The anthocyanin peaks of elderberry were eluted in the following order: cyanidin 
3-sambubioside-5-glucoside, cyanidin 3,5-diglucoside, cyanidin 3-sambubioside, and 
cyanidin 3-glucoside (Figure 16). Comparison to the nearly identical crude elderberry 
chromatogram reported by Youdim et al. (2000) validated the peak identities. 
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Comparing the pooled fractions chromatogram peaks for P16, P24, and P29 to the crude 
elderberry chromatogram, it was revealed that P16 contained 85% cyanidin 3-
sambubioside (Figure 17). Pool 24 contained a combination of 7% cyanidin 3-
sambubioside-5-glucoside, 18% cyanidin 3,5-diglucoside, 42% cyanidin 3-sambubioside, 
and 31% cyanidin 3-glucoside (Figure 18). P29 contained 83% cyanidin 3-glucoside 
(Figure 19). 
 
 
Figure 16. HPLC chromatogram of crude elderberry anthocyanins measured at 520 nm. 
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Figure 17. HPLC chromatogram of 1:50 diluted pooled fraction P16 anthocyanins 
measured at 520 nm. 
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Figure 18. HPLC chromatogram of 1:50 diluted pooled fraction P24 anthocyanins 
measured at 520 nm. 
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Figure 19. HPLC chromatogram of 1:50 diluted pooled fraction P29 anthocyanins 
measured at 520 nm. 
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DISCUSSION 
 
The use of bioactive foods as naturopathic treatments for many diseases and 
health conditions is a growing field of interest.  Phytochemicals from dark-pigmented 
berries have been the focus of many studies that examine natural therapeutic modulators 
of cardiac disease, neurological disease, viral infection, and cancers. The pathways and 
proteins affected by berry extracts that lead to their beneficial activity are still not well 
understood.  It was the objective of this research to identify the active components of 
elderberry capable of inhibiting melanoma cell proliferation in vitro and in vivo and to 
determine the effect of active elderberry components on T lymphocyte proliferation and 
IL-2 concentration.  The immune system plays an important role in tumor cell detection 
and removal. By inhibiting tumor cell growth directly and by increasing the immune 
response against cancerous cells by natural means, elderberry extracts could be a 
bioactive food of interest in the fight against cancer and other diseases. Also, this 
research aimed to chemically identify the active components of elderberry capable of 
eliciting this ‘dual-edged’ sword effect to further contribute to the growing field of 
alternative and complementary medicinal studies. 
Crude elderberry extracts and multiple pooled elderberry fractions exhibited 
tumor suppressive ability in both human and murine melanoma cell lines. The B16-F10 
cell proliferation assay demonstrated that all pooled elderberry fractions, as well as the 10 
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mg/mL crude elderberry sample, were able to significantly decrease melanoma cell 
growth in vitro compared to the control. Over half of the pooled elderberry fractions 
decreased B16-F10 cell proliferation more than the 10 mg/mL crude elderberry sample. 
These results suggest some of the separated components of elderberry are capable of 
inhibiting melanoma growth to a greater extent than crude elderberry treatments. All 
pooled fractions also significantly decreased human neuroblastoma cell proliferation, 
demonstrating the ubiquitous activity of the pooled fractions, suggesting that elderberry 
extracts may be useful in directly suppressing the growth of multiple cancers.  Once 
again, the 10 mg/mL crude elderberry sample also significantly decreased SH-SY5Y cell 
proliferation, but there were multiple pooled fractions that decreased SH-SY5Y cell 
proliferation to a greater degree. 
Interestingly, when crude and pooled elderberry fractions were added to CHO-K1 
noncancerous transformed cells, only 25 of the 39 pooled fractions decreased CHO-K1 
cells significantly, and both the 10 mg/mL and 1 mg/mL crude elderberry treatments did 
not significantly suppress transformed cell growth. Many of the pooled fractions that 
significantly decreased both B16-F10 and SH-SY5Y cell proliferation did not 
significantly suppress CHO-K1 cell growth in vitro, suggesting that the pooled fractions 
may have a more selective killing effect on cancerous cell lines compared to transformed, 
noncancerous cell lines.  
Elderly people are at a higher risk for illnesses, such as cancer, due to 
immunosenescence. Extracts from dark-pigmented berries may also have immune-
boosting benefits, which may indirectly lead to cancer cell suppression by augmenting 
proliferation of T lymphocytes and secretion of important cytokines, including IL-2. 
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Spleen cells from a mouse (11 months old) incubated with pooled fractions and Con A 
did not increase spleen cell proliferation greater than spleen cells incubated with Con A 
only, suggesting that 10 µL treatments may not be the optimal concentration of pooled 
fraction to increase spleen cell proliferation in this in vitro assay. When spleen cells from 
a young mouse (5 mounts old) and a senescent, retired breeder mouse (18 months old) 
were incubated with pooled fractions and Con A were compared, the results suggest that 
the same concentration of pooled sample increases spleen cell proliferation in senescent 
mice more than in young mice. The percent increase of senescent, retired breeder spleen 
cell proliferation compared to young mouse spleen cell proliferation ranged from a 3-
53% increase. These results demonstrate that pooled elderberry fractions may be able to 
induce T lymphocyte proliferation in elderly individuals, who are more susceptible to 
disease, compared to younger individuals, who are more likely to have maintained 
functional immunity.  Three pooled fractions incubated with Con A elicited a stronger IL-
2 response from mouse spleen cells compared to spleen cells incubated with Con A only 
in vitro, suggesting that these pooled fractions may act in an additive manner with Con A 
to affect the growth and differentiation of T lymphocytes. It is important to note that the 
three pooled fractions that increased IL-2 secretion also increased the proliferation of 
senescent, retired breeder mouse spleen cells between 13-33% when compared to young 
mouse spleen cell proliferation. 
To examine the tumor-suppressive ability of crude elderberry and certain pooled 
elderberry fractions in vivo, randomly sorted groups of mice were given either sterile 
water i.p. injections or 10 mg/mL crude elderberry or pooled elderberry i.p. injections. 
The initial and final weights of the mice were not significantly different from each other 
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across all treatment groups, suggesting that injection of elderberry samples does not have 
an adverse effect on mouse weight and health. On average, the tumors dissected from 
tumor-bearing senescent control mice were larger than the tumors dissected from tumor-
bearing senescent elderberry treated mice. Young mice were used in a second in vivo 
experiment and the tumors from tumor-bearing young control mice were on average 
larger than those dissected from tumor-bearing young mice given crude elderberry 
treatments. The increase in body weight of control mice pre-tumor injection and before 
sacrifice was significant, supporting the quantitative analysis of control mouse tumor 
weights. Also, 67% of young control mouse tumors metastasized into the peritoneal 
cavity, whereas all crude elderberry treatment mouse tumors remained local, suggesting 
that crude elderberry treatment may also decrease risk of tumor metastasis.  
In the murine in vivo experiment using pooled fractions P16, P24 and P29, mice 
treated with pooled fractions died before the end of the experiment, suggesting that the 
pooled fractions collection directly from the columns were too concentrated to be used in 
0.5 mL injection volumes. This result supports the idea that the pooled fractions from the 
column have more potent activity compared to the crude 10 mg/mL elderberry samples, 
and a diluted version of the pooled fractions should be used in future murine melanoma 
models.  
Preliminary identification of active components in pooled fractions was 
accomplished by heating pooled fractions to denature any proteins found within the 
pooled fractions. It was hypothesized that any active proteins would lose their function 
after heating, and would not suppress B16-F10 murine melanoma proliferation 
significantly. All treatments regardless of heating with the exception of the 1 mg/mL 
78 
 
crude elderberry non-heated sample significantly decreased proliferation of B16-F10 
cells in vitro, suggesting that the active component in these samples was not a protein. 
The 1 mg/mL crude elderberry sample was not expected to result in significant B16-F10 
cell proliferation based on previous studies.   Interestingly, heating the crude 10 mg/mL 
elderberry sample, as well as heating pooled fractions 16 and 29, further decreased the 
proliferation of B16-F10 cells significantly compared to their respective non-heated 
samples. Yue and Xu reported that heating anthocyanins extracted from bilberry, a 
similar dark-pigmented berry to elderberry, resulted in increased free radical scavenging 
ability (2008).  Heating anthocyanins can cleave the sugar moiety from the compound, 
producing the corresponding anthocyanidin, which are also much more effective in tumor 
killing compared to their respective anthocyanin (Jing, 2006). Another possible 
explanation for the increased tumor-inhibiting activity of heated pooled fractions is the 
presence of proteins that inhibit anthocyanins. When the pooled fractions are heated, 
these inhibitors of anthocyanins would be denatured. It was then hypothesized that the 
tumor suppressive and immune-increasing activity of the pooled fractions 16 and 29 
could be due to anthocyanins present in elderberry. 
When the same heated pooled fractions were applied to mouse spleen cells in a 
proliferation assay, the non-heated crude 1 mg/mL elderberry treatment and the non-
heated pool 16 treatment were the only treatments that did not significantly decrease 
spleen cell proliferation. These results suggest that the potency of the elderberry 
treatments increases upon heating, likely for the same reason tumor suppressive ability is 
increased. It is noted that the pool 16 non-heated treatment did not significantly affect 
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spleen cell proliferation, and validates further studies for the use of certain pooled 
fractions as immunotherapeutic agents to combat disease.  
To further identify the chemical identity of the active pooled elderberry fractions, 
a crude elderberry sample was first analyzed by HPLC to generate a chromatogram of the 
four primary anthocyanins present in elderberry. P16, P24, and P29 were diluted and 
analyzed using the same gradient elution as the crude elderberry analysis through HPLC. 
P16 contained 85% cyanidin 3-sambubioside (the third peak eluted from the crude 
elderberry sample), and P29 contained 83% cyanidin 3-glucoside (the fourth peak eluted 
from the crude elderberry sample).  These results support the hypothesis that many active 
components responsible for tumor suppression and immune cell modulation are 
anthocyanins in elderberry, and validate the need for further study regarding the 
medicinal properties of these naturally derived phytochemicals. There is still much to 
learn concerning the signal pathways affected in response to anthocyanin treatment, and 
an understanding of these interactions may lead to the identification of novel naturopathic 
treatments to prevent the onset of cancer and other diseases. 
Future directions for this research include identifying anti-metastatic activity of 
pooled elderberry fractions, characterization of additional immunological and antioxidant 
mechanisms affected by pooled elderberry fractions, and performing additional analytical 
chemistry methods to confirm with certainty the presence of anthocyanins in the pooled 
fractions, as well as additional factors in the pooled fractions. The severity of many 
cancers increases dramatically after metastatic events; therefore utilization of natural 
factors able to suppress metastatic events may lower the risk of fatal cancer development. 
Identification of metastasis-suppressing pooled fractions can be achieved by analyzing 
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suppression of matrix metalloproteinases (MMP), proteinases whose expression is 
overexpressed in cancerous cells and assist in degrading the extracellular matrix, 
facilitating invasion of cancerous cells into adjacent tissues. Matchett et al. were able to 
show that flavonoids from blueberries possessed the ability to inhibit matrix 
metalloproteinases in human prostate cancer cells (2005).  
Our studies have shown that pooled elderberry fractions directly prepared by 
column chromatography may be too concentrated to elicit a positive spleen cell 
proliferation response. Spleen cell proliferation assays utilizing dilution of the pooled 
elderberry fractions should be formed to determine an optimal concentration for spleen 
cell proliferation. There are many other immunological factors that may be affected by 
pooled elderberry fractions that have not yet been investigated. Studies involving other 
berry phytochemicals show promise in protecting cellular integrity by inhibiting VEGF 
receptor-2 phosphorylation (Lamy et al., 2006), and inhibiting the pro-survival function 
of NF-κB (Hafeez, et al., 2008). There is also a need for the examination of the disease-
preventative mechanisms implemented by pooled elderberry fractions and elderberry 
anthocyanins. One article by Youdim et al. shows evidence that elderberry anthocyanins 
may be useful to prevent DNA damage by protecting against oxidative stress (2000).   
Further analysis of the antioxidant activity of elderberry anthocyanins may further 
support the use of berry extracts as a preventative strategy against the onset of multiple 
diseases, including cancer.  
To be certain of the exact anthocyanins present in elderberry, nuclear magnetic 
resonance (NMR) and infrared spectroscopy (IR) can be performed to identify functional 
groups present in the phytochemicals’ structure by analyzing chemical shifts and 
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spectrum peaks, respectively. Mass spectroscopy (MS) may also be useful in 
differentiating anthocyanins and other phytochemicals based upon differing molecular 
weights. Acquisition of pure anthocyanin standards may also be used under identical 
HPLC gradient elution conditions, and the peaks from the consequent chromatogram 
could be compared to the peaks generated from pooled fraction chromatograms to 
validate the identity of the assumed anthocyanins. 
The results of this thesis work characterize the direct tumor killing activity of 
pooled elderberry fractions, touch on the immune inducing effects of the pooled 
elderberry fractions on spleen cell proliferation in senescent mice and on IL-2 secretion, 
and identify the major component of active pooled elderberry fractions as anthocyanins.  
Specifically, cyanidin 3-sambubioside and cyanidin 3-glucoside were the anthocyanins 
with the most beneficial activity concerning modulation of melanoma cancer cells. 
Further study using the fractions separated from elderberry may validate their use in 
immunotherapy and natural chemotherapy, as well as support their use as a disease-
preventative, naturopathic treatment for melanoma.  
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Appendix A: Tables 
Table A1. Results for B16-F10 cell proliferation assay with Column #2 individual samples.  
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 41389 100.0% N/A 
Average 10 mg/mL Elderberry 17683 42.7% N/A 
Average 1 mg/mL Elderberry 27227 65.8% N/A 
Column #2 Sample 1 52 0.1% 0% MeOH / 100% H2O 
Column #2 Sample 2 40 0.1% 0% MeOH / 100% H2O 
Column #2 Sample 3 49 0.1% 0% MeOH / 100% H2O 
Column #2 Sample 4 68 0.2% 0% MeOH / 100% H2O 
Column #2 Sample 5 67 0.2% 0% MeOH / 100% H2O 
Column #2 Sample 6 49 0.1% Transition 
Column #2 Sample 7 70 0.2% 10% MeOH / 90% H2O 
Column #2 Sample 8 56 0.1% 10% MeOH / 90% H2O 
Column #2 Sample 9 198 0.5% 10% MeOH / 90% H2O 
Column #2 Sample 10 11626 28.1% 10% MeOH / 90% H2O 
Column #2 Sample 11 21671 52.4% 10% MeOH / 90% H2O 
Column #2 Sample 12 43429 104.9% 10% MeOH / 90% H2O 
Column #2 Sample 13 57995 140.1% 10% MeOH / 90% H2O 
Column #2 Sample 14 53455 129.2% 10% MeOH / 90% H2O 
Column #2 Sample 15 46866 113.2% 10% MeOH / 90% H2O 
Column #2 Sample 16 38163 92.2% 10% MeOH / 90% H2O 
Column #2 Sample 17 38668 93.4% Transition 
Column #2 Sample 18 42985 103.9% 20% MeOH / 80% H2O 
Column #2 Sample 19 37350 90.2% 20% MeOH / 80% H2O 
Column #2 Sample 20 34672 83.8% 20% MeOH / 80% H2O 
Column #2 Sample 21 36727 88.7% 20% MeOH / 80% H2O 
Column #2 Sample 22 38948 94.1% 20% MeOH / 80% H2O 
Column #2 Sample 23 22393 54.1% 20% MeOH / 80% H2O 
Column #2 Sample 24 18475 44.6% 20% MeOH / 80% H2O 
Column #2 Sample 25 19836 47.9% 20% MeOH / 80% H2O 
Column #2 Sample 26 16295 39.4% 20% MeOH / 80% H2O 
Column #2 Sample 27 16069 38.8% 20% MeOH / 80% H2O 
Column #2 Sample 28 16769 40.5% transition 
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Table A1, continued. 
Column #2 Sample 29 13401 32.4% 30% MeOH / 70% H2O 
Column #2 Sample 30 15988 38.6% 30% MeOH / 70% H2O 
Column #2 Sample 31 19102 46.2% 30% MeOH / 70% H2O 
Column #2 Sample 32 34146 82.5% 30% MeOH / 70% H2O 
Column #2 Sample 33 40363 97.5% 30% MeOH / 70% H2O 
Column #2 Sample 34 34518 83.4% 30% MeOH / 70% H2O 
Column #2 Sample 35 32376 78.2% 30% MeOH / 70% H2O 
Column #2 Sample 36 27712 67.0% 30% MeOH / 70% H2O 
Column #2 Sample 37 24175 58.4% 30% MeOH / 70% H2O 
Column #2 Sample 38 29357 70.9% 30% MeOH / 70% H2O 
Column #2 Sample 39 21396 51.7% transition 
Column #2 Sample 40 24130 58.3% 40% MeOH / 60% H2O 
Column #2 Sample 41 25978 62.8% 40% MeOH / 60% H2O 
Column #2 Sample 42 6265 15.1% 40% MeOH / 60% H2O 
Column #2 Sample 43 8005 19.3% 40% MeOH / 60% H2O 
Column #2 Sample 44 4613 11.1% 40% MeOH / 60% H2O 
Column #2 Sample 45 3327 8.0% 40% MeOH / 60% H2O 
Column #2 Sample 46 3737 9.0% 40% MeOH / 60% H2O 
Column #2 Sample 47 3587 8.7% 40% MeOH / 60% H2O 
Column #2 Sample 48 4811 11.6% 40% MeOH / 60% H2O 
Column #2 Sample 49 1611 3.9% 40% MeOH / 60% H2O 
Column #2 Sample 50 3636 8.8% transition 
Column #2 Sample 51 4212 10.2% 50% MeOH / 50% H2O 
Column #2 Sample 52 7977 19.3% 50% MeOH / 50% H2O 
Column #2 Sample 53 14912 36.0% 50% MeOH / 50% H2O 
Column #2 Sample 54 15212 36.8% 50% MeOH / 50% H2O 
Column #2 Sample 55 10483 25.3% 50% MeOH / 50% H2O 
Column #2 Sample 56 4370 10.6% 50% MeOH / 50% H2O 
Column #2 Sample 57 19505 47.1% 50% MeOH / 50% H2O 
Column #2 Sample 58 8314 20.1% 50% MeOH / 50% H2O 
Column #2 Sample 59 7547 18.2% 50% MeOH / 50% H2O 
Column #2 Sample 60 5615 13.6% 50% MeOH / 50% H2O 
Column #2 Sample 61 13976 33.8% transition 
91 
 
Table A1, continued. 
Column #2 Sample 62 6791 16.4% 60% MeOH / 40% H2O 
Column #2 Sample 63 9372 22.6% 60% MeOH / 40% H2O 
Column #2 Sample 64 8700 21.0% 60% MeOH / 40% H2O 
Column #2 Sample 65 5255 12.7% 60% MeOH / 40% H2O 
Column #2 Sample 66 5581 13.5% 60% MeOH / 40% H2O 
Column #2 Sample 67 5857 14.2% 60% MeOH / 40% H2O 
Column #2 Sample 68 6547 15.8% 60% MeOH / 40% H2O 
Column #2 Sample 69 3245 7.8% 60% MeOH / 40% H2O 
Column #2 Sample 70 4334 10.5% 60% MeOH / 40% H2O 
Column #2 Sample 71 8620 20.8% 60% MeOH / 40% H2O 
Column #2 Sample 72 9938 24.0% transition 
Column #2 Sample 73 7389 17.9% 70% MeOH / 30% H2O 
Column #2 Sample 74 7646 18.5% 70% MeOH / 30% H2O 
Column #2 Sample 75 2927 7.1% 70% MeOH / 30% H2O 
Column #2 Sample 76 10150 24.5% 70% MeOH / 30% H2O 
Column #2 Sample 77 11414 27.6% 70% MeOH / 30% H2O 
Column #2 Sample 78 9093 22.0% 70% MeOH / 30% H2O 
Column #2 Sample 79 5901 14.3% 70% MeOH / 30% H2O 
Column #2 Sample 80 7182 17.4% 70% MeOH / 30% H2O 
Column #2 Sample 81 10759 26.0% 70% MeOH / 30% H2O 
Column #2 Sample 82 20702 50.0% 70% MeOH / 30% H2O 
Column #2 Sample 83 7671 18.5% transition 
Column #2 Sample 84 9516 23.0% 80% MeOH / 20% H2O 
Column #2 Sample 85 8466 20.5% 80% MeOH / 20% H2O 
Column #2 Sample 86 9052 21.9% 80% MeOH / 20% H2O 
Column #2 Sample 87 9220 22.3% 80% MeOH / 20% H2O 
Column #2 Sample 88 9585 23.2% 80% MeOH / 20% H2O 
Column #2 Sample 89 9996 24.2% 80% MeOH / 20% H2O 
Column #2 Sample 90 7352 17.8% 80% MeOH / 20% H2O 
Column #2 Sample 91 8670 20.9% 80% MeOH / 20% H2O 
Column #2 Sample 92 7188 17.4% 80% MeOH / 20% H2O 
Column #2 Sample 93 8284 20.0% 80% MeOH / 20% H2O 
Column #2 Sample 94 7498 18.1% transition 
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Table A1, continued. 
Column #2 Sample 95 6104 14.7% 90% MeOH / 10% H2O 
Column #2 Sample 96 6360 15.4% 90% MeOH / 10% H2O 
Column #2 Sample 97 5324 12.9% 90% MeOH / 10% H2O 
Column #2 Sample 98 6652 16.1% 90% MeOH / 10% H2O 
Column #2 Sample 99 5639 13.6% 90% MeOH / 10% H2O 
Column #2 Sample 100 6683 16.1% 90% MeOH / 10% H2O 
Column #2 Sample 101 6656 16.1% 90% MeOH / 10% H2O 
Column #2 Sample 102 2847 6.9% 90% MeOH / 10% H2O 
Column #2 Sample 103 6500 15.7% 90% MeOH / 10% H2O 
Column #2 Sample 104 7488 18.1% 90% MeOH / 10% H2O 
Column #2 Sample 105 6958 16.8% transition 
Column #2 Sample 106 6970 16.8% 100% MeOH / 0% H2O 
Column #2 Sample 107 4894 11.8% 100% MeOH / 0% H2O 
Column #2 Sample 108 7735 18.7% 100% MeOH / 0% H2O 
Column #2 Sample 109 5634 13.6% 100% MeOH / 0% H2O 
Column #2 Sample 110 1370 3.3% 100% MeOH / 0% H2O 
Column #2 Sample 111 5136 12.4% 100% MeOH / 0% H2O 
Column #2 Sample 112 7442 18.0% 100% MeOH / 0% H2O 
Column #2 Sample 113 9571 23.1% 100% MeOH / 0% H2O 
Column #2 Sample 114 16465 39.8% 100% MeOH / 0% H2O 
Column #2 Sample 115 15239 36.8% 100% MeOH / 0% H2O 
 
Table A2. Results for B16-F10 cell proliferation assay with Column #3 individual samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 48855 100.0% N/A 
Average 10 mg/mL Elderberry 31877 65.2% N/A 
Column #3 Sample 1 100 0.2% 0% MeOH / 100% H2O 
Column #3 Sample 2 69 0.1% 0% MeOH / 100% H2O 
Column #3 Sample 3 85 0.2% 0% MeOH / 100% H2O 
Column #3 Sample 4 65 0.1% 0% MeOH / 100% H2O 
Column #3 Sample 5 61 0.1% transition 
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Table A2, continued.  
Column #3 Sample 6 52 0.1% 10% MeOH / 90% H2O 
Column #3 Sample 7 54 0.1% 10% MeOH / 90% H2O 
Column #3 Sample 8 64 0.1% 10% MeOH / 90% H2O 
Column #3 Sample 9 244 0.5% 10% MeOH / 90% H2O 
Column #3 Sample 10 69 0.1% 10% MeOH / 90% H2O 
Column #3 Sample 11 43 0.1% 10% MeOH / 90% H2O 
Column #3 Sample 12 13649 27.9% 10% MeOH / 90% H2O 
Column #3 Sample 13 2674 5.5% 10% MeOH / 90% H2O 
Column #3 Sample 14 11562 23.7% 10% MeOH / 90% H2O 
Column #3 Sample 15 9050 18.5% 10% MeOH / 90% H2O 
Column #3 Sample 16 8006 16.4% transition 
Column #3 Sample 17 11162 22.8% 20% MeOH / 80% H2O 
Column #3 Sample 18 1659 3.4% 20% MeOH / 80% H2O 
Column #3 Sample 19 2280 4.7% 20% MeOH / 80% H2O 
Column #3 Sample 20 14223 29.1% 20% MeOH / 80% H2O 
Column #3 Sample 21 12928 26.5% 20% MeOH / 80% H2O 
Column #3 Sample 22 16241 33.2% 20% MeOH / 80% H2O 
Column #3 Sample 23 11254 23.0% 20% MeOH / 80% H2O 
Column #3 Sample 24 11069 22.7% 20% MeOH / 80% H2O 
Column #3 Sample 25 5619 11.5% 20% MeOH / 80% H2O 
Column #3 Sample 26 3316 6.8% 20% MeOH / 80% H2O 
Column #3 Sample 27 294 0.6% transition 
Column #3 Sample 28 7317 15.0% 30% MeOH / 70% H2O 
Column #3 Sample 29 8691 17.8% 30% MeOH / 70% H2O 
Column #3 Sample 30 86 0.2% 30% MeOH / 70% H2O 
Column #3 Sample 31 8667 17.7% 30% MeOH / 70% H2O 
Column #3 Sample 32 9341 19.1% 30% MeOH / 70% H2O 
Column #3 Sample 33 7536 15.4% 30% MeOH / 70% H2O 
Column #3 Sample 34 8465 17.3% 30% MeOH / 70% H2O 
Column #3 Sample 35 15733 32.2% 30% MeOH / 70% H2O 
Column #3 Sample 36 13755 28.2% 30% MeOH / 70% H2O 
Column #3 Sample 37 16576 33.9% 30% MeOH / 70% H2O 
Column #3 Sample 38 18992 38.9% transition 
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Table A2, continued. 
Column #3 Sample 39 19144 39.2% 40% MeOH / 60% H2O 
Column #3 Sample 40 19914 40.8% 40% MeOH / 60% H2O 
Column #3 Sample 41 21953 44.9% 40% MeOH / 60% H2O 
Column #3 Sample 42 20312 41.6% 40% MeOH / 60% H2O 
Column #3 Sample 43 17788 36.4% 40% MeOH / 60% H2O 
Column #3 Sample 44 14397 29.5% 40% MeOH / 60% H2O 
Column #3 Sample 45 5547 11.4% 40% MeOH / 60% H2O 
Column #3 Sample 46 6240 12.8% 40% MeOH / 60% H2O 
Column #3 Sample 47 7212 14.8% 40% MeOH / 60% H2O 
Column #3 Sample 48 9224 18.9% 40% MeOH / 60% H2O 
Column #3 Sample 49 3917 8.0% transition 
Column #3 Sample 50 7479 15.3% 50% MeOH / 50% H2O 
Column #3 Sample 51 6723 13.8% 50% MeOH / 50% H2O 
Column #3 Sample 52 7130 14.6% 50% MeOH / 50% H2O 
Column #3 Sample 53 2007 4.1% 50% MeOH / 50% H2O 
Column #3 Sample 54 4960 10.2% 50% MeOH / 50% H2O 
Column #3 Sample 55 15970 32.7% 50% MeOH / 50% H2O 
Column #3 Sample 56 11037 22.6% 50% MeOH / 50% H2O 
Column #3 Sample 57 11154 22.8% 50% MeOH / 50% H2O 
Column #3 Sample 58 9427 19.3% 50% MeOH / 50% H2O 
Column #3 Sample 59 15286 31.3% 50% MeOH / 50% H2O 
Column #3 Sample 60 9966 20.4% transition 
Column #3 Sample 61 7618 15.6% 60% MeOH / 40% H2O 
Column #3 Sample 62 7290 14.9% 60% MeOH / 40% H2O 
Column #3 Sample 63 7004 14.3% 60% MeOH / 40% H2O 
Column #3 Sample 64 8185 16.8% 60% MeOH / 40% H2O 
Column #3 Sample 65 1425 2.9% 60% MeOH / 40% H2O 
Column #3 Sample 66 5005 10.2% 60% MeOH / 40% H2O 
Column #3 Sample 67 5655 11.6% 60% MeOH / 40% H2O 
Column #3 Sample 68 63 0.1% 60% MeOH / 40% H2O 
Column #3 Sample 69 1906 3.9% 60% MeOH / 40% H2O 
Column #3 Sample 70 5717 11.7% 60% MeOH / 40% H2O 
Column #3 Sample 71 3692 7.6% transition 
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Table A2, continued. 
Column #3 Sample 72 2402 4.9% 70% MeOH / 30% H2O 
Column #3 Sample 73 3349 6.9% 70% MeOH / 30% H2O 
Column #3 Sample 74 3425 7.0% 70% MeOH / 30% H2O 
Column #3 Sample 75 13975 28.6% 70% MeOH / 30% H2O 
Column #3 Sample 76 5787 11.8% 70% MeOH / 30% H2O 
Column #3 Sample 77 7543 15.4% 70% MeOH / 30% H2O 
Column #3 Sample 78 9988 20.4% 70% MeOH / 30% H2O 
Column #3 Sample 79 7923 16.2% 70% MeOH / 30% H2O 
Column #3 Sample 80 9032 18.5% 70% MeOH / 30% H2O 
Column #3 Sample 81 16001 32.8% 70% MeOH / 30% H2O 
Column #3 Sample 82 9316 19.1% transition 
Column #3 Sample 83 11196 22.9% 80% MeOH / 20% H2O 
Column #3 Sample 84 646 1.3% 80% MeOH / 20% H2O 
Column #3 Sample 85 13387 27.4% 80% MeOH / 20% H2O 
Column #3 Sample 86 9133 18.7% 80% MeOH / 20% H2O 
Column #3 Sample 87 9703 19.9% 80% MeOH / 20% H2O 
Column #3 Sample 88 13082 26.8% 80% MeOH / 20% H2O 
Column #3 Sample 89 11094 22.7% 80% MeOH / 20% H2O 
Column #3 Sample 90 11020 22.6% 80% MeOH / 20% H2O 
Column #3 Sample 91 12612 25.8% 80% MeOH / 20% H2O 
 
Table A3. Results for B16-F10 cell proliferation assay with Column #4 individual samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 36128 100.0% N/A 
Average 10 mg/mL Elderberry 12873 35.6% N/A 
Column #4 Sample 1 75 0.2% 0% MeOH / 100% H2O 
Column #4 Sample 2 70 0.2% 0% MeOH / 100% H2O 
Column #4 Sample 3 68 0.2% 0% MeOH / 100% H2O 
Column #4 Sample 4 75 0.2% 0% MeOH / 100% H2O 
Column #4 Sample 5 42 0.1% 0% MeOH / 100% H2O 
Column #4 Sample 6 35 0.1% 0% MeOH / 100% H2O 
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Table A3, continued.  
Column #4 Sample 7 52 0.1% transition 
Column #4 Sample 8 51 0.1% 10% MeOH / 90% H2O 
Column #4 Sample 9 67 0.2% 10% MeOH / 90% H2O 
Column #4 Sample 10 54 0.1% 10% MeOH / 90% H2O 
Column #4 Sample 11 58 0.2% 10% MeOH / 90% H2O 
Column #4 Sample 12 37236 103.1% 10% MeOH / 90% H2O 
Column #4 Sample 13 2564 7.1% 10% MeOH / 90% H2O 
Column #4 Sample 14 440 1.2% 10% MeOH / 90% H2O 
Column #4 Sample 15 660 1.8% 10% MeOH / 90% H2O 
Column #4 Sample 16 98 0.3% 10% MeOH / 90% H2O 
Column #4 Sample 17 35767 99.0% 10% MeOH / 90% H2O 
Column #4 Sample 18 206 0.6% transition 
Column #4 Sample 19 2019 5.6% 20% MeOH / 80% H2O 
Column #4 Sample 20 7177 19.9% 20% MeOH / 80% H2O 
Column #4 Sample 21 11739 32.5% 20% MeOH / 80% H2O 
Column #4 Sample 22 14218 39.4% 20% MeOH / 80% H2O 
Column #4 Sample 23 4583 12.7% 20% MeOH / 80% H2O 
Column #4 Sample 24 2460 6.8% 20% MeOH / 80% H2O 
Column #4 Sample 25 18601 51.5% 20% MeOH / 80% H2O 
Column #4 Sample 26 23554 65.2% 20% MeOH / 80% H2O 
Column #4 Sample 27 21861 60.5% 20% MeOH / 80% H2O 
Column #4 Sample 28 13477 37.3% 20% MeOH / 80% H2O 
Column #4 Sample 29 16261 45.0% transition 
Column #4 Sample 30 16639 46.1% 30% MeOH / 70% H2O 
Column #4 Sample 31 11518 31.9% 30% MeOH / 70% H2O 
Column #4 Sample 32 10965 30.4% 30% MeOH / 70% H2O 
Column #4 Sample 33 10781 29.8% 30% MeOH / 70% H2O 
Column #4 Sample 34 1584 4.4% 30% MeOH / 70% H2O 
Column #4 Sample 35 6532 18.1% 30% MeOH / 70% H2O 
Column #4 Sample 36 28360 78.5% 30% MeOH / 70% H2O 
Column #4 Sample 37 25265 69.9% 30% MeOH / 70% H2O 
Column #4 Sample 38 10496 29.1% 30% MeOH / 70% H2O 
Column #4 Sample 39 21896 60.6% 30% MeOH / 70% H2O 
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Table A3, continued. 
 
Column #4 Sample 40 27133 75.1% transition 
Column #4 Sample 41 23016 63.7% 40% MeOH / 60% H2O 
Column #4 Sample 42 21787 60.3% 40% MeOH / 60% H2O 
Column #4 Sample 43 29564 81.8% 40% MeOH / 60% H2O 
Column #4 Sample 44 22981 63.6% 40% MeOH / 60% H2O 
Column #4 Sample 45 40393 111.8% 40% MeOH / 60% H2O 
Column #4 Sample 46 33031 91.4% 40% MeOH / 60% H2O 
Column #4 Sample 47 29565 81.8% 40% MeOH / 60% H2O 
Column #4 Sample 48 30023 83.1% 40% MeOH / 60% H2O 
Column #4 Sample 49 22881 63.3% 40% MeOH / 60% H2O 
Column #4 Sample 50 22783 63.1% 40% MeOH / 60% H2O 
Column #4 Sample 51 18265 50.6% transition 
Column #4 Sample 52 19646 54.4% 50% MeOH / 50% H2O 
Column #4 Sample 53 19862 55.0% 50% MeOH / 50% H2O 
Column #4 Sample 54 16143 44.7% 50% MeOH / 50% H2O 
Column #4 Sample 55 213 0.6% 50% MeOH / 50% H2O 
Column #4 Sample 56 3524 9.8% 50% MeOH / 50% H2O 
Column #4 Sample 57 87 0.2% 50% MeOH / 50% H2O 
Column #4 Sample 58 13566 37.5% 50% MeOH / 50% H2O 
Column #4 Sample 59 15813 43.8% 50% MeOH / 50% H2O 
Column #4 Sample 60 20294 56.2% 50% MeOH / 50% H2O 
Column #4 Sample 61 23564 65.2% transition 
Column #4 Sample 62 21322 59.0% 60% MeOH / 40% H2O 
Column #4 Sample 63 21500 59.5% 60% MeOH / 40% H2O 
Column #4 Sample 64 14928 41.3% 60% MeOH / 40% H2O 
Column #4 Sample 65 17772 49.2% 60% MeOH / 40% H2O 
Column #4 Sample 66 14859 41.1% 60% MeOH / 40% H2O 
Column #4 Sample 67 17263 47.8% 60% MeOH / 40% H2O 
Column #4 Sample 68 16293 45.1% 60% MeOH / 40% H2O 
Column #4 Sample 69 14354 39.7% 60% MeOH / 40% H2O 
Column #4 Sample 70 13414 37.1% 60% MeOH / 40% H2O 
Column #4 Sample 71 12798 35.4% 60% MeOH / 40% H2O 
Column #4 Sample 72 7566 20.9% transition 
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Table A3, continued. 
Column #4 Sample 73 1323 3.7% 70% MeOH / 30% H2O 
Column #4 Sample 74 1091 3.0% 70% MeOH / 30% H2O 
Column #4 Sample 75 11731 32.5% 70% MeOH / 30% H2O 
Column #4 Sample 76 14640 40.5% 70% MeOH / 30% H2O 
Column #4 Sample 77 15418 42.7% 70% MeOH / 30% H2O 
Column #4 Sample 78 19787 54.8% 70% MeOH / 30% H2O 
Column #4 Sample 79 23174 64.1% 70% MeOH / 30% H2O 
Column #4 Sample 80 18114 50.1% 70% MeOH / 30% H2O 
Column #4 Sample 81 24605 68.1% 70% MeOH / 30% H2O 
Column #4 Sample 82 13562 37.5% 70% MeOH / 30% H2O 
Column #4 Sample 83 23604 65.3% transition 
Column #4 Sample 84 17434 48.3% 80% MeOH / 20% H2O 
Column #4 Sample 85 15350 42.5% 80% MeOH / 20% H2O 
Column #4 Sample 86 11827 32.7% 80% MeOH / 20% H2O 
Column #4 Sample 87 16919 46.8% 80% MeOH / 20% H2O 
Column #4 Sample 88 14823 41.0% 80% MeOH / 20% H2O 
Column #4 Sample 89 23519 65.1% 80% MeOH / 20% H2O 
Column #4 Sample 90 22277 61.7% 80% MeOH / 20% H2O 
Column #4 Sample 91 14378 39.8% 80% MeOH / 20% H2O 
Column #4 Sample 92 24157 66.9% 80% MeOH / 20% H2O 
Column #4 Sample 93 32431 89.8% 80% MeOH / 20% H2O 
 
Table A4. Results for B16-F10 cell proliferation assay with Column #5 individual samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 48315 100.0% N/A 
Average 10 mg/mL Elderberry 33912 70.2% N/A 
Column #5 Sample 1 77 0.2% 0% MeOH / 100% H2O 
Column #5 Sample 2 48 0.1% 0% MeOH / 100% H2O 
Column #5 Sample 3 82 0.2% 0% MeOH / 100% H2O 
Column #5 Sample 4 80 0.2% 0% MeOH / 100% H2O 
Column #5 Sample 5 44 0.1% 0% MeOH / 100% H2O 
99 
 
Table A4, continued. 
Column #5 Sample 6 46 0.1% transition  
Column #5 Sample 7 32 0.1% 10% MeOH / 90% H2O  
Column #5 Sample 8 53 0.1% 10% MeOH / 90% H2O  
Column #5 Sample 9 76 0.2% 10% MeOH / 90% H2O  
Column #5 Sample 10 147 0.3% 10% MeOH / 90% H2O  
Column #5 Sample 11 27986 57.9% 10% MeOH / 90% H2O  
Column #5 Sample 12 180 0.4% 10% MeOH / 90% H2O  
Column #5 Sample 13 117 0.2% 10% MeOH / 90% H2O  
Column #5 Sample 14 7681 15.9% 10% MeOH / 90% H2O  
Column #5 Sample 15 722 1.5% 10% MeOH / 90% H2O  
Column #5 Sample 16 720 1.5% 10% MeOH / 90% H2O  
Column #5 Sample 17 1246 2.6% transition  
Column #5 Sample 18 10105 20.9% 20% MeOH / 80% H2O  
Column #5 Sample 19 17666 36.6% 20% MeOH / 80% H2O  
Column #5 Sample 20 22182 45.9% 20% MeOH / 80% H2O  
Column #5 Sample 21 22374 46.3% 20% MeOH / 80% H2O  
Column #5 Sample 22 16252 33.6% 20% MeOH / 80% H2O  
Column #5 Sample 23 18966 39.3% 20% MeOH / 80% H2O  
Column #5 Sample 24 7072 14.6% 20% MeOH / 80% H2O  
Column #5 Sample 25 14584 30.2% 20% MeOH / 80% H2O  
Column #5 Sample 26 16278 33.7% 20% MeOH / 80% H2O  
Column #5 Sample 27 14841 30.7% 20% MeOH / 80% H2O  
Column #5 Sample 28 22224 46.0% transition  
Column #5 Sample 29 14674 30.4% 30% MeOH / 70% H2O  
Column #5 Sample 30 617 1.3% 30% MeOH / 70% H2O  
Column #5 Sample 31 1631 3.4% 30% MeOH / 70% H2O  
Column #5 Sample 32 8683 18.0% 30% MeOH / 70% H2O  
Column #5 Sample 33 12052 24.9% 30% MeOH / 70% H2O  
Column #5 Sample 34 1749 3.6% 30% MeOH / 70% H2O  
Column #5 Sample 35 35387 73.2% 30% MeOH / 70% H2O  
Column #5 Sample 36 25290 52.3% 30% MeOH / 70% H2O  
Column #5 Sample 37 24141 50.0% 30% MeOH / 70% H2O  
Column #5 Sample 38 23159 47.9% 30% MeOH / 70% H2O  
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Table A4, continued. 
Column #5 Sample 39 29120 60.3% transition 
Column #5 Sample 40 31903 66.0% 40% MeOH / 60% H2O 
Column #5 Sample 41 30018 62.1% 40% MeOH / 60% H2O 
Column #5 Sample 42 313 0.6% 40% MeOH / 60% H2O 
Column #5 Sample 43 13872 28.7% 40% MeOH / 60% H2O 
Column #5 Sample 44 6725 13.9% 40% MeOH / 60% H2O 
Column #5 Sample 45 20648 42.7% 40% MeOH / 60% H2O 
Column #5 Sample 46 17246 35.7% 40% MeOH / 60% H2O 
Column #5 Sample 47 11460 23.7% 40% MeOH / 60% H2O 
Column #5 Sample 48 17664 36.6% 40% MeOH / 60% H2O 
Column #5 Sample 49 17138 35.5% 40% MeOH / 60% H2O 
Column #5 Sample 50 13097 27.1% transition 
Column #5 Sample 51 9958 20.6% 50% MeOH / 50% H2O 
Column #5 Sample 52 7149 14.8% 50% MeOH / 50% H2O 
Column #5 Sample 53 3593 7.4% 50% MeOH / 50% H2O 
Column #5 Sample 54 352 0.7% 50% MeOH / 50% H2O 
Column #5 Sample 55 17534 36.3% 50% MeOH / 50% H2O 
Column #5 Sample 56 22791 47.2% 50% MeOH / 50% H2O 
Column #5 Sample 57 222 0.5% 50% MeOH / 50% H2O 
Column #5 Sample 58 16631 34.4% 50% MeOH / 50% H2O 
Column #5 Sample 59 26417 54.7% 50% MeOH / 50% H2O 
Column #5 Sample 60 19664 40.7% 50% MeOH / 50% H2O 
Column #5 Sample 61 17836 36.9% transition 
Column #5 Sample 62 16880 34.9% 60% MeOH / 40% H2O 
Column #5 Sample 63 3543 7.3% 60% MeOH / 40% H2O 
Column #5 Sample 64 13138 27.2% 60% MeOH / 40% H2O 
Column #5 Sample 65 8554 17.7% 60% MeOH / 40% H2O 
Column #5 Sample 66 54 0.1% 60% MeOH / 40% H2O 
Column #5 Sample 67 8662 17.9% 60% MeOH / 40% H2O 
Column #5 Sample 68 7012 14.5% 60% MeOH / 40% H2O 
Column #5 Sample 69 4733 9.8% 60% MeOH / 40% H2O 
Column #5 Sample 70 4136 8.6% 60% MeOH / 40% H2O 
Column #5 Sample 71 7241 15.0% 60% MeOH / 40% H2O 
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Table A4, continued. 
Column #5 Sample 72 3198 6.6% transition 
Column #5 Sample 73 2076 4.3% 70% MeOH / 30% H2O 
Column #5 Sample 74 2774 5.7% 70% MeOH / 30% H2O 
Column #5 Sample 75 16474 34.1% 70% MeOH / 30% H2O 
Column #5 Sample 76 2828 5.9% 70% MeOH / 30% H2O 
Column #5 Sample 77 10486 21.7% 70% MeOH / 30% H2O 
Column #5 Sample 78 5097 10.5% 70% MeOH / 30% H2O 
Column #5 Sample 79 4028 8.3% 70% MeOH / 30% H2O 
Column #5 Sample 80 9730 20.1% 70% MeOH / 30% H2O 
Column #5 Sample 81 1890 3.9% 70% MeOH / 30% H2O 
Column #5 Sample 82 6088 12.6% 70% MeOH / 30% H2O 
Column #5 Sample 83 491 1.0% transition 
Column #5 Sample 84 7037 14.6% 80% MeOH / 20% H2O 
Column #5 Sample 85 1057 2.2% 80% MeOH / 20% H2O 
Column #5 Sample 86 1480 3.1% 80% MeOH / 20% H2O 
Column #5 Sample 87 97 0.2% 80% MeOH / 20% H2O 
Column #5 Sample 88 860 1.8% 80% MeOH / 20% H2O 
Column #5 Sample 89 479 1.0% 80% MeOH / 20% H2O 
Column #5 Sample 90 512 1.1% 80% MeOH / 20% H2O 
Column #5 Sample 91 1145 2.4% 80% MeOH / 20% H2O 
Column #5 Sample 92 261 0.5% 80% MeOH / 20% H2O 
 
Table A5. Results for B16-F10 cell proliferation assay with Column #6 individual samples. 
Sample Identity CPM %Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 47472 100.0% N/A 
Average 10 mg/mL Elderberry 26053 54.9% N/A 
Column #6 Sample 1 66 0.1% 0% MeOH / 100% H2O 
Column #6 Sample 2 73 0.2% 0% MeOH / 100% H2O 
Column #6 Sample 3 60 0.1% 0% MeOH / 100% H2O 
Column #6 Sample 4 60 0.1% 0% MeOH / 100% H2O 
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Table A5, continued. 
Column #6 Sample 5 61 0.1% 0% MeOH / 100% H2O 
Column #6 Sample 6 57 0.1% transition 
Column #6 Sample 7 61 0.1% 10% MeOH / 90% H2O 
Column #6 Sample 8 73 0.2% 10% MeOH / 90% H2O 
Column #6 Sample 9 112 0.2% 10% MeOH / 90% H2O 
Column #6 Sample 10 1004 2.1% 10% MeOH / 90% H2O 
Column #6 Sample 11 64 0.1% 10% MeOH / 90% H2O 
Column #6 Sample 12 63 0.1% 10% MeOH / 90% H2O 
Column #6 Sample 13 5621 11.8% 10% MeOH / 90% H2O 
Column #6 Sample 14 6056 12.8% 10% MeOH / 90% H2O 
Column #6 Sample 15 6394 13.5% 10% MeOH / 90% H2O 
Column #6 Sample 16 8497 17.9% 10% MeOH / 90% H2O 
Column #6 Sample 17 856 1.8% transition 
Column #6 Sample 18 17027 35.9% 20% MeOH / 80% H2O 
Column #6 Sample 19 12150 25.6% 20% MeOH / 80% H2O 
Column #6 Sample 20 13565 28.6% 20% MeOH / 80% H2O 
Column #6 Sample 21 11891 25.0% 20% MeOH / 80% H2O 
Column #6 Sample 22 3724 7.8% 20% MeOH / 80% H2O 
Column #6 Sample 23 1235 2.6% 20% MeOH / 80% H2O 
Column #6 Sample 24 3363 7.1% 20% MeOH / 80% H2O 
Column #6 Sample 25 1424 3.0% 20% MeOH / 80% H2O 
Column #6 Sample 26 95 0.2% 20% MeOH / 80% H2O 
Column #6 Sample 27 12295 25.9% 20% MeOH / 80% H2O 
Column #6 Sample 28 9620 20.3% transition 
Column #6 Sample 29 10880 22.9% 30% MeOH / 70% H2O 
Column #6 Sample 30 10115 21.3% 30% MeOH / 70% H2O 
Column #6 Sample 31 846 1.8% 30% MeOH / 70% H2O 
Column #6 Sample 32 7110 15.0% 30% MeOH / 70% H2O 
Column #6 Sample 33 513 1.1% 30% MeOH / 70% H2O 
Column #6 Sample 34 1434 3.0% 30% MeOH / 70% H2O 
Column #6 Sample 35 12870 27.1% 30% MeOH / 70% H2O 
Column #6 Sample 36 16047 33.8% 30% MeOH / 70% H2O 
Column #6 Sample 37 15847 33.4% 30% MeOH / 70% H2O 
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Table A5, continued. 
Column #6 Sample 38 94 0.2% 30% MeOH / 70% H2O 
Column #6 Sample 39 157 0.3% transition 
Column #6 Sample 40 13930 29.3% 40% MeOH / 60% H2O 
Column #6 Sample 41 18414 38.8% 40% MeOH / 60% H2O 
Column #6 Sample 42 12110 25.5% 40% MeOH / 60% H2O 
Column #6 Sample 43 6395 13.5% 40% MeOH / 60% H2O 
Column #6 Sample 44 794 1.7% 40% MeOH / 60% H2O 
Column #6 Sample 45 4639 9.8% 40% MeOH / 60% H2O 
Column #6 Sample 46 410 0.9% 40% MeOH / 60% H2O 
Column #6 Sample 47 3623 7.6% 40% MeOH / 60% H2O 
Column #6 Sample 48 1198 2.5% 40% MeOH / 60% H2O 
Column #6 Sample 49 2306 4.9% 40% MeOH / 60% H2O 
Column #6 Sample 50 821 1.7% transition 
Column #6 Sample 51 1162 2.4% 50% MeOH / 50% H2O 
Column #6 Sample 52 267 0.6% 50% MeOH / 50% H2O 
Column #6 Sample 53 712 1.5% 50% MeOH / 50% H2O 
Column #6 Sample 54 631 1.3% 50% MeOH / 50% H2O 
Column #6 Sample 55 13835 29.1% 50% MeOH / 50% H2O 
Column #6 Sample 56 6754 14.2% 50% MeOH / 50% H2O 
Column #6 Sample 57 5390 11.4% 50% MeOH / 50% H2O 
Column #6 Sample 58 5701 12.0% 50% MeOH / 50% H2O 
Column #6 Sample 59 7093 14.9% 50% MeOH / 50% H2O 
Column #6 Sample 60 5289 11.1% 50% MeOH / 50% H2O 
Column #6 Sample 61 9456 19.9% transition 
Column #6 Sample 62 3998 8.4% 60% MeOH / 40% H2O 
Column #6 Sample 63 7868 16.6% 60% MeOH / 40% H2O 
Column #6 Sample 64 5036 10.6% 60% MeOH / 40% H2O 
Column #6 Sample 65 3215 6.8% 60% MeOH / 40% H2O 
Column #6 Sample 66 3260 6.9% 60% MeOH / 40% H2O 
Column #6 Sample 67 3374 7.1% 60% MeOH / 40% H2O 
Column #6 Sample 68 2709 5.7% 60% MeOH / 40% H2O 
Column #6 Sample 69 2491 5.2% 60% MeOH / 40% H2O 
Column #6 Sample 70 1261 2.7% 60% MeOH / 40% H2O 
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Table A5, continued. 
Column #6 Sample 71 1843 3.9% 60% MeOH / 40% H2O 
Column #6 Sample 72 825 1.7% transition 
Column #6 Sample 73 758 1.6% 70% MeOH / 30% H2O 
Column #6 Sample 74 857 1.8% 70% MeOH / 30% H2O 
Column #6 Sample 75 5002 10.5% 70% MeOH / 30% H2O 
Column #6 Sample 76 9578 20.2% 70% MeOH / 30% H2O 
Column #6 Sample 77 9248 19.5% 70% MeOH / 30% H2O 
Column #6 Sample 78 12537 26.4% 70% MeOH / 30% H2O 
Column #6 Sample 79 2830 6.0% 70% MeOH / 30% H2O 
Column #6 Sample 80 8937 18.8% 70% MeOH / 30% H2O 
Column #6 Sample 81 10465 22.0% 70% MeOH / 30% H2O 
Column #6 Sample 82 14247 30.0% 70% MeOH / 30% H2O 
Column #6 Sample 83 11608 24.5% transition 
Column #6 Sample 84 4704 9.9% 80% MeOH / 20% H2O 
Column #6 Sample 85 6945 14.6% 80% MeOH / 20% H2O 
Column #6 Sample 86 500 1.1% 80% MeOH / 20% H2O 
Column #6 Sample 87 92 0.2% 80% MeOH / 20% H2O 
Column #6 Sample 88 56 0.1% 80% MeOH / 20% H2O 
Column #6 Sample 89 70 0.1% 80% MeOH / 20% H2O 
 
Table A6. Results for B16-F10 cell proliferation assay with Column #7 individual samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 40183 100.0% N/A 
Average 10 mg/mL Elderberry 24796 61.7% N/A 
Column #7 Sample 1 105 0.3% 0% MeOH / 100% H2O 
Column #7 Sample 2 67 0.2% 0% MeOH / 100% H2O 
Column #7 Sample 3 64 0.2% 0% MeOH / 100% H2O 
Column #7 Sample 4 41 0.1% 0% MeOH / 100% H2O 
Column #7 Sample 5 62 0.2% 0% MeOH / 100% H2O 
Column #7 Sample 6 76 0.2% transition 
Column #7 Sample 7 86 0.2% 10% MeOH / 90% H2O 
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Table A6, continued. 
Column #7 Sample 8 86 0.2% 10% MeOH / 90% H2O 
Column #7 Sample 9 80 0.2% 10% MeOH / 90% H2O 
Column #7 Sample 10 66 0.2% 10% MeOH / 90% H2O 
Column #7 Sample 11 6346 15.8% 10% MeOH / 90% H2O 
Column #7 Sample 12 4230 10.5% 10% MeOH / 90% H2O 
Column #7 Sample 13 41 0.1% 10% MeOH / 90% H2O 
Column #7 Sample 14 94 0.2% 10% MeOH / 90% H2O 
Column #7 Sample 15 194 0.5% 10% MeOH / 90% H2O 
Column #7 Sample 16 1093 2.7% 10% MeOH / 90% H2O 
Column #7 Sample 17 122 0.3% transition 
Column #7 Sample 18 140 0.3% 20% MeOH / 80% H2O 
Column #7 Sample 19 91 0.2% 20% MeOH / 80% H2O 
Column #7 Sample 20 364 0.9% 20% MeOH / 80% H2O 
Column #7 Sample 21 8303 20.7% 20% MeOH / 80% H2O 
Column #7 Sample 22 5913 14.7% 20% MeOH / 80% H2O 
Column #7 Sample 23 345 0.9% 20% MeOH / 80% H2O 
Column #7 Sample 24 259 0.6% 20% MeOH / 80% H2O 
Column #7 Sample 25 9712 24.2% 20% MeOH / 80% H2O 
Column #7 Sample 26 9018 22.4% 20% MeOH / 80% H2O 
Column #7 Sample 27 12454 31.0% 20% MeOH / 80% H2O 
Column #7 Sample 28 9379 23.3% transition 
Column #7 Sample 29 6238 15.5% 30% MeOH / 70% H2O 
Column #7 Sample 30 6522 16.2% 30% MeOH / 70% H2O 
Column #7 Sample 31 8729 21.7% 30% MeOH / 70% H2O 
Column #7 Sample 32 6311 15.7% 30% MeOH / 70% H2O 
Column #7 Sample 33 9834 24.5% 30% MeOH / 70% H2O 
Column #7 Sample 34 657 1.6% 30% MeOH / 70% H2O 
Column #7 Sample 35 16776 41.7% 30% MeOH / 70% H2O 
Column #7 Sample 36 8854 22.0% 30% MeOH / 70% H2O 
Column #7 Sample 37 18773 46.7% 30% MeOH / 70% H2O 
Column #7 Sample 38 17193 42.8% 30% MeOH / 70% H2O 
Column #7 Sample 39 13997 34.8% transition 
Column #7 Sample 40 9963 24.8% 40% MeOH / 60% H2O 
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Table A6, continued. 
Column #7 Sample 41 7878 19.6% 40% MeOH / 60% H2O 
Column #7 Sample 42 7285 18.1% 40% MeOH / 60% H2O 
Column #7 Sample 43 6543 16.3% 40% MeOH / 60% H2O 
Column #7 Sample 44 1636 4.1% 40% MeOH / 60% H2O 
Column #7 Sample 45 9208 22.9% 40% MeOH / 60% H2O 
Column #7 Sample 46 6973 17.4% 40% MeOH / 60% H2O 
Column #7 Sample 47 4294 10.7% 40% MeOH / 60% H2O 
Column #7 Sample 48 4379 10.9% 40% MeOH / 60% H2O 
Column #7 Sample 49 8550 21.3% 40% MeOH / 60% H2O 
Column #7 Sample 50 1563 3.9% transition 
Column #7 Sample 51 1212 3.0% 50% MeOH / 50% H2O 
Column #7 Sample 52 192 0.5% 50% MeOH / 50% H2O 
Column #7 Sample 53 231 0.6% 50% MeOH / 50% H2O 
Column #7 Sample 54 264 0.7% 50% MeOH / 50% H2O 
Column #7 Sample 55 14907 37.1% 50% MeOH / 50% H2O 
Column #7 Sample 56 18244 45.4% 50% MeOH / 50% H2O 
Column #7 Sample 57 6622 16.5% 50% MeOH / 50% H2O 
Column #7 Sample 58 12692 31.6% 50% MeOH / 50% H2O 
Column #7 Sample 59 7532 18.7% 50% MeOH / 50% H2O 
Column #7 Sample 60 7555 18.8% 50% MeOH / 50% H2O 
Column #7 Sample 61 10246 25.5% transition 
Column #7 Sample 62 8713 21.7% 60% MeOH / 40% H2O 
Column #7 Sample 63 8026 20.0% 60% MeOH / 40% H2O 
Column #7 Sample 64 2439 6.1% 60% MeOH / 40% H2O 
Column #7 Sample 65 1746 4.3% 60% MeOH / 40% H2O 
Column #7 Sample 66 1322 3.3% 60% MeOH / 40% H2O 
Column #7 Sample 67 1598 4.0% 60% MeOH / 40% H2O 
Column #7 Sample 68 1913 4.8% 60% MeOH / 40% H2O 
Column #7 Sample 69 2064 5.1% 60% MeOH / 40% H2O 
Column #7 Sample 70 1393 3.5% 60% MeOH / 40% H2O 
Column #7 Sample 71 774 1.9% 60% MeOH / 40% H2O 
Column #7 Sample 72 819 2.0% transition 
Column #7 Sample 73 196 0.5% 70% MeOH / 30% H2O 
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Table A6, continued. 
Column #7 Sample 74 211 0.5% 70% MeOH / 30% H2O 
Column #7 Sample 75 6947 17.3% 70% MeOH / 30% H2O 
Column #7 Sample 76 3517 8.8% 70% MeOH / 30% H2O 
Column #7 Sample 77 4743 11.8% 70% MeOH / 30% H2O 
Column #7 Sample 78 2097 5.2% 70% MeOH / 30% H2O 
Column #7 Sample 79 4789 11.9% 70% MeOH / 30% H2O 
Column #7 Sample 80 5104 12.7% 70% MeOH / 30% H2O 
Column #7 Sample 81 9064 22.6% 70% MeOH / 30% H2O 
Column #7 Sample 82 2909 7.2% transition 
Column #7 Sample 83 164 0.4% 80% MeOH / 20% H2O 
Column #7 Sample 84 1369 3.4% 80% MeOH / 20% H2O 
Column #7 Sample 85 119 0.3% 80% MeOH / 20% H2O 
Column #7 Sample 86 774 1.9% 80% MeOH / 20% H2O 
Column #7 Sample 87 91 0.2% 80% MeOH / 20% H2O 
Column #7 Sample 88 552 1.4% 80% MeOH / 20% H2O 
Column #7 Sample 89 341 0.8% 80% MeOH / 20% H2O 
Column #7 Sample 90 340 0.8% 80% MeOH / 20% H2O 
Column #7 Sample 91 1105 2.7% 80% MeOH / 20% H2O 
Column #7 Sample 92 1133 2.8% 80% MeOH / 20% H2O 
 
Table A7. Results for B16-F10 cell proliferation assay with Column #8 individual samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 31548 100.0% N/A 
Average 10 mg/mL Elderberry 16893 53.5% N/A 
Column #8 Sample 1 82 0.3% 0% MeOH / 100% H2O 
Column #8 Sample 2 93 0.3% 0% MeOH / 100% H2O 
Column #8 Sample 3 72 0.2% 0% MeOH / 100% H2O 
Column #8 Sample 4 67 0.2% 0% MeOH / 100% H2O 
Column #8 Sample 5 56 0.2% 0% MeOH / 100% H2O 
Column #8 Sample 6 42 0.1% transition 
Column #8 Sample 7 57 0.2% 10% MeOH / 90% H2O 
108 
 
Table A7, continued. 
Column #8 Sample 8 60 0.2% 10% MeOH / 90% H2O 
Column #8 Sample 9 62 0.2% 10% MeOH / 90% H2O 
Column #8 Sample 10 59 0.2% 10% MeOH / 90% H2O 
Column #8 Sample 11 10780 34.2% 10% MeOH / 90% H2O 
Column #8 Sample 12 86 0.3% 10% MeOH / 90% H2O 
Column #8 Sample 13 112 0.4% 10% MeOH / 90% H2O 
Column #8 Sample 14 209 0.7% 10% MeOH / 90% H2O 
Column #8 Sample 15 122 0.4% 10% MeOH / 90% H2O 
Column #8 Sample 16 8297 26.3% 10% MeOH / 90% H2O 
Column #8 Sample 17 64 0.2% transition 
Column #8 Sample 18 75 0.2% 20% MeOH / 80% H2O 
Column #8 Sample 19 513 1.6% 20% MeOH / 80% H2O 
Column #8 Sample 20 285 0.9% 20% MeOH / 80% H2O 
Column #8 Sample 21 6506 20.6% 20% MeOH / 80% H2O 
Column #8 Sample 22 10621 33.7% 20% MeOH / 80% H2O 
Column #8 Sample 23 6602 20.9% 20% MeOH / 80% H2O 
Column #8 Sample 24 6756 21.4% 20% MeOH / 80% H2O 
Column #8 Sample 25 1427 4.5% 20% MeOH / 80% H2O 
Column #8 Sample 26 1715 5.4% 20% MeOH / 80% H2O 
Column #8 Sample 27 3562 11.3% 20% MeOH / 80% H2O 
Column #8 Sample 28 3451 10.9% transition 
Column #8 Sample 29 3772 12.0% 30% MeOH / 70% H2O 
Column #8 Sample 30 4678 14.8% 30% MeOH / 70% H2O 
Column #8 Sample 31 4789 15.2% 30% MeOH / 70% H2O 
Column #8 Sample 32 3225 10.2% 30% MeOH / 70% H2O 
Column #8 Sample 33 4015 12.7% 30% MeOH / 70% H2O 
Column #8 Sample 34 4753 15.1% 30% MeOH / 70% H2O 
Column #8 Sample 35 16805 53.3% 30% MeOH / 70% H2O 
Column #8 Sample 36 14262 45.2% 30% MeOH / 70% H2O 
Column #8 Sample 37 15158 48.0% 30% MeOH / 70% H2O 
Column #8 Sample 38 17160 54.4% 30% MeOH / 70% H2O 
Column #8 Sample 39 15760 50.0% transition 
Column #8 Sample 40 13234 41.9% 40% MeOH / 60% H2O 
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Table A7, continued. 
Column #8 Sample 41 14901 47.2% 40% MeOH / 60% H2O 
Column #8 Sample 42 11558 36.6% 40% MeOH / 60% H2O 
Column #8 Sample 43 10756 34.1% 40% MeOH / 60% H2O 
Column #8 Sample 44 9748 30.9% 40% MeOH / 60% H2O 
Column #8 Sample 45 10146 32.2% 40% MeOH / 60% H2O 
Column #8 Sample 46 10084 32.0% 40% MeOH / 60% H2O 
Column #8 Sample 47 8061 25.6% 40% MeOH / 60% H2O 
Column #8 Sample 48 10571 33.5% 40% MeOH / 60% H2O 
Column #8 Sample 49 8850 28.1% 40% MeOH / 60% H2O 
Column #8 Sample 50 6621 21.0% transition 
Column #8 Sample 51 6529 20.7% 50% MeOH / 50% H2O 
Column #8 Sample 52 1046 3.3% 50% MeOH / 50% H2O 
Column #8 Sample 53 1013 3.2% 50% MeOH / 50% H2O 
Column #8 Sample 54 2294 7.3% 50% MeOH / 50% H2O 
Column #8 Sample 55 23891 75.7% 50% MeOH / 50% H2O 
Column #8 Sample 56 16343 51.8% 50% MeOH / 50% H2O 
Column #8 Sample 57 17584 55.7% 50% MeOH / 50% H2O 
Column #8 Sample 58 11952 37.9% 50% MeOH / 50% H2O 
Column #8 Sample 59 13380 42.4% 50% MeOH / 50% H2O 
Column #8 Sample 60 19642 62.3% 50% MeOH / 50% H2O 
Column #8 Sample 61 14145 44.8% transition 
Column #8 Sample 62 19813 62.8% 60% MeOH / 40% H2O 
Column #8 Sample 63 15190 48.1% 60% MeOH / 40% H2O 
Column #8 Sample 64 15397 48.8% 60% MeOH / 40% H2O 
Column #8 Sample 65 5104 16.2% 60% MeOH / 40% H2O 
Column #8 Sample 66 2505 7.9% 60% MeOH / 40% H2O 
Column #8 Sample 67 2395 7.6% 60% MeOH / 40% H2O 
Column #8 Sample 68 2718 8.6% 60% MeOH / 40% H2O 
Column #8 Sample 69 2726 8.6% 60% MeOH / 40% H2O 
Column #8 Sample 70 2483 7.9% 60% MeOH / 40% H2O 
Column #8 Sample 71 2554 8.1% 60% MeOH / 40% H2O 
Column #8 Sample 72 3150 10.0% transition 
Column #8 Sample 73 766 2.4% 70% MeOH / 30% H2O 
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Table A7, continued. 
Column #8 Sample 74 1755 5.6% 70% MeOH / 30% H2O 
Column #8 Sample 75 9966 31.6% 70% MeOH / 30% H2O 
Column #8 Sample 76 8614 27.3% 70% MeOH / 30% H2O 
Column #8 Sample 77 8903 28.2% 70% MeOH / 30% H2O 
Column #8 Sample 78 9225 29.2% 70% MeOH / 30% H2O 
Column #8 Sample 79 9279 29.4% 70% MeOH / 30% H2O 
Column #8 Sample 80 7845 24.9% 70% MeOH / 30% H2O 
Column #8 Sample 81 9762 30.9% 70% MeOH / 30% H2O 
Column #8 Sample 82 12822 40.6% 70% MeOH / 30% H2O 
Column #8 Sample 83 10701 33.9% transition 
Column #8 Sample 84 8158 25.9% 80% MeOH / 20% H2O 
Column #8 Sample 85 6923 21.9% 80% MeOH / 20% H2O 
Column #8 Sample 86 9859 31.3% 80% MeOH / 20% H2O 
Column #8 Sample 87 9299 29.5% 80% MeOH / 20% H2O 
Column #8 Sample 88 5860 18.6% 80% MeOH / 20% H2O 
Column #8 Sample 89 7870 24.9% 80% MeOH / 20% H2O 
Column #8 Sample 90 6489 20.6% 80% MeOH / 20% H2O 
Column #8 Sample 91 4234 13.4% 80% MeOH / 20% H2O 
Column #8 Sample 92 5095 16.1% 80% MeOH / 20% H2O 
Column #8 Sample 93 3843 12.2% 80% MeOH / 20% H2O 
 
Table A8. Results for B16-F10 cell proliferation assay with Column #9 individual samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 92120 100.0% N/A 
Average 10 mg/mL Elderberry 71605 77.7% N/A 
Column #9 Sample 1 90 0.1% 0% MeOH / 100% H2O 
Column #9 Sample 2 133 0.1% 0% MeOH / 100% H2O 
Column #9 Sample 3 50 0.1% 0% MeOH / 100% H2O 
Column #9 Sample 4 57 0.1% 0% MeOH / 100% H2O 
Column #9 Sample 5 51 0.1% 0% MeOH / 100% H2O 
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Table A8, continued. 
Column #9 Sample 6 47 0.1% transition 
Column #9 Sample 7 43 0.0% 10% MeOH / 90% H2O 
Column #9 Sample 8 65 0.1% 10% MeOH / 90% H2O 
Column #9 Sample 9 76 0.1% 10% MeOH / 90% H2O 
Column #9 Sample 10 146 0.2% 10% MeOH / 90% H2O 
Column #9 Sample 11 602 0.7% 10% MeOH / 90% H2O 
Column #9 Sample 12 23397 25.4% 10% MeOH / 90% H2O 
Column #9 Sample 13 23488 25.5% 10% MeOH / 90% H2O 
Column #9 Sample 14 31276 34.0% 10% MeOH / 90% H2O 
Column #9 Sample 15 60029 65.2% 10% MeOH / 90% H2O 
Column #9 Sample 16 58216 63.2% 10% MeOH / 90% H2O 
Column #9 Sample 17 42738 46.4% transition 
Column #9 Sample 18 41560 45.1% 20% MeOH / 80% H2O 
Column #9 Sample 19 34502 37.5% 20% MeOH / 80% H2O 
Column #9 Sample 20 27625 30.0% 20% MeOH / 80% H2O 
Column #9 Sample 21 44168 47.9% 20% MeOH / 80% H2O 
Column #9 Sample 22 40392 43.8% 20% MeOH / 80% H2O 
Column #9 Sample 23 40108 43.5% 20% MeOH / 80% H2O 
Column #9 Sample 24 31723 34.4% 20% MeOH / 80% H2O 
Column #9 Sample 25 41747 45.3% 20% MeOH / 80% H2O 
Column #9 Sample 26 28162 30.6% 20% MeOH / 80% H2O 
Column #9 Sample 27 29709 32.3% 20% MeOH / 80% H2O 
Column #9 Sample 28 20967 22.8% transition 
Column #9 Sample 29 23259 25.2% 30% MeOH / 70% H2O 
Column #9 Sample 30 22495 24.4% 30% MeOH / 70% H2O 
Column #9 Sample 31 18007 19.5% 30% MeOH / 70% H2O 
Column #9 Sample 32 12870 14.0% 30% MeOH / 70% H2O 
Column #9 Sample 33 16621 18.0% 30% MeOH / 70% H2O 
Column #9 Sample 34 15167 16.5% 30% MeOH / 70% H2O 
Column #9 Sample 35 58548 63.6% 30% MeOH / 70% H2O 
Column #9 Sample 36 68835 74.7% 30% MeOH / 70% H2O 
Column #9 Sample 37 40103 43.5% 30% MeOH / 70% H2O 
Column #9 Sample 38 59931 65.1% 30% MeOH / 70% H2O 
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Table A8, continued. 
Column #9 Sample 39 43906 47.7% transition 
Column #9 Sample 40 42724 46.4% 40% MeOH / 60% H2O 
Column #9 Sample 41 55508 60.3% 40% MeOH / 60% H2O 
Column #9 Sample 42 38460 41.7% 40% MeOH / 60% H2O 
Column #9 Sample 43 43059 46.7% 40% MeOH / 60% H2O 
Column #9 Sample 44 61538 66.8% 40% MeOH / 60% H2O 
Column #9 Sample 45 39215 42.6% 40% MeOH / 60% H2O 
Column #9 Sample 46 32219 35.0% 40% MeOH / 60% H2O 
Column #9 Sample 47 43845 47.6% 40% MeOH / 60% H2O 
Column #9 Sample 48 30352 32.9% 40% MeOH / 60% H2O 
Column #9 Sample 49 36159 39.3% 40% MeOH / 60% H2O 
Column #9 Sample 50 11703 12.7% transition 
Column #9 Sample 51 28931 31.4% 50% MeOH / 50% H2O 
Column #9 Sample 52 33827 36.7% 50% MeOH / 50% H2O 
Column #9 Sample 53 18899 20.5% 50% MeOH / 50% H2O 
Column #9 Sample 54 7385 8.0% 50% MeOH / 50% H2O 
Column #9 Sample 55 62641 68.0% 50% MeOH / 50% H2O 
Column #9 Sample 56 60184 65.3% 50% MeOH / 50% H2O 
Column #9 Sample 57 42572 46.2% 50% MeOH / 50% H2O 
Column #9 Sample 58 24616 26.7% 50% MeOH / 50% H2O 
Column #9 Sample 59 36581 39.7% 50% MeOH / 50% H2O 
Column #9 Sample 60 56916 61.8% 50% MeOH / 50% H2O 
Column #9 Sample 61 53994 58.6% transition 
Column #9 Sample 62 64663 70.2% 60% MeOH / 40% H2O 
Column #9 Sample 63 55462 60.2% 60% MeOH / 40% H2O 
Column #9 Sample 64 69282 75.2% 60% MeOH / 40% H2O 
Column #9 Sample 65 26369 28.6% 60% MeOH / 40% H2O 
Column #9 Sample 66 29933 32.5% 60% MeOH / 40% H2O 
Column #9 Sample 67 14621 15.9% 60% MeOH / 40% H2O 
Column #9 Sample 68 23338 25.3% 60% MeOH / 40% H2O 
Column #9 Sample 69 27125 29.4% 60% MeOH / 40% H2O 
Column #9 Sample 70 25299 27.5% 60% MeOH / 40% H2O 
Column #9 Sample 71 13354 14.5% 60% MeOH / 40% H2O 
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Table A8, continued. 
Column #9 Sample 72 18310 19.9% transition 
Column #9 Sample 73 7107 7.7% 70% MeOH / 30% H2O 
Column #9 Sample 74 4873 5.3% 70% MeOH / 30% H2O 
Column #9 Sample 75 31223 33.9% 70% MeOH / 30% H2O 
Column #9 Sample 76 30535 33.1% 70% MeOH / 30% H2O 
Column #9 Sample 77 27443 29.8% 70% MeOH / 30% H2O 
Column #9 Sample 78 31461 34.2% 70% MeOH / 30% H2O 
Column #9 Sample 79 36154 39.2% 70% MeOH / 30% H2O 
Column #9 Sample 80 33025 35.8% 70% MeOH / 30% H2O 
Column #9 Sample 81 48963 53.2% 70% MeOH / 30% H2O 
Column #9 Sample 82 45255 49.1% 70% MeOH / 30% H2O 
Column #9 Sample 83 56945 61.8% transition 
Column #9 Sample 84 47327 51.4% 80% MeOH / 20% H2O 
Column #9 Sample 85 55210 59.9% 80% MeOH / 20% H2O 
Column #9 Sample 86 39221 42.6% 80% MeOH / 20% H2O 
Column #9 Sample 87 32432 35.2% 80% MeOH / 20% H2O 
Column #9 Sample 88 36000 39.1% 80% MeOH / 20% H2O 
Column #9 Sample 89 24458 26.6% 80% MeOH / 20% H2O 
Column #9 Sample 90 4417 4.8% 80% MeOH / 20% H2O 
Column #9 Sample 91 11388 12.4% 80% MeOH / 20% H2O 
Column #9 Sample 92 28617 31.1% 80% MeOH / 20% H2O 
 
Table A9. Results for B16-F10 cell proliferation assay with Column #10 individual 
samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 32984 100.0% N/A 
Average 10 mg/mL Elderberry 8562 26.0% N/A 
Column #10 Sample 1 71 0.2% 0% MeOH / 100% H2O 
Column #10 Sample 2 129 0.4% 0% MeOH / 100% H2O 
Column #10 Sample 3 99 0.3% 0% MeOH / 100% H2O 
Column #10 Sample 4 93 0.3% 0% MeOH / 100% H2O 
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Table A9, continued. 
Column #10 Sample 5 76 0.2% 0% MeOH / 100% H2O 
Column #10 Sample 6 61 0.2% transition 
Column #10 Sample 7 58 0.2% 10% MeOH / 90% H2O 
Column #10 Sample 8 75 0.2% 10% MeOH / 90% H2O 
Column #10 Sample 9 100 0.3% 10% MeOH / 90% H2O 
Column #10 Sample 10 73 0.2% 10% MeOH / 90% H2O 
Column #10 Sample 11 78 0.2% 10% MeOH / 90% H2O 
Column #10 Sample 12 113 0.3% 10% MeOH / 90% H2O 
Column #10 Sample 13 154 0.5% 10% MeOH / 90% H2O 
Column #10 Sample 14 2099 6.4% 10% MeOH / 90% H2O 
Column #10 Sample 15 1900 5.8% 10% MeOH / 90% H2O 
Column #10 Sample 16 7116 21.6% 10% MeOH / 90% H2O 
Column #10 Sample 17 1694 5.1% transition 
Column #10 Sample 18 3307 10.0% 20% MeOH / 80% H2O 
Column #10 Sample 19 7524 22.8% 20% MeOH / 80% H2O 
Column #10 Sample 20 7204 21.8% 20% MeOH / 80% H2O 
Column #10 Sample 21 10730 32.5% 20% MeOH / 80% H2O 
Column #10 Sample 22 8209 24.9% 20% MeOH / 80% H2O 
Column #10 Sample 23 11506 34.9% 20% MeOH / 80% H2O 
Column #10 Sample 24 5070 15.4% 20% MeOH / 80% H2O 
Column #10 Sample 25 9630 29.2% 20% MeOH / 80% H2O 
Column #10 Sample 26 7353 22.3% 20% MeOH / 80% H2O 
Column #10 Sample 27 3282 10.0% 20% MeOH / 80% H2O 
Column #10 Sample 28 2678 8.1% transition 
Column #10 Sample 29 1946 5.9% 30% MeOH / 70% H2O 
Column #10 Sample 30 1733 5.3% 30% MeOH / 70% H2O 
Column #10 Sample 31 2986 9.1% 30% MeOH / 70% H2O 
Column #10 Sample 32 998 3.0% 30% MeOH / 70% H2O 
Column #10 Sample 33 1178 3.6% 30% MeOH / 70% H2O 
Column #10 Sample 34 2960 9.0% 30% MeOH / 70% H2O 
Column #10 Sample 35 20885 63.3% 30% MeOH / 70% H2O 
Column #10 Sample 36 10410 31.6% 30% MeOH / 70% H2O 
Column #10 Sample 37 2912 8.8% 30% MeOH / 70% H2O 
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Table A9, continued. 
Column #10 Sample 38 7247 22.0% transition 
Column #10 Sample 39 3721 11.3% 40% MeOH / 60% H2O 
Column #10 Sample 40 1999 6.1% 40% MeOH / 60% H2O 
Column #10 Sample 41 1785 5.4% 40% MeOH / 60% H2O 
Column #10 Sample 42 465 1.4% 40% MeOH / 60% H2O 
Column #10 Sample 43 9298 28.2% 40% MeOH / 60% H2O 
Column #10 Sample 44 5909 17.9% 40% MeOH / 60% H2O 
Column #10 Sample 45 1550 4.7% 40% MeOH / 60% H2O 
Column #10 Sample 46 1841 5.6% 40% MeOH / 60% H2O 
Column #10 Sample 47 250 0.8% 40% MeOH / 60% H2O 
Column #10 Sample 48 412 1.2% 40% MeOH / 60% H2O 
Column #10 Sample 49 1504 4.6% transition 
Column #10 Sample 50 345 1.0% 50% MeOH / 50% H2O 
Column #10 Sample 51 352 1.1% 50% MeOH / 50% H2O 
Column #10 Sample 52 237 0.7% 50% MeOH / 50% H2O 
Column #10 Sample 53 202 0.6% 50% MeOH / 50% H2O 
Column #10 Sample 54 2773 8.4% 50% MeOH / 50% H2O 
Column #10 Sample 55 9329 28.3% 50% MeOH / 50% H2O 
Column #10 Sample 56 2357 7.1% 50% MeOH / 50% H2O 
Column #10 Sample 57 857 2.6% 50% MeOH / 50% H2O 
Column #10 Sample 58 3090 9.4% 50% MeOH / 50% H2O 
Column #10 Sample 59 14278 43.3% 50% MeOH / 50% H2O 
Column #10 Sample 60 681 2.1% transition 
Column #10 Sample 61 1620 4.9% 60% MeOH / 40% H2O 
Column #10 Sample 62 6845 20.8% 60% MeOH / 40% H2O 
Column #10 Sample 63 1480 4.5% 60% MeOH / 40% H2O 
Column #10 Sample 64 13755 41.7% 60% MeOH / 40% H2O 
Column #10 Sample 65 6217 18.8% 60% MeOH / 40% H2O 
Column #10 Sample 66 3961 12.0% 60% MeOH / 40% H2O 
Column #10 Sample 67 1576 4.8% 60% MeOH / 40% H2O 
Column #10 Sample 68 4253 12.9% 60% MeOH / 40% H2O 
Column #10 Sample 69 4854 14.7% 60% MeOH / 40% H2O 
Column #10 Sample 70 7485 22.7% 60% MeOH / 40% H2O 
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Table A9, continued. 
Column #10 Sample 71 4637 14.1% transition 
Column #10 Sample 72 2461 7.5% 70% MeOH / 30% H2O 
Column #10 Sample 73 1066 3.2% 70% MeOH / 30% H2O 
Column #10 Sample 74 1004 3.0% 70% MeOH / 30% H2O 
Column #10 Sample 75 13774 41.8% 70% MeOH / 30% H2O 
Column #10 Sample 76 3541 10.7% 70% MeOH / 30% H2O 
Column #10 Sample 77 3738 11.3% 70% MeOH / 30% H2O 
Column #10 Sample 78 3637 11.0% 70% MeOH / 30% H2O 
Column #10 Sample 79 3318 10.1% 70% MeOH / 30% H2O 
Column #10 Sample 80 2557 7.8% transition 
Column #10 Sample 81 2650 8.0% 80% MeOH / 20% H2O 
Column #10 Sample 82 7813 23.7% 80% MeOH / 20% H2O 
Column #10 Sample 83 1585 4.8% 80% MeOH / 20% H2O 
Column #10 Sample 84 6387 19.4% 80% MeOH / 20% H2O 
Column #10 Sample 85 4038 12.2% 80% MeOH / 20% H2O 
Column #10 Sample 86 228 0.7% 80% MeOH / 20% H2O 
Column #10 Sample 87 768 2.3% 80% MeOH / 20% H2O 
Column #10 Sample 88 466 1.4% 80% MeOH / 20% H2O 
Column #10 Sample 89 149 0.5% 80% MeOH / 20% H2O 
Column #10 Sample 90 7678 23.3% 80% MeOH / 20% H2O 
 
Table A10. Results for B16-F10 cell proliferation assay with Column #11 individual 
samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 16646 100.0% N/A 
Average 10 mg/mL Elderberry 4744 28.5% N/A 
Column #11 Sample 1 63 0.4% 0% MeOH / 100% H2O 
Column #11 Sample 2 78 0.5% 0% MeOH / 100% H2O 
Column #11 Sample 3 64 0.4% 0% MeOH / 100% H2O 
Column #11 Sample 4 45 0.3% 0% MeOH / 100% H2O 
Column #11 Sample 5 43 0.3% 0% MeOH / 100% H2O 
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Table A10, continued. 
Column #11 Sample 6 43 0.3% transition 
Column #11 Sample 7 53 0.3% 10% MeOH / 90% H2O 
Column #11 Sample 8 43 0.3% 10% MeOH / 90% H2O 
Column #11 Sample 9 53 0.3% 10% MeOH / 90% H2O 
Column #11 Sample 10 32 0.2% 10% MeOH / 90% H2O 
Column #11 Sample 11 42 0.3% 10% MeOH / 90% H2O 
Column #11 Sample 12 41 0.2% 10% MeOH / 90% H2O 
Column #11 Sample 13 272 1.6% 10% MeOH / 90% H2O 
Column #11 Sample 14 383 2.3% 10% MeOH / 90% H2O 
Column #11 Sample 15 8520 51.2% 10% MeOH / 90% H2O 
Column #11 Sample 16 1219 7.3% 10% MeOH / 90% H2O 
Column #11 Sample 17 626 3.8% transition 
Column #11 Sample 18 1931 11.6% 20% MeOH / 80% H2O 
Column #11 Sample 19 1075 6.5% 20% MeOH / 80% H2O 
Column #11 Sample 20 412 2.5% 20% MeOH / 80% H2O 
Column #11 Sample 21 2961 17.8% 20% MeOH / 80% H2O 
Column #11 Sample 22 2709 16.3% 20% MeOH / 80% H2O 
Column #11 Sample 23 1840 11.1% 20% MeOH / 80% H2O 
Column #11 Sample 24 808 4.9% 20% MeOH / 80% H2O 
Column #11 Sample 25 6646 39.9% 20% MeOH / 80% H2O 
Column #11 Sample 26 1513 9.1% 20% MeOH / 80% H2O 
Column #11 Sample 27 2000 12.0% 20% MeOH / 80% H2O 
Column #11 Sample 28 5409 32.5% transition 
Column #11 Sample 29 2539 15.3% 30% MeOH / 70% H2O 
Column #11 Sample 30 3825 23.0% 30% MeOH / 70% H2O 
Column #11 Sample 31 2080 12.5% 30% MeOH / 70% H2O 
Column #11 Sample 32 653 3.9% 30% MeOH / 70% H2O 
Column #11 Sample 33 524 3.1% 30% MeOH / 70% H2O 
Column #11 Sample 34 3350 20.1% 30% MeOH / 70% H2O 
Column #11 Sample 35 6971 41.9% 30% MeOH / 70% H2O 
Column #11 Sample 36 5311 31.9% 30% MeOH / 70% H2O 
Column #11 Sample 37 1920 11.5% 30% MeOH / 70% H2O 
Column #11 Sample 38 439 2.6% transition 
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Table A10, continued. 
Column #11 Sample 39 2154 12.9% 40% MeOH / 60% H2O 
Column #11 Sample 40 1240 7.4% 40% MeOH / 60% H2O 
Column #11 Sample 41 155 0.9% 40% MeOH / 60% H2O 
Column #11 Sample 42 1344 8.1% 40% MeOH / 60% H2O 
Column #11 Sample 43 280 1.7% 40% MeOH / 60% H2O 
Column #11 Sample 44 4706 28.3% 40% MeOH / 60% H2O 
Column #11 Sample 45 1445 8.7% 40% MeOH / 60% H2O 
Column #11 Sample 46 311 1.9% 40% MeOH / 60% H2O 
Column #11 Sample 47 442 2.7% 40% MeOH / 60% H2O 
Column #11 Sample 48 368 2.2% 40% MeOH / 60% H2O 
Column #11 Sample 49 325 2.0% transition 
Column #11 Sample 50 311 1.9% 50% MeOH / 50% H2O 
Column #11 Sample 51 341 2.0% 50% MeOH / 50% H2O 
Column #11 Sample 52 254 1.5% 50% MeOH / 50% H2O 
Column #11 Sample 53 297 1.8% 50% MeOH / 50% H2O 
Column #11 Sample 54 639 3.8% 50% MeOH / 50% H2O 
Column #11 Sample 55 5006 30.1% 50% MeOH / 50% H2O 
Column #11 Sample 56 501 3.0% 50% MeOH / 50% H2O 
Column #11 Sample 57 307 1.8% 50% MeOH / 50% H2O 
Column #11 Sample 58 421 2.5% 50% MeOH / 50% H2O 
Column #11 Sample 59 1156 6.9% 50% MeOH / 50% H2O 
Column #11 Sample 60 524 3.1% transition 
Column #11 Sample 61 379 2.3% 60% MeOH / 40% H2O 
Column #11 Sample 62 566 3.4% 60% MeOH / 40% H2O 
Column #11 Sample 63 395 2.4% 60% MeOH / 40% H2O 
Column #11 Sample 64 801 4.8% 60% MeOH / 40% H2O 
Column #11 Sample 65 487 2.9% 60% MeOH / 40% H2O 
Column #11 Sample 66 527 3.2% 60% MeOH / 40% H2O 
Column #11 Sample 67 1127 6.8% 60% MeOH / 40% H2O 
Column #11 Sample 68 708 4.3% 60% MeOH / 40% H2O 
Column #11 Sample 69 278 1.7% 60% MeOH / 40% H2O 
Column #11 Sample 70 2323 14.0% 60% MeOH / 40% H2O 
Column #11 Sample 71 660 4.0% transition 
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Table A10, continued. 
Column #11 Sample 72 200 1.2% 70% MeOH / 30% H2O 
Column #11 Sample 73 611 3.7% 70% MeOH / 30% H2O 
Column #11 Sample 74 532 3.2% 70% MeOH / 30% H2O 
Column #11 Sample 75 6073 36.5% 70% MeOH / 30% H2O 
Column #11 Sample 76 12112 72.8% 70% MeOH / 30% H2O 
Column #11 Sample 77 1422 8.5% 70% MeOH / 30% H2O 
Column #11 Sample 78 952 5.7% 70% MeOH / 30% H2O 
Column #11 Sample 79 520 3.1% 70% MeOH / 30% H2O 
Column #11 Sample 80 1748 10.5% 70% MeOH / 30% H2O 
Column #11 Sample 81 1897 11.4% transition 
Column #11 Sample 82 4619 27.7% 80% MeOH / 20% H2O 
Column #11 Sample 83 933 5.6% 80% MeOH / 20% H2O 
Column #11 Sample 84 3497 21.0% 80% MeOH / 20% H2O 
Column #11 Sample 85 3274 19.7% 80% MeOH / 20% H2O 
Column #11 Sample 86 915 5.5% 80% MeOH / 20% H2O 
Column #11 Sample 87 190 1.1% 80% MeOH / 20% H2O 
Column #11 Sample 88 574 3.4% 80% MeOH / 20% H2O 
Column #11 Sample 89 617 3.7% 80% MeOH / 20% H2O 
Column #11 Sample 90 2307 13.9% 80% MeOH / 20% H2O 
Column #11 Sample 91 652 3.9% 80% MeOH / 20% H2O 
 
Table A11. Results for B16-F10 cell proliferation assay with Column #12 individual 
samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 119971 100.0% N/A 
Average 10 mg/mL Elderberry 62496 52.1% N/A 
Column #12 Sample 1 75 0.1% 0% MeOH / 100% H2O 
Column #12 Sample 2 103 0.1% 0% MeOH / 100% H2O 
Column #12 Sample 3 90 0.1% 0% MeOH / 100% H2O 
Column #12 Sample 4 82 0.1% 0% MeOH / 100% H2O 
Column #12 Sample 5 69 0.1% transition 
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Table A11, continued. 
Column #12 Sample 6 90 0.1% 10% MeOH / 90% H2O 
Column #12 Sample 7 75 0.1% 10% MeOH / 90% H2O 
Column #12 Sample 8 392 0.3% 10% MeOH / 90% H2O 
Column #12 Sample 9 72 0.1% 10% MeOH / 90% H2O 
Column #12 Sample 10 63 0.1% 10% MeOH / 90% H2O 
Column #12 Sample 11 78 0.1% 10% MeOH / 90% H2O 
Column #12 Sample 12 69 0.1% 10% MeOH / 90% H2O 
Column #12 Sample 13 185 0.2% 10% MeOH / 90% H2O 
Column #12 Sample 14 1788 1.5% 10% MeOH / 90% H2O 
Column #12 Sample 15 43795 36.5% 10% MeOH / 90% H2O 
Column #12 Sample 16 38056 31.7% transition 
Column #12 Sample 17 22892 19.1% 20% MeOH / 80% H2O 
Column #12 Sample 18 13002 10.8% 20% MeOH / 80% H2O 
Column #12 Sample 19 21478 17.9% 20% MeOH / 80% H2O 
Column #12 Sample 20 16952 14.1% 20% MeOH / 80% H2O 
Column #12 Sample 21 15513 12.9% 20% MeOH / 80% H2O 
Column #12 Sample 22 11761 9.8% 20% MeOH / 80% H2O 
Column #12 Sample 23 14245 11.9% 20% MeOH / 80% H2O 
Column #12 Sample 24 19176 16.0% 20% MeOH / 80% H2O 
Column #12 Sample 25 21082 17.6% 20% MeOH / 80% H2O 
Column #12 Sample 26 10322 8.6% 20% MeOH / 80% H2O 
Column #12 Sample 27 12355 10.3% transition 
Column #12 Sample 28 9909 8.3% 30% MeOH / 70% H2O 
Column #12 Sample 29 5499 4.6% 30% MeOH / 70% H2O 
Column #12 Sample 30 6402 5.3% 30% MeOH / 70% H2O 
Column #12 Sample 31 4996 4.2% 30% MeOH / 70% H2O 
Column #12 Sample 32 4166 3.5% 30% MeOH / 70% H2O 
Column #12 Sample 33 370 0.3% 30% MeOH / 70% H2O 
Column #12 Sample 34 1419 1.2% 30% MeOH / 70% H2O 
Column #12 Sample 35 31822 26.5% 30% MeOH / 70% H2O 
Column #12 Sample 36 16675 13.9% 30% MeOH / 70% H2O 
Column #12 Sample 37 28196 23.5% 30% MeOH / 70% H2O 
Column #12 Sample 38 21062 17.6% transition 
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Table A11, continued. 
Column #12 Sample 39 16619 13.9% 40% MeOH / 60% H2O 
Column #12 Sample 40 15558 13.0% 40% MeOH / 60% H2O 
Column #12 Sample 41 14456 12.0% 40% MeOH / 60% H2O 
Column #12 Sample 42 18770 15.6% 40% MeOH / 60% H2O 
Column #12 Sample 43 24588 20.5% 40% MeOH / 60% H2O 
Column #12 Sample 44 47316 39.4% 40% MeOH / 60% H2O 
Column #12 Sample 45 46094 38.4% 40% MeOH / 60% H2O 
Column #12 Sample 46 24304 20.3% 40% MeOH / 60% H2O 
Column #12 Sample 47 15160 12.6% 40% MeOH / 60% H2O 
Column #12 Sample 48 13286 11.1% 40% MeOH / 60% H2O 
Column #12 Sample 49 10519 8.8% transition 
Column #12 Sample 50 11906 9.9% 50% MeOH / 50% H2O 
Column #12 Sample 51 3055 2.5% 50% MeOH / 50% H2O 
Column #12 Sample 52 9122 7.6% 50% MeOH / 50% H2O 
Column #12 Sample 53 9266 7.7% 50% MeOH / 50% H2O 
Column #12 Sample 54 29094 24.3% 50% MeOH / 50% H2O 
Column #12 Sample 55 37432 31.2% 50% MeOH / 50% H2O 
Column #12 Sample 56 35728 29.8% 50% MeOH / 50% H2O 
Column #12 Sample 57 20514 17.1% 50% MeOH / 50% H2O 
Column #12 Sample 58 4029 3.4% 50% MeOH / 50% H2O 
Column #12 Sample 59 24142 20.1% transition 
Column #12 Sample 60 30604 25.5% 60% MeOH / 40% H2O 
Column #12 Sample 61 26050 21.7% 60% MeOH / 40% H2O 
Column #12 Sample 62 45107 37.6% 60% MeOH / 40% H2O 
Column #12 Sample 63 25098 20.9% 60% MeOH / 40% H2O 
Column #12 Sample 64 40076 33.4% 60% MeOH / 40% H2O 
Column #12 Sample 65 10219 8.5% 60% MeOH / 40% H2O 
Column #12 Sample 66 8552 7.1% 60% MeOH / 40% H2O 
Column #12 Sample 67 3272 2.7% 60% MeOH / 40% H2O 
Column #12 Sample 68 17358 14.5% 60% MeOH / 40% H2O 
Column #12 Sample 69 7643 6.4% transition 
Column #12 Sample 70 7224 6.0% 70% MeOH / 30% H2O 
Column #12 Sample 71 2923 2.4% 70% MeOH / 30% H2O 
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Table A11, continued. 
Column #12 Sample 72 4603 3.8% 70% MeOH / 30% H2O 
Column #12 Sample 73 5234 4.4% 70% MeOH / 30% H2O 
Column #12 Sample 74 2825 2.4% 70% MeOH / 30% H2O 
Column #12 Sample 75 15589 13.0% 70% MeOH / 30% H2O 
Column #12 Sample 76 14034 11.7% 70% MeOH / 30% H2O 
Column #12 Sample 77 43648 36.4% 70% MeOH / 30% H2O 
Column #12 Sample 78 35152 29.3% 70% MeOH / 30% H2O 
Column #12 Sample 79 74538 62.1% transition 
Column #12 Sample 80 47150 39.3% 80% MeOH / 20% H2O 
Column #12 Sample 81 48355 40.3% 80% MeOH / 20% H2O 
Column #12 Sample 82 50574 42.2% 80% MeOH / 20% H2O 
Column #12 Sample 83 61052 50.9% 80% MeOH / 20% H2O 
Column #12 Sample 84 62154 51.8% 80% MeOH / 20% H2O 
Column #12 Sample 85 43980 36.7% 80% MeOH / 20% H2O 
Column #12 Sample 86 15251 12.7% 80% MeOH / 20% H2O 
Column #12 Sample 87 18561 15.5% 80% MeOH / 20% H2O 
Column #12 Sample 88 15346 12.8% 80% MeOH / 20% H2O 
 
Table A12. Results for B16-F10 cell proliferation assay with Column #13 individual 
samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 119971 100.0% N/A 
Average 10 mg/mL Elderberry 62496 52.1% N/A 
Column #13 Sample 1 84 0.1% 0% MeOH / 100% H2O 
Column #13 Sample 2 74 0.1% 0% MeOH / 100% H2O 
Column #13 Sample 3 85 0.1% 0% MeOH / 100% H2O 
Column #13 Sample 4 59 0.0% 0% MeOH / 100% H2O 
Column #13 Sample 5 118 0.1% 0% MeOH / 100% H2O 
Column #13 Sample 6 123 0.1% transition 
Column #13 Sample 7 90 0.1% 10% MeOH / 90% H2O 
Column #13 Sample 8 171 0.1% 10% MeOH / 90% H2O 
Column #13 Sample 9 131 0.1% 10% MeOH / 90% H2O 
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Table A12, continued. 
Column #13 Sample 10 140 0.1% 10% MeOH / 90% H2O 
Column #13 Sample 11 151 0.1% 10% MeOH / 90% H2O 
Column #13 Sample 12 259 0.2% 10% MeOH / 90% H2O 
Column #13 Sample 13 6398 5.3% 10% MeOH / 90% H2O 
Column #13 Sample 14 1732 1.4% 10% MeOH / 90% H2O 
Column #13 Sample 15 18122 15.1% 10% MeOH / 90% H2O 
Column #13 Sample 16 20328 16.9% 10% MeOH / 90% H2O 
Column #13 Sample 17 4387 3.7% transition 
Column #13 Sample 18 11496 9.6% 20% MeOH / 80% H2O 
Column #13 Sample 19 5084 4.2% 20% MeOH / 80% H2O 
Column #13 Sample 20 41459 34.6% 20% MeOH / 80% H2O 
Column #13 Sample 21 22242 18.5% 20% MeOH / 80% H2O 
Column #13 Sample 22 19926 16.6% 20% MeOH / 80% H2O 
Column #13 Sample 23 10296 8.6% 20% MeOH / 80% H2O 
Column #13 Sample 24 8681 7.2% 20% MeOH / 80% H2O 
Column #13 Sample 25 8266 6.9% 20% MeOH / 80% H2O 
Column #13 Sample 26 10030 8.4% 20% MeOH / 80% H2O 
Column #13 Sample 27 12767 10.6% 20% MeOH / 80% H2O 
Column #13 Sample 28 10823 9.0% transition 
Column #13 Sample 29 6361 5.3% 30% MeOH / 70% H2O 
Column #13 Sample 30 16044 13.4% 30% MeOH / 70% H2O 
Column #13 Sample 31 6561 5.5% 30% MeOH / 70% H2O 
Column #13 Sample 32 5261 4.4% 30% MeOH / 70% H2O 
Column #13 Sample 33 2850 2.4% 30% MeOH / 70% H2O 
Column #13 Sample 34 2560 2.1% 30% MeOH / 70% H2O 
Column #13 Sample 35 2428 2.0% 30% MeOH / 70% H2O 
Column #13 Sample 36 2133 1.8% 30% MeOH / 70% H2O 
Column #13 Sample 37 1965 1.6% 30% MeOH / 70% H2O 
Column #13 Sample 38 3629 3.0% transition 
Column #13 Sample 39 9735 8.1% 40% MeOH / 60% H2O 
Column #13 Sample 40 6041 5.0% 40% MeOH / 60% H2O 
Column #13 Sample 41 14344 12.0% 40% MeOH / 60% H2O 
Column #13 Sample 42 8221 6.9% 40% MeOH / 60% H2O 
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Table A12, continued. 
Column #13 Sample 43 7190 6.0% 40% MeOH / 60% H2O 
Column #13 Sample 44 10670 8.9% 40% MeOH / 60% H2O 
Column #13 Sample 45 8143 6.8% 40% MeOH / 60% H2O 
Column #13 Sample 46 4096 3.4% 40% MeOH / 60% H2O 
Column #13 Sample 47 8364 7.0% 40% MeOH / 60% H2O 
Column #13 Sample 48 1328 1.1% 40% MeOH / 60% H2O 
Column #13 Sample 49 20215 16.8% 40% MeOH / 60% H2O 
Column #13 Sample 50 20515 17.1% transition 
Column #13 Sample 51 17458 14.6% 50% MeOH / 50% H2O 
Column #13 Sample 52 8942 7.5% 50% MeOH / 50% H2O 
Column #13 Sample 53 9557 8.0% 50% MeOH / 50% H2O 
Column #13 Sample 54 8122 6.8% 50% MeOH / 50% H2O 
Column #13 Sample 55 9742 8.1% 50% MeOH / 50% H2O 
Column #13 Sample 56 3608 3.0% 50% MeOH / 50% H2O 
Column #13 Sample 57 3434 2.9% 50% MeOH / 50% H2O 
Column #13 Sample 58 3338 2.8% 50% MeOH / 50% H2O 
Column #13 Sample 59 2460 2.1% 50% MeOH / 50% H2O 
Column #13 Sample 60 11048 9.2% 50% MeOH / 50% H2O 
Column #13 Sample 61 19198 16.0% transition 
Column #13 Sample 62 15499 12.9% 60% MeOH / 40% H2O 
Column #13 Sample 63 28343 23.6% 60% MeOH / 40% H2O 
Column #13 Sample 64 14668 12.2% 60% MeOH / 40% H2O 
Column #13 Sample 65 25493 21.2% 60% MeOH / 40% H2O 
Column #13 Sample 66 20568 17.1% 60% MeOH / 40% H2O 
Column #13 Sample 67 29516 24.6% 60% MeOH / 40% H2O 
Column #13 Sample 68 20676 17.2% 60% MeOH / 40% H2O 
Column #13 Sample 69 26396 22.0% 60% MeOH / 40% H2O 
Column #13 Sample 70 28419 23.7% 60% MeOH / 40% H2O 
Column #13 Sample 71 27487 22.9% transition 
Column #13 Sample 72 19126 15.9% 70% MeOH / 30% H2O 
Column #13 Sample 73 7511 6.3% 70% MeOH / 30% H2O 
Column #13 Sample 74 522 0.4% 70% MeOH / 30% H2O 
Column #13 Sample 75 608 0.5% 70% MeOH / 30% H2O 
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Table A12, continued. 
Column #13 Sample 76 731 0.6% 70% MeOH / 30% H2O 
Column #13 Sample 77 628 0.5% 70% MeOH / 30% H2O 
Column #13 Sample 78 4735 3.9% 70% MeOH / 30% H2O 
Column #13 Sample 79 5632 4.7% 70% MeOH / 30% H2O 
Column #13 Sample 80 697 0.6% 70% MeOH / 30% H2O 
Column #13 Sample 81 10194 8.5% transition 
Column #13 Sample 82 1179 1.0% 80% MeOH / 20% H2O 
Column #13 Sample 83 975 0.8% 80% MeOH / 20% H2O 
Column #13 Sample 84 277 0.2% 80% MeOH / 20% H2O 
Column #13 Sample 85 1087 0.9% 80% MeOH / 20% H2O 
Column #13 Sample 86 968 0.8% 80% MeOH / 20% H2O 
Column #13 Sample 87 2177 1.8% 80% MeOH / 20% H2O 
Column #13 Sample 88 179 0.1% 80% MeOH / 20% H2O 
Column #13 Sample 89 1629 1.4% 80% MeOH / 20% H2O 
Column #13 Sample 90 585 0.5% 80% MeOH / 20% H2O 
Column #13 Sample 91 26604 22.2% 80% MeOH / 20% H2O 
 
Table A13. Results for B16-F10 cell proliferation assay with Column #14 individual 
samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 16646 100.0% N/A 
Average 10 mg/mL Elderberry 4744 28.5% N/A 
Column #14 Sample 1 86 0.5% 0% MeOH / 100% H2O 
Column #14 Sample 2 41 0.2% 0% MeOH / 100% H2O 
Column #14 Sample 3 42 0.3% 0% MeOH / 100% H2O 
Column #14 Sample 4 67 0.4% 0% MeOH / 100% H2O 
Column #14 Sample 5 38 0.2% 0% MeOH / 100% H2O 
Column #14 Sample 6 41 0.2% transition 
Column #14 Sample 7 53 0.3% 10% MeOH / 90% H2O 
Column #14 Sample 8 53 0.3% 10% MeOH / 90% H2O 
Column #14 Sample 9 39 0.2% 10% MeOH / 90% H2O 
Column #14 Sample 10 46 0.3% 10% MeOH / 90% H2O 
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Table A13, continued. 
Column #14 Sample 11 42 0.3% 10% MeOH / 90% H2O 
Column #14 Sample 12 63 0.4% 10% MeOH / 90% H2O 
Column #14 Sample 13 344 2.1% 10% MeOH / 90% H2O 
Column #14 Sample 14 526 3.2% 10% MeOH / 90% H2O 
Column #14 Sample 15 533 3.2% 10% MeOH / 90% H2O 
Column #14 Sample 16 667 4.0% 10% MeOH / 90% H2O 
Column #14 Sample 17 561 3.4% transition 
Column #14 Sample 18 418 2.5% 20% MeOH / 80% H2O 
Column #14 Sample 19 634 3.8% 20% MeOH / 80% H2O 
Column #14 Sample 20 4008 24.1% 20% MeOH / 80% H2O 
Column #14 Sample 21 15111 90.8% 20% MeOH / 80% H2O 
Column #14 Sample 22 7658 46.0% 20% MeOH / 80% H2O 
Column #14 Sample 23 655 3.9% 20% MeOH / 80% H2O 
Column #14 Sample 24 1592 9.6% 20% MeOH / 80% H2O 
Column #14 Sample 25 648 3.9% 20% MeOH / 80% H2O 
Column #14 Sample 26 747 4.5% 20% MeOH / 80% H2O 
Column #14 Sample 27 749 4.5% transition 
Column #14 Sample 28 2536 15.2% 30% MeOH / 70% H2O 
Column #14 Sample 29 609 3.7% 30% MeOH / 70% H2O 
Column #14 Sample 30 4359 26.2% 30% MeOH / 70% H2O 
Column #14 Sample 31 3119 18.7% 30% MeOH / 70% H2O 
Column #14 Sample 32 1377 8.3% 30% MeOH / 70% H2O 
Column #14 Sample 33 1051 6.3% 30% MeOH / 70% H2O 
Column #14 Sample 34 699 4.2% 30% MeOH / 70% H2O 
Column #14 Sample 35 733 4.4% 30% MeOH / 70% H2O 
Column #14 Sample 36 778 4.7% 30% MeOH / 70% H2O 
Column #14 Sample 37 1696 10.2% 30% MeOH / 70% H2O 
Column #14 Sample 38 658 4.0% transition 
Column #14 Sample 39 605 3.6% 40% MeOH / 60% H2O 
Column #14 Sample 40 508 3.1% 40% MeOH / 60% H2O 
Column #14 Sample 41 22218 133.5% 40% MeOH / 60% H2O 
Column #14 Sample 42 5180 31.1% 40% MeOH / 60% H2O 
Column #14 Sample 43 663 4.0% 40% MeOH / 60% H2O 
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Table A13, continued. 
Column #14 Sample 44 1674 10.1% 40% MeOH / 60% H2O 
Column #14 Sample 45 712 4.3% 40% MeOH / 60% H2O 
Column #14 Sample 46 1472 8.8% 40% MeOH / 60% H2O 
Column #14 Sample 47 1112 6.7% 40% MeOH / 60% H2O 
Column #14 Sample 48 3987 24.0% 40% MeOH / 60% H2O 
Column #14 Sample 49 822 4.9% transition 
Column #14 Sample 50 10374 62.3% 50% MeOH / 50% H2O 
Column #14 Sample 51 6657 40.0% 50% MeOH / 50% H2O 
Column #14 Sample 52 5512 33.1% 50% MeOH / 50% H2O 
Column #14 Sample 53 5900 35.4% 50% MeOH / 50% H2O 
Column #14 Sample 54 903 5.4% 50% MeOH / 50% H2O 
Column #14 Sample 55 6245 37.5% 50% MeOH / 50% H2O 
Column #14 Sample 56 2997 18.0% 50% MeOH / 50% H2O 
Column #14 Sample 57 601 3.6% 50% MeOH / 50% H2O 
Column #14 Sample 58 862 5.2% 50% MeOH / 50% H2O 
Column #14 Sample 59 1756 10.5% transition 
Column #14 Sample 60 556 3.3% 60% MeOH / 40% H2O 
Column #14 Sample 61 5044 30.3% 60% MeOH / 40% H2O 
Column #14 Sample 62 1600 9.6% 60% MeOH / 40% H2O 
Column #14 Sample 63 1465 8.8% 60% MeOH / 40% H2O 
Column #14 Sample 64 617 3.7% 60% MeOH / 40% H2O 
Column #14 Sample 65 980 5.9% 60% MeOH / 40% H2O 
Column #14 Sample 66 1886 11.3% 60% MeOH / 40% H2O 
Column #14 Sample 67 239 1.4% 60% MeOH / 40% H2O 
Column #14 Sample 68 466 2.8% 60% MeOH / 40% H2O 
Column #14 Sample 69 4017 24.1% 60% MeOH / 40% H2O 
Column #14 Sample 70 1839 11.0% transition 
Column #14 Sample 71 633 3.8% 70% MeOH / 30% H2O 
Column #14 Sample 72 496 3.0% 70% MeOH / 30% H2O 
Column #14 Sample 73 249 1.5% 70% MeOH / 30% H2O 
Column #14 Sample 74 759 4.6% 70% MeOH / 30% H2O 
Column #14 Sample 75 408 2.5% 70% MeOH / 30% H2O 
Column #14 Sample 76 340 2.0% 70% MeOH / 30% H2O 
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Table A13, continued. 
Column #14 Sample 77 130 0.8% 70% MeOH / 30% H2O 
Column #14 Sample 78 209 1.3% 70% MeOH / 30% H2O 
Column #14 Sample 79 243 1.5% 70% MeOH / 30% H2O 
Column #14 Sample 80 1016 6.1% transition 
Column #14 Sample 81 1563 9.4% 80% MeOH / 20% H2O 
Column #14 Sample 82 2745 16.5% 80% MeOH / 20% H2O 
Column #14 Sample 83 210 1.3% 80% MeOH / 20% H2O 
Column #14 Sample 84 799 4.8% 80% MeOH / 20% H2O 
Column #14 Sample 85 429 2.6% 80% MeOH / 20% H2O 
Column #14 Sample 86 1366 8.2% 80% MeOH / 20% H2O 
Column #14 Sample 87 417 2.5% 80% MeOH / 20% H2O 
Column #14 Sample 88 4573 27.5% 80% MeOH / 20% H2O 
Column #14 Sample 89 219 1.3% 80% MeOH / 20% H2O 
 
Table A14. Results for B16-F10 cell proliferation assay with Column #15 individual 
samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 90426 100.0% N/A 
Average 10 mg/mL Elderberry 38638 42.7% N/A 
Column #15 Sample 1 294 0.3% 0% MeOH / 100% H2O 
Column #15 Sample 2 189 0.2% 0% MeOH / 100% H2O 
Column #15 Sample 3 66 0.1% 0% MeOH / 100% H2O 
Column #15 Sample 4 67 0.1% 0% MeOH / 100% H2O 
Column #15 Sample 5 59 0.1% 0% MeOH / 100% H2O 
Column #15 Sample 6 57 0.1% 0% MeOH / 100% H2O 
Column #15 Sample 7 57 0.1% transition 
Column #15 Sample 8 45 0.0% 10% MeOH / 90% H2O 
Column #15 Sample 9 186 0.2% 10% MeOH / 90% H2O 
Column #15 Sample 10 68 0.1% 10% MeOH / 90% H2O 
Column #15 Sample 11 56 0.1% 10% MeOH / 90% H2O 
Column #15 Sample 12 72 0.1% 10% MeOH / 90% H2O 
Column #15 Sample 13 549 0.6% 10% MeOH / 90% H2O 
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Table A14, continued. 
Column #15 Sample 14 1399 1.5% 10% MeOH / 90% H2O 
Column #15 Sample 15 1689 1.9% 10% MeOH / 90% H2O 
Column #15 Sample 16 820 0.9% 10% MeOH / 90% H2O 
Column #15 Sample 17 14695 16.3% transition 
Column #15 Sample 18 11516 12.7% 20% MeOH / 80% H2O 
Column #15 Sample 19 11835 13.1% 20% MeOH / 80% H2O 
Column #15 Sample 20 5660 6.3% 20% MeOH / 80% H2O 
Column #15 Sample 21 24322 26.9% 20% MeOH / 80% H2O 
Column #15 Sample 22 12245 13.5% 20% MeOH / 80% H2O 
Column #15 Sample 23 24769 27.4% 20% MeOH / 80% H2O 
Column #15 Sample 24 16067 17.8% 20% MeOH / 80% H2O 
Column #15 Sample 25 16285 18.0% 20% MeOH / 80% H2O 
Column #15 Sample 26 8849 9.8% transition 
Column #15 Sample 27 4507 5.0% 30% MeOH / 70% H2O 
Column #15 Sample 28 2892 3.2% 30% MeOH / 70% H2O 
Column #15 Sample 29 2597 2.9% 30% MeOH / 70% H2O 
Column #15 Sample 30 3533 3.9% 30% MeOH / 70% H2O 
Column #15 Sample 31 1954 2.2% 30% MeOH / 70% H2O 
Column #15 Sample 32 2707 3.0% 30% MeOH / 70% H2O 
Column #15 Sample 33 256 0.3% 30% MeOH / 70% H2O 
Column #15 Sample 34 5621 6.2% 30% MeOH / 70% H2O 
Column #15 Sample 35 15542 17.2% 30% MeOH / 70% H2O 
Column #15 Sample 36 20378 22.5% 30% MeOH / 70% H2O 
Column #15 Sample 37 10473 11.6% transition 
Column #15 Sample 38 10221 11.3% 40% MeOH / 60% H2O 
Column #15 Sample 39 9383 10.4% 40% MeOH / 60% H2O 
Column #15 Sample 40 15425 17.1% 40% MeOH / 60% H2O 
Column #15 Sample 41 7464 8.3% 40% MeOH / 60% H2O 
Column #15 Sample 42 21701 24.0% 40% MeOH / 60% H2O 
Column #15 Sample 43 16474 18.2% 40% MeOH / 60% H2O 
Column #15 Sample 44 22236 24.6% 40% MeOH / 60% H2O 
Column #15 Sample 45 9230 10.2% 40% MeOH / 60% H2O 
Column #15 Sample 46 3518 3.9% 40% MeOH / 60% H2O 
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Table A14, continued. 
Column #15 Sample 47 3846 4.3% 40% MeOH / 60% H2O 
Column #15 Sample 48 2820 3.1% transition 
Column #15 Sample 49 2920 3.2% 50% MeOH / 50% H2O 
Column #15 Sample 50 1993 2.2% 50% MeOH / 50% H2O 
Column #15 Sample 51 2038 2.3% 50% MeOH / 50% H2O 
Column #15 Sample 52 761 0.8% 50% MeOH / 50% H2O 
Column #15 Sample 53 1620 1.8% 50% MeOH / 50% H2O 
Column #15 Sample 54 4922 5.4% 50% MeOH / 50% H2O 
Column #15 Sample 55 26135 28.9% 50% MeOH / 50% H2O 
Column #15 Sample 56 11142 12.3% 50% MeOH / 50% H2O 
Column #15 Sample 57 9534 10.5% 50% MeOH / 50% H2O 
Column #15 Sample 58 11612 12.8% 50% MeOH / 50% H2O 
Column #15 Sample 59 12003 13.3% transition 
Column #15 Sample 60 19887 22.0% 60% MeOH / 40% H2O 
Column #15 Sample 61 23968 26.5% 60% MeOH / 40% H2O 
Column #15 Sample 62 15243 16.9% 60% MeOH / 40% H2O 
Column #15 Sample 63 7486 8.3% 60% MeOH / 40% H2O 
Column #15 Sample 64 27139 30.0% 60% MeOH / 40% H2O 
Column #15 Sample 65 4835 5.3% 60% MeOH / 40% H2O 
Column #15 Sample 66 5862 6.5% 60% MeOH / 40% H2O 
Column #15 Sample 67 4974 5.5% 60% MeOH / 40% H2O 
Column #15 Sample 68 5770 6.4% 60% MeOH / 40% H2O 
Column #15 Sample 69 3060 3.4% transition 
Column #15 Sample 70 4314 4.8% 70% MeOH / 30% H2O 
Column #15 Sample 71 674 0.7% 70% MeOH / 30% H2O 
Column #15 Sample 72 1741 1.9% 70% MeOH / 30% H2O 
Column #15 Sample 73 1142 1.3% 70% MeOH / 30% H2O 
Column #15 Sample 74 1416 1.6% 70% MeOH / 30% H2O 
Column #15 Sample 75 18176 20.1% 70% MeOH / 30% H2O 
Column #15 Sample 76 15620 17.3% 70% MeOH / 30% H2O 
Column #15 Sample 77 9445 10.4% 70% MeOH / 30% H2O 
Column #15 Sample 78 13754 15.2% transition 
Column #15 Sample 79 16706 18.5% 80% MeOH / 20% H2O 
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Table A14, continued. 
Column #15 Sample 80 13186 14.6% 80% MeOH / 20% H2O 
Column #15 Sample 81 12010 13.3% 80% MeOH / 20% H2O 
Column #15 Sample 82 19324 21.4% 80% MeOH / 20% H2O 
Column #15 Sample 83 6747 7.5% 80% MeOH / 20% H2O 
Column #15 Sample 84 8147 9.0% 80% MeOH / 20% H2O 
Column #15 Sample 85 15487 17.1% 80% MeOH / 20% H2O 
Column #15 Sample 86 16579 18.3% 80% MeOH / 20% H2O 
Column #15 Sample 87 19463 21.5% 80% MeOH / 20% H2O 
 
Table A15. Results for B16-F10 cell proliferation assay with Column #16 individual 
samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 12243 100.0% N/A 
Average 10 mg/mL Elderberry 5003 40.9% N/A 
Column #16 Sample 1 230 1.9% 0% MeOH / 100% H2O 
Column #16 Sample 2 427 3.5% 0% MeOH / 100% H2O 
Column #16 Sample 3 262 2.1% 0% MeOH / 100% H2O 
Column #16 Sample 4 235 1.9% 0% MeOH / 100% H2O 
Column #16 Sample 5 257 2.1% 0% MeOH / 100% H2O 
Column #16 Sample 6 269 2.2% transition 
Column #16 Sample 7 510 4.2% 10% MeOH / 90% H2O 
Column #16 Sample 8 211 1.7% 10% MeOH / 90% H2O 
Column #16 Sample 9 295 2.4% 10% MeOH / 90% H2O 
Column #16 Sample 10 294 2.4% 10% MeOH / 90% H2O 
Column #16 Sample 11 316 2.6% 10% MeOH / 90% H2O 
Column #16 Sample 12 323 2.6% 10% MeOH / 90% H2O 
Column #16 Sample 13 603 4.9% 10% MeOH / 90% H2O 
Column #16 Sample 14 501 4.1% 10% MeOH / 90% H2O 
Column #16 Sample 15 1612 13.2% 10% MeOH / 90% H2O 
Column #16 Sample 16 819 6.7% 10% MeOH / 90% H2O 
Column #16 Sample 17 1066 8.7% transition 
Column #16 Sample 18 904 7.4% 20% MeOH / 80% H2O 
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Table A15, continued. 
Column #16 Sample 19 1360 11.1% 20% MeOH / 80% H2O 
Column #16 Sample 20 1972 16.1% 20% MeOH / 80% H2O 
Column #16 Sample 21 3474 28.4% 20% MeOH / 80% H2O 
Column #16 Sample 22 1248 10.2% 20% MeOH / 80% H2O 
Column #16 Sample 23 4226 34.5% 20% MeOH / 80% H2O 
Column #16 Sample 24 8393 68.6% 20% MeOH / 80% H2O 
Column #16 Sample 25 5453 44.5% 20% MeOH / 80% H2O 
Column #16 Sample 26 2440 19.9% 20% MeOH / 80% H2O 
Column #16 Sample 27 1854 15.1% 20% MeOH / 80% H2O 
Column #16 Sample 28 1098 9.0% transition 
Column #16 Sample 29 920 7.5% 30% MeOH / 70% H2O 
Column #16 Sample 30 1866 15.2% 30% MeOH / 70% H2O 
Column #16 Sample 31 1198 9.8% 30% MeOH / 70% H2O 
Column #16 Sample 32 1182 9.7% 30% MeOH / 70% H2O 
Column #16 Sample 33 1152 9.4% 30% MeOH / 70% H2O 
Column #16 Sample 34 3867 31.6% 30% MeOH / 70% H2O 
Column #16 Sample 35 7811 63.8% 30% MeOH / 70% H2O 
Column #16 Sample 36 3604 29.4% 30% MeOH / 70% H2O 
Column #16 Sample 37 2525 20.6% 30% MeOH / 70% H2O 
Column #16 Sample 38 2282 18.6% transition 
Column #16 Sample 39 1355 11.1% 40% MeOH / 60% H2O 
Column #16 Sample 40 3367 27.5% 40% MeOH / 60% H2O 
Column #16 Sample 41 1507 12.3% 40% MeOH / 60% H2O 
Column #16 Sample 42 5461 44.6% 40% MeOH / 60% H2O 
Column #16 Sample 43 2881 23.5% 40% MeOH / 60% H2O 
Column #16 Sample 44 10573 86.4% 40% MeOH / 60% H2O 
Column #16 Sample 45 5884 48.1% 40% MeOH / 60% H2O 
Column #16 Sample 46 1957 16.0% 40% MeOH / 60% H2O 
Column #16 Sample 47 1439 11.8% 40% MeOH / 60% H2O 
Column #16 Sample 48 803 6.6% transition 
Column #16 Sample 49 1137 9.3% 50% MeOH / 50% H2O 
Column #16 Sample 50 1149 9.4% 50% MeOH / 50% H2O 
Column #16 Sample 51 945 7.7% 50% MeOH / 50% H2O 
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Table A15, continued. 
Column #16 Sample 52 690 5.6% 50% MeOH / 50% H2O 
Column #16 Sample 53 1404 11.5% 50% MeOH / 50% H2O 
Column #16 Sample 54 1265 10.3% 50% MeOH / 50% H2O 
Column #16 Sample 55 5611 45.8% 50% MeOH / 50% H2O 
Column #16 Sample 56 1151 9.4% 50% MeOH / 50% H2O 
Column #16 Sample 57 597 4.9% 50% MeOH / 50% H2O 
Column #16 Sample 58 1918 15.7% 50% MeOH / 50% H2O 
Column #16 Sample 59 1144 9.3% transition 
Column #16 Sample 60 828 6.8% 60% MeOH / 40% H2O 
Column #16 Sample 61 602 4.9% 60% MeOH / 40% H2O 
Column #16 Sample 62 1210 9.9% 60% MeOH / 40% H2O 
Column #16 Sample 63 1059 8.6% 60% MeOH / 40% H2O 
Column #16 Sample 64 1270 10.4% 60% MeOH / 40% H2O 
Column #16 Sample 65 7338 59.9% 60% MeOH / 40% H2O 
Column #16 Sample 66 2376 19.4% 60% MeOH / 40% H2O 
Column #16 Sample 67 1822 14.9% 60% MeOH / 40% H2O 
Column #16 Sample 68 4747 38.8% 60% MeOH / 40% H2O 
Column #16 Sample 69 2181 17.8% transition 
Column #16 Sample 70 1496 12.2% 70% MeOH / 30% H2O 
Column #16 Sample 71 607 5.0% 70% MeOH / 30% H2O 
Column #16 Sample 72 1903 15.5% 70% MeOH / 30% H2O 
Column #16 Sample 73 668 5.5% 70% MeOH / 30% H2O 
Column #16 Sample 74 1075 8.8% 70% MeOH / 30% H2O 
Column #16 Sample 75 2797 22.8% 70% MeOH / 30% H2O 
Column #16 Sample 76 1136 9.3% 70% MeOH / 30% H2O 
Column #16 Sample 77 96 0.8% 70% MeOH / 30% H2O 
Column #16 Sample 78 285 2.3% 70% MeOH / 30% H2O 
Column #16 Sample 79 586 4.8% transition 
Column #16 Sample 80 229 1.9% 80% MeOH / 20% H2O 
Column #16 Sample 81 269 2.2% 80% MeOH / 20% H2O 
Column #16 Sample 82 616 5.0% 80% MeOH / 20% H2O 
Column #16 Sample 83 645 5.3% 80% MeOH / 20% H2O 
Column #16 Sample 84 126 1.0% 80% MeOH / 20% H2O 
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Table A15, continued. 
Column #16 Sample 85 241 2.0% 80% MeOH / 20% H2O 
Column #16 Sample 86 973 7.9% 80% MeOH / 20% H2O 
Column #16 Sample 87 221 1.8% 80% MeOH / 20% H2O 
Column #16 Sample 88 219 1.8% 80% MeOH / 20% H2O 
Column #16 Sample 89 7578 61.9% 80% MeOH / 20% H2O 
 
Table A16. Results for B16-F10 cell proliferation assay with Column #17 individual 
samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 12636 100.0% N/A 
Average 10 mg/mL Elderberry 4762 37.7% N/A 
Column #17 Sample 1 156 1.2% 0% MeOH / 100% H2O 
Column #17 Sample 2 189 1.5% 0% MeOH / 100% H2O 
Column #17 Sample 3 111 0.9% 0% MeOH / 100% H2O 
Column #17 Sample 4 92 0.7% 0% MeOH / 100% H2O 
Column #17 Sample 5 136 1.1% 0% MeOH / 100% H2O 
Column #17 Sample 6 97 0.8% transition 
Column #17 Sample 7 147 1.2% 10% MeOH / 90% H2O 
Column #17 Sample 8 121 1.0% 10% MeOH / 90% H2O 
Column #17 Sample 9 90 0.7% 10% MeOH / 90% H2O 
Column #17 Sample 10 112 0.9% 10% MeOH / 90% H2O 
Column #17 Sample 11 122 1.0% 10% MeOH / 90% H2O 
Column #17 Sample 12 131 1.0% 10% MeOH / 90% H2O 
Column #17 Sample 13 121 1.0% 10% MeOH / 90% H2O 
Column #17 Sample 14 305 2.4% 10% MeOH / 90% H2O 
Column #17 Sample 15 542 4.3% 10% MeOH / 90% H2O 
Column #17 Sample 16 459 3.6% 10% MeOH / 90% H2O 
Column #17 Sample 17 1918 15.2% transition 
Column #17 Sample 18 503 4.0% 20% MeOH / 80% H2O 
Column #17 Sample 19 1507 11.9% 20% MeOH / 80% H2O 
Column #17 Sample 20 3877 30.7% 20% MeOH / 80% H2O 
Column #17 Sample 21 3732 29.5% 20% MeOH / 80% H2O 
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Table A16, continued. 
Column #17 Sample 22 2625 20.8% 20% MeOH / 80% H2O 
Column #17 Sample 23 4216 33.4% 20% MeOH / 80% H2O 
Column #17 Sample 24 7476 59.2% 20% MeOH / 80% H2O 
Column #17 Sample 25 3981 31.5% 20% MeOH / 80% H2O 
Column #17 Sample 26 6780 53.7% 20% MeOH / 80% H2O 
Column #17 Sample 27 4777 37.8% 20% MeOH / 80% H2O 
Column #17 Sample 28 5275 41.7% transition 
Column #17 Sample 29 6261 49.5% 30% MeOH / 70% H2O 
Column #17 Sample 30 5656 44.8% 30% MeOH / 70% H2O 
Column #17 Sample 31 5160 40.8% 30% MeOH / 70% H2O 
Column #17 Sample 32 4414 34.9% 30% MeOH / 70% H2O 
Column #17 Sample 33 3905 30.9% 30% MeOH / 70% H2O 
Column #17 Sample 34 1441 11.4% 30% MeOH / 70% H2O 
Column #17 Sample 35 10035 79.4% 30% MeOH / 70% H2O 
Column #17 Sample 36 7212 57.1% 30% MeOH / 70% H2O 
Column #17 Sample 37 8585 67.9% 30% MeOH / 70% H2O 
Column #17 Sample 38 9140 72.3% 30% MeOH / 70% H2O 
Column #17 Sample 39 9598 76.0% transition 
Column #17 Sample 40 8918 70.6% 40% MeOH / 60% H2O 
Column #17 Sample 41 7615 60.3% 40% MeOH / 60% H2O 
Column #17 Sample 42 8191 64.8% 40% MeOH / 60% H2O 
Column #17 Sample 43 8419 66.6% 40% MeOH / 60% H2O 
Column #17 Sample 44 8912 70.5% 40% MeOH / 60% H2O 
Column #17 Sample 45 2719 21.5% 40% MeOH / 60% H2O 
Column #17 Sample 46 12177 96.4% 40% MeOH / 60% H2O 
Column #17 Sample 47 9601 76.0% 40% MeOH / 60% H2O 
Column #17 Sample 48 6001 47.5% 40% MeOH / 60% H2O 
Column #17 Sample 49 9766 77.3% 40% MeOH / 60% H2O 
Column #17 Sample 50 8305 65.7% transition 
Column #17 Sample 51 5150 40.8% 50% MeOH / 50% H2O 
Column #17 Sample 52 7661 60.6% 50% MeOH / 50% H2O 
Column #17 Sample 53 1656 13.1% 50% MeOH / 50% H2O 
Column #17 Sample 54 1403 11.1% 50% MeOH / 50% H2O 
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Table A16, continued. 
Column #17 Sample 55 1063 8.4% 50% MeOH / 50% H2O 
Column #17 Sample 56 5058 40.0% 50% MeOH / 50% H2O 
Column #17 Sample 57 177 1.4% 50% MeOH / 50% H2O 
Column #17 Sample 58 179 1.4% 50% MeOH / 50% H2O 
Column #17 Sample 59 271 2.1% 50% MeOH / 50% H2O 
Column #17 Sample 60 121 1.0% transition 
Column #17 Sample 61 203 1.6% 60% MeOH / 40% H2O 
Column #17 Sample 62 74 0.6% 60% MeOH / 40% H2O 
Column #17 Sample 63 129 1.0% 60% MeOH / 40% H2O 
Column #17 Sample 64 3321 26.3% 60% MeOH / 40% H2O 
Column #17 Sample 65 96 0.8% 60% MeOH / 40% H2O 
Column #17 Sample 66 126 1.0% 60% MeOH / 40% H2O 
Column #17 Sample 67 2011 15.9% 60% MeOH / 40% H2O 
Column #17 Sample 68 3645 28.8% 60% MeOH / 40% H2O 
Column #17 Sample 69 121 1.0% transition 
Column #17 Sample 70 1333 10.5% 70% MeOH / 30% H2O 
Column #17 Sample 71 89 0.7% 70% MeOH / 30% H2O 
Column #17 Sample 72 277 2.2% 70% MeOH / 30% H2O 
Column #17 Sample 73 443 3.5% 70% MeOH / 30% H2O 
Column #17 Sample 74 108 0.9% 70% MeOH / 30% H2O 
Column #17 Sample 75 141 1.1% 70% MeOH / 30% H2O 
Column #17 Sample 76 109 0.9% 70% MeOH / 30% H2O 
Column #17 Sample 77 161 1.3% 70% MeOH / 30% H2O 
Column #17 Sample 78 1250 9.9% 70% MeOH / 30% H2O 
Column #17 Sample 79 6224 49.3% 70% MeOH / 30% H2O 
Column #17 Sample 80 2440 19.3% transition 
Column #17 Sample 81 6764 53.5% 80% MeOH / 20% H2O 
Column #17 Sample 82 10156 80.4% 80% MeOH / 20% H2O 
Column #17 Sample 83 5374 42.5% 80% MeOH / 20% H2O 
Column #17 Sample 84 7535 59.6% 80% MeOH / 20% H2O 
Column #17 Sample 85 5982 47.3% 80% MeOH / 20% H2O 
Column #17 Sample 86 3996 31.6% 80% MeOH / 20% H2O 
Column #17 Sample 87 93 0.7% 80% MeOH / 20% H2O 
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Table A16, continued. 
Column #17 Sample 88 107 0.8% 80% MeOH / 20% H2O 
Column #17 Sample 89 13533 107.1% 80% MeOH / 20% H2O 
 
Table A17. Results for B16-F10 cell proliferation assay with Column #18 individual 
samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 7159 100.0% N/A 
Average 10 mg/mL Elderberry 2257 31.5% N/A 
Column #18 Sample 1 154 2.2% 0% MeOH / 100% H2O 
Column #18 Sample 2 243 3.4% 0% MeOH / 100% H2O 
Column #18 Sample 3 158 2.2% 0% MeOH / 100% H2O 
Column #18 Sample 4 82 1.1% 0% MeOH / 100% H2O 
Column #18 Sample 5 103 1.4% 0% MeOH / 100% H2O 
Column #18 Sample 6 136 1.9% transition 
Column #18 Sample 7 97 1.4% 10% MeOH / 90% H2O 
Column #18 Sample 8 95 1.3% 10% MeOH / 90% H2O 
Column #18 Sample 9 101 1.4% 10% MeOH / 90% H2O 
Column #18 Sample 10 79 1.1% 10% MeOH / 90% H2O 
Column #18 Sample 11 90 1.3% 10% MeOH / 90% H2O 
Column #18 Sample 12 330 4.6% 10% MeOH / 90% H2O 
Column #18 Sample 13 101 1.4% 10% MeOH / 90% H2O 
Column #18 Sample 14 162 2.3% 10% MeOH / 90% H2O 
Column #18 Sample 15 145 2.0% 10% MeOH / 90% H2O 
Column #18 Sample 16 1488 20.8% 10% MeOH / 90% H2O 
Column #18 Sample 17 579 8.1% transition 
Column #18 Sample 18 133 1.9% 20% MeOH / 80% H2O 
Column #18 Sample 19 130 1.8% 20% MeOH / 80% H2O 
Column #18 Sample 20 136 1.9% 20% MeOH / 80% H2O 
Column #18 Sample 21 135 1.9% 20% MeOH / 80% H2O 
Column #18 Sample 22 532 7.4% 20% MeOH / 80% H2O 
Column #18 Sample 23 896 12.5% 20% MeOH / 80% H2O 
Column #18 Sample 24 112 1.6% 20% MeOH / 80% H2O 
Column #18 Sample 25 633 8.8% 20% MeOH / 80% H2O 
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Table A17, continued. 
Column #18 Sample 26 2732 38.2% 20% MeOH / 80% H2O 
Column #18 Sample 27 3728 52.1% transition 
Column #18 Sample 28 1597 22.3% 30% MeOH / 70% H2O 
Column #18 Sample 29 2679 37.4% 30% MeOH / 70% H2O 
Column #18 Sample 30 3010 42.0% 30% MeOH / 70% H2O 
Column #18 Sample 31 82 1.1% 30% MeOH / 70% H2O 
Column #18 Sample 32 1403 19.6% 30% MeOH / 70% H2O 
Column #18 Sample 33 60 0.8% 30% MeOH / 70% H2O 
Column #18 Sample 34 2194 30.6% 30% MeOH / 70% H2O 
Column #18 Sample 35 180 2.5% 30% MeOH / 70% H2O 
Column #18 Sample 36 1210 16.9% 30% MeOH / 70% H2O 
Column #18 Sample 37 6253 87.3% 30% MeOH / 70% H2O 
Column #18 Sample 38 4524 63.2% transition 
Column #18 Sample 39 129 1.8% 40% MeOH / 60% H2O 
Column #18 Sample 40 2074 29.0% 40% MeOH / 60% H2O 
Column #18 Sample 41 4386 61.3% 40% MeOH / 60% H2O 
Column #18 Sample 42 3188 44.5% 40% MeOH / 60% H2O 
Column #18 Sample 43 1287 18.0% 40% MeOH / 60% H2O 
Column #18 Sample 44 1862 26.0% 40% MeOH / 60% H2O 
Column #18 Sample 45 2052 28.7% 40% MeOH / 60% H2O 
Column #18 Sample 46 1945 27.2% 40% MeOH / 60% H2O 
Column #18 Sample 47 3008 42.0% 40% MeOH / 60% H2O 
Column #18 Sample 48 2110 29.5% 40% MeOH / 60% H2O 
Column #18 Sample 49 3303 46.1% transition 
Column #18 Sample 50 2199 30.7% 50% MeOH / 50% H2O 
Column #18 Sample 51 2041 28.5% 50% MeOH / 50% H2O 
Column #18 Sample 52 1765 24.7% 50% MeOH / 50% H2O 
Column #18 Sample 53 2111 29.5% 50% MeOH / 50% H2O 
Column #18 Sample 54 1948 27.2% 50% MeOH / 50% H2O 
Column #18 Sample 55 4796 67.0% 50% MeOH / 50% H2O 
Column #18 Sample 56 6866 95.9% 50% MeOH / 50% H2O 
Column #18 Sample 57 1970 27.5% 50% MeOH / 50% H2O 
Column #18 Sample 58 8151 113.9% 50% MeOH / 50% H2O 
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Table A17, continued. 
Column #18 Sample 59 4958 69.3% 50% MeOH / 50% H2O 
Column #18 Sample 60 215 3.0% transition 
Column #18 Sample 61 3647 50.9% 60% MeOH / 40% H2O 
Column #18 Sample 62 1741 24.3% 60% MeOH / 40% H2O 
Column #18 Sample 63 8061 112.6% 60% MeOH / 40% H2O 
Column #18 Sample 64 4158 58.1% 60% MeOH / 40% H2O 
Column #18 Sample 65 2941 41.1% 60% MeOH / 40% H2O 
Column #18 Sample 66 1799 25.1% 60% MeOH / 40% H2O 
Column #18 Sample 67 2895 40.4% 60% MeOH / 40% H2O 
Column #18 Sample 68 1268 17.7% 60% MeOH / 40% H2O 
Column #18 Sample 69 1656 23.1% 60% MeOH / 40% H2O 
Column #18 Sample 70 1624 22.7% 60% MeOH / 40% H2O 
Column #18 Sample 71 1772 24.8% transition 
Column #18 Sample 72 323 4.5% 70% MeOH / 30% H2O 
Column #18 Sample 73 535 7.5% 70% MeOH / 30% H2O 
Column #18 Sample 74 983 13.7% 70% MeOH / 30% H2O 
Column #18 Sample 75 380 5.3% 70% MeOH / 30% H2O 
Column #18 Sample 76 114 1.6% 70% MeOH / 30% H2O 
Column #18 Sample 77 132 1.8% 70% MeOH / 30% H2O 
Column #18 Sample 78 116 1.6% 70% MeOH / 30% H2O 
Column #18 Sample 79 88 1.2% 70% MeOH / 30% H2O 
Column #18 Sample 80 176 2.5% 70% MeOH / 30% H2O 
Column #18 Sample 81 108 1.5% transition 
Column #18 Sample 82 123 1.7% 80% MeOH / 20% H2O 
Column #18 Sample 83 134 1.9% 80% MeOH / 20% H2O 
Column #18 Sample 84 88 1.2% 80% MeOH / 20% H2O 
Column #18 Sample 85 93 1.3% 80% MeOH / 20% H2O 
Column #18 Sample 86 148 2.1% 80% MeOH / 20% H2O 
Column #18 Sample 87 90 1.3% 80% MeOH / 20% H2O 
Column #18 Sample 88 70 1.0% 80% MeOH / 20% H2O 
Column #18 Sample 89 82 1.1% 80% MeOH / 20% H2O 
Column #18 Sample 90 76 1.1% 80% MeOH / 20% H2O 
Column #18 Sample 91 1348 18.8% 80% MeOH / 20% H2O 
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Table A18. Results for B16-F10 cell proliferation assay with Column #19 individual 
samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 14189 100.0% N/A 
Average 10 mg/mL Elderberry 3525 24.8% N/A 
Column #19 Sample 1 110 0.8% 0% MeOH / 100% H2O 
Column #19 Sample 2 140 1.0% 0% MeOH / 100% H2O 
Column #19 Sample 3 133 0.9% 0% MeOH / 100% H2O 
Column #19 Sample 4 84 0.6% 0% MeOH / 100% H2O 
Column #19 Sample 5 69 0.5% transition 
Column #19 Sample 6 74 0.5% 10% MeOH / 90% H2O 
Column #19 Sample 7 81 0.6% 10% MeOH / 90% H2O 
Column #19 Sample 8 85 0.6% 10% MeOH / 90% H2O 
Column #19 Sample 9 95 0.7% 10% MeOH / 90% H2O 
Column #19 Sample 10 119 0.8% 10% MeOH / 90% H2O 
Column #19 Sample 11 85 0.6% 10% MeOH / 90% H2O 
Column #19 Sample 12 68 0.5% 10% MeOH / 90% H2O 
Column #19 Sample 13 96 0.7% 10% MeOH / 90% H2O 
Column #19 Sample 14 89 0.6% 10% MeOH / 90% H2O 
Column #19 Sample 15 96 0.7% 10% MeOH / 90% H2O 
Column #19 Sample 16 115 0.8% transition 
Column #19 Sample 17 100 0.7% 20% MeOH / 80% H2O 
Column #19 Sample 18 164 1.2% 20% MeOH / 80% H2O 
Column #19 Sample 19 651 4.6% 20% MeOH / 80% H2O 
Column #19 Sample 20 2371 16.7% 20% MeOH / 80% H2O 
Column #19 Sample 21 781 5.5% 20% MeOH / 80% H2O 
Column #19 Sample 22 2895 20.4% 20% MeOH / 80% H2O 
Column #19 Sample 23 99 0.7% 20% MeOH / 80% H2O 
Column #19 Sample 24 147 1.0% 20% MeOH / 80% H2O 
Column #19 Sample 25 120 0.8% 20% MeOH / 80% H2O 
Column #19 Sample 26 2374 16.7% 20% MeOH / 80% H2O 
Column #19 Sample 27 67 0.5% transition 
Column #19 Sample 28 77 0.5% 30% MeOH / 70% H2O 
Column #19 Sample 29 71 0.5% 30% MeOH / 70% H2O 
Column #19 Sample 30 1426 10.1% 30% MeOH / 70% H2O 
Column #19 Sample 31 61 0.4% 30% MeOH / 70% H2O 
141 
 
Table A18, continued. 
Column #19 Sample 32 88 0.6% 30% MeOH / 70% H2O 
Column #19 Sample 33 77 0.5% 30% MeOH / 70% H2O 
Column #19 Sample 34 2334 16.4% 30% MeOH / 70% H2O 
Column #19 Sample 35 97 0.7% 30% MeOH / 70% H2O 
Column #19 Sample 36 107 0.8% 30% MeOH / 70% H2O 
Column #19 Sample 37 1808 12.7% 30% MeOH / 70% H2O 
Column #19 Sample 38 696 4.9% transition 
Column #19 Sample 39 107 0.8% 40% MeOH / 60% H2O 
Column #19 Sample 40 154 1.1% 40% MeOH / 60% H2O 
Column #19 Sample 41 70 0.5% 40% MeOH / 60% H2O 
Column #19 Sample 42 104 0.7% 40% MeOH / 60% H2O 
Column #19 Sample 43 133 0.9% 40% MeOH / 60% H2O 
Column #19 Sample 44 5219 36.8% 40% MeOH / 60% H2O 
Column #19 Sample 45 234 1.6% 40% MeOH / 60% H2O 
Column #19 Sample 46 67 0.5% 40% MeOH / 60% H2O 
Column #19 Sample 47 302 2.1% 40% MeOH / 60% H2O 
Column #19 Sample 48 890 6.3% 40% MeOH / 60% H2O 
Column #19 Sample 49 139 1.0% transition 
Column #19 Sample 50 6012 42.4% 50% MeOH / 50% H2O 
Column #19 Sample 51 4316 30.4% 50% MeOH / 50% H2O 
Column #19 Sample 52 6799 47.9% 50% MeOH / 50% H2O 
Column #19 Sample 53 2706 19.1% 50% MeOH / 50% H2O 
Column #19 Sample 54 3463 24.4% 50% MeOH / 50% H2O 
Column #19 Sample 55 7213 50.8% 50% MeOH / 50% H2O 
Column #19 Sample 56 12487 88.0% 50% MeOH / 50% H2O 
Column #19 Sample 57 11205 79.0% 50% MeOH / 50% H2O 
Column #19 Sample 58 4939 34.8% 50% MeOH / 50% H2O 
Column #19 Sample 59 6616 46.6% 50% MeOH / 50% H2O 
Column #19 Sample 60 8650 61.0% transition 
Column #19 Sample 61 844 5.9% 60% MeOH / 40% H2O 
Column #19 Sample 62 995 7.0% 60% MeOH / 40% H2O 
Column #19 Sample 63 108 0.8% 60% MeOH / 40% H2O 
Column #19 Sample 64 257 1.8% 60% MeOH / 40% H2O 
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Table A18, continued. 
Column #19 Sample 65 59 0.4% 60% MeOH / 40% H2O 
Column #19 Sample 66 3018 21.3% 60% MeOH / 40% H2O 
Column #19 Sample 67 84 0.6% 60% MeOH / 40% H2O 
Column #19 Sample 68 76 0.5% 60% MeOH / 40% H2O 
Column #19 Sample 69 94 0.7% 60% MeOH / 40% H2O 
Column #19 Sample 70 167 1.2% transition 
Column #19 Sample 71 2344 16.5% 70% MeOH / 30% H2O 
Column #19 Sample 72 1006 7.1% 70% MeOH / 30% H2O 
Column #19 Sample 73 114 0.8% 70% MeOH / 30% H2O 
Column #19 Sample 74 1057 7.4% 70% MeOH / 30% H2O 
Column #19 Sample 75 665 4.7% 70% MeOH / 30% H2O 
Column #19 Sample 76 6545 46.1% 70% MeOH / 30% H2O 
Column #19 Sample 77 4760 33.5% 70% MeOH / 30% H2O 
Column #19 Sample 78 3325 23.4% 70% MeOH / 30% H2O 
Column #19 Sample 79 415 2.9% 70% MeOH / 30% H2O 
Column #19 Sample 80 1399 9.9% 70% MeOH / 30% H2O 
Column #19 Sample 81 1633 11.5% transition 
Column #19 Sample 82 119 0.8% 80% MeOH / 20% H2O 
Column #19 Sample 83 197 1.4% 80% MeOH / 20% H2O 
Column #19 Sample 84 341 2.4% 80% MeOH / 20% H2O 
Column #19 Sample 85 81 0.6% 80% MeOH / 20% H2O 
Column #19 Sample 86 98 0.7% 80% MeOH / 20% H2O 
Column #19 Sample 87 122 0.9% 80% MeOH / 20% H2O 
Column #19 Sample 88 78 0.5% 80% MeOH / 20% H2O 
Column #19 Sample 89 104 0.7% 80% MeOH / 20% H2O 
Column #19 Sample 90 118 0.8% 80% MeOH / 20% H2O 
Column #19 Sample 91 167 1.2% 80% MeOH / 20% H2O 
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Table A19. Results for B16-F10 cell proliferation assay with Column #20 individual 
samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 35762 100.0% N/A 
Average 10 mg/mL Elderberry 14552 40.7% N/A 
Column #20 Sample 1 160 0.4% 0% MeOH / 100% H2O 
Column #20 Sample 2 131 0.4% 0% MeOH / 100% H2O 
Column #20 Sample 3 96 0.3% 0% MeOH / 100% H2O 
Column #20 Sample 4 51 0.1% 0% MeOH / 100% H2O 
Column #20 Sample 5 102 0.3% 0% MeOH / 100% H2O 
Column #20 Sample 6 53 0.1% 0% MeOH / 100% H2O 
Column #20 Sample 7 51 0.1% transition 
Column #20 Sample 8 23 0.1% 10% MeOH / 90% H2O 
Column #20 Sample 9 50 0.1% 10% MeOH / 90% H2O 
Column #20 Sample 10 94 0.3% 10% MeOH / 90% H2O 
Column #20 Sample 11 71 0.2% 10% MeOH / 90% H2O 
Column #20 Sample 12 87 0.2% 10% MeOH / 90% H2O 
Column #20 Sample 13 53 0.1% 10% MeOH / 90% H2O 
Column #20 Sample 14 78 0.2% 10% MeOH / 90% H2O 
Column #20 Sample 15 105 0.3% 10% MeOH / 90% H2O 
Column #20 Sample 16 1799 5.0% 10% MeOH / 90% H2O 
Column #20 Sample 17 154 0.4% 10% MeOH / 90% H2O 
Column #20 Sample 18 656 1.8% transition 
Column #20 Sample 19 11099 31.0% 20% MeOH / 80% H2O 
Column #20 Sample 20 1056 3.0% 20% MeOH / 80% H2O 
Column #20 Sample 21 4232 11.8% 20% MeOH / 80% H2O 
Column #20 Sample 22 165 0.5% 20% MeOH / 80% H2O 
Column #20 Sample 23 4796 13.4% 20% MeOH / 80% H2O 
Column #20 Sample 24 23703 66.3% 20% MeOH / 80% H2O 
Column #20 Sample 25 1200 3.4% 20% MeOH / 80% H2O 
Column #20 Sample 26 17718 49.5% 20% MeOH / 80% H2O 
Column #20 Sample 27 20270 56.7% transition 
Column #20 Sample 28 1072 3.0% 30% MeOH / 70% H2O 
Column #20 Sample 29 194 0.5% 30% MeOH / 70% H2O 
Column #20 Sample 30 95 0.3% 30% MeOH / 70% H2O 
Column #20 Sample 31 3092 8.6% 30% MeOH / 70% H2O 
144 
 
Table A19, continued. 
Column #20 Sample 32 98 0.3% 30% MeOH / 70% H2O 
Column #20 Sample 33 96 0.3% 30% MeOH / 70% H2O 
Column #20 Sample 34 2268 6.3% 30% MeOH / 70% H2O 
Column #20 Sample 35 290 0.8% 30% MeOH / 70% H2O 
Column #20 Sample 36 129 0.4% 30% MeOH / 70% H2O 
Column #20 Sample 37 165 0.5% 30% MeOH / 70% H2O 
Column #20 Sample 38 212 0.6% transition 
Column #20 Sample 39 130 0.4% 40% MeOH / 60% H2O 
Column #20 Sample 40 190 0.5% 40% MeOH / 60% H2O 
Column #20 Sample 41 109 0.3% 40% MeOH / 60% H2O 
Column #20 Sample 42 3422 9.6% 40% MeOH / 60% H2O 
Column #20 Sample 43 37291 104.3% 40% MeOH / 60% H2O 
Column #20 Sample 44 8214 23.0% 40% MeOH / 60% H2O 
Column #20 Sample 45 129 0.4% 40% MeOH / 60% H2O 
Column #20 Sample 46 162 0.5% 40% MeOH / 60% H2O 
Column #20 Sample 47 472 1.3% 40% MeOH / 60% H2O 
Column #20 Sample 48 12078 33.8% 40% MeOH / 60% H2O 
Column #20 Sample 49 2068 5.8% transition 
Column #20 Sample 50 95 0.3% 50% MeOH / 50% H2O 
Column #20 Sample 51 2042 5.7% 50% MeOH / 50% H2O 
Column #20 Sample 52 4100 11.5% 50% MeOH / 50% H2O 
Column #20 Sample 53 85 0.2% 50% MeOH / 50% H2O 
Column #20 Sample 54 15569 43.5% 50% MeOH / 50% H2O 
Column #20 Sample 55 140 0.4% 50% MeOH / 50% H2O 
Column #20 Sample 56 16609 46.4% 50% MeOH / 50% H2O 
Column #20 Sample 57 990 2.8% 50% MeOH / 50% H2O 
Column #20 Sample 58 4106 11.5% 50% MeOH / 50% H2O 
Column #20 Sample 59 1515 4.2% transition 
Column #20 Sample 60 140 0.4% 60% MeOH / 40% H2O 
Column #20 Sample 61 99 0.3% 60% MeOH / 40% H2O 
Column #20 Sample 62 2519 7.0% 60% MeOH / 40% H2O 
Column #20 Sample 63 115 0.3% 60% MeOH / 40% H2O 
Column #20 Sample 64 6449 18.0% 60% MeOH / 40% H2O 
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Table A19, continued. 
Column #20 Sample 65 84 0.2% 60% MeOH / 40% H2O 
Column #20 Sample 66 93 0.3% 60% MeOH / 40% H2O 
Column #20 Sample 67 2420 6.8% 60% MeOH / 40% H2O 
Column #20 Sample 68 16925 47.3% 60% MeOH / 40% H2O 
Column #20 Sample 69 78 0.2% transition 
Column #20 Sample 70 131 0.4% 70% MeOH / 30% H2O 
Column #20 Sample 71 5219 14.6% 70% MeOH / 30% H2O 
Column #20 Sample 72 5159 14.4% 70% MeOH / 30% H2O 
Column #20 Sample 73 1527 4.3% 70% MeOH / 30% H2O 
Column #20 Sample 74 766 2.1% 70% MeOH / 30% H2O 
Column #20 Sample 75 2215 6.2% 70% MeOH / 30% H2O 
Column #20 Sample 76 191 0.5% 70% MeOH / 30% H2O 
Column #20 Sample 77 651 1.8% 70% MeOH / 30% H2O 
Column #20 Sample 78 1326 3.7% 70% MeOH / 30% H2O 
Column #20 Sample 79 136 0.4% transition 
Column #20 Sample 80 161 0.5% 80% MeOH / 20% H2O 
Column #20 Sample 81 240 0.7% 80% MeOH / 20% H2O 
Column #20 Sample 82 164 0.5% 80% MeOH / 20% H2O 
Column #20 Sample 83 1283 3.6% 80% MeOH / 20% H2O 
Column #20 Sample 84 82 0.2% 80% MeOH / 20% H2O 
Column #20 Sample 85 238 0.7% 80% MeOH / 20% H2O 
Column #20 Sample 86 65 0.2% 80% MeOH / 20% H2O 
Column #20 Sample 87 44 0.1% 80% MeOH / 20% H2O 
Column #20 Sample 88 128 0.4% 80% MeOH / 20% H2O 
Column #20 Sample 89 293 0.8% 80% MeOH / 20% H2O 
 
Table A20. Results for B16-F10 cell proliferation assay with Column #21 individual 
samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 38021 100.0% N/A 
Average 10 mg/mL Elderberry 14552 38.3% N/A 
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Table A20, continued. 
Column #21 Sample 1 96 0.3% 0% MeOH / 100% H2O 
Column #21 Sample 2 136 0.4% 0% MeOH / 100% H2O 
Column #21 Sample 3 99 0.3% 0% MeOH / 100% H2O 
Column #21 Sample 4 91 0.2% 0% MeOH / 100% H2O 
Column #21 Sample 5 85 0.2% 0% MeOH / 100% H2O 
Column #21 Sample 6 47 0.1% transition 
Column #21 Sample 7 50 0.1% 10% MeOH / 90% H2O 
Column #21 Sample 8 67 0.2% 10% MeOH / 90% H2O 
Column #21 Sample 9 60 0.2% 10% MeOH / 90% H2O 
Column #21 Sample 10 58 0.2% 10% MeOH / 90% H2O 
Column #21 Sample 11 58 0.2% 10% MeOH / 90% H2O 
Column #21 Sample 12 54 0.1% 10% MeOH / 90% H2O 
Column #21 Sample 13 3843 10.1% 10% MeOH / 90% H2O 
Column #21 Sample 14 196 0.5% 10% MeOH / 90% H2O 
Column #21 Sample 15 184 0.5% 10% MeOH / 90% H2O 
Column #21 Sample 16 12791 33.6% 10% MeOH / 90% H2O 
Column #21 Sample 17 380 1.0% transition 
Column #21 Sample 18 935 2.5% 20% MeOH / 80% H2O 
Column #21 Sample 19 6919 18.2% 20% MeOH / 80% H2O 
Column #21 Sample 20 4023 10.6% 20% MeOH / 80% H2O 
Column #21 Sample 21 6186 16.3% 20% MeOH / 80% H2O 
Column #21 Sample 22 19949 52.5% 20% MeOH / 80% H2O 
Column #21 Sample 23 17975 47.3% 20% MeOH / 80% H2O 
Column #21 Sample 24 24311 63.9% 20% MeOH / 80% H2O 
Column #21 Sample 25 7850 20.6% 20% MeOH / 80% H2O 
Column #21 Sample 26 10454 27.5% 20% MeOH / 80% H2O 
Column #21 Sample 27 12937 34.0% 20% MeOH / 80% H2O 
Column #21 Sample 28 7587 20.0% transition 
Column #21 Sample 29 13765 36.2% 30% MeOH / 70% H2O 
Column #21 Sample 30 14369 37.8% 30% MeOH / 70% H2O 
Column #21 Sample 31 9125 24.0% 30% MeOH / 70% H2O 
Column #21 Sample 32 7569 19.9% 30% MeOH / 70% H2O 
Column #21 Sample 33 14767 38.8% 30% MeOH / 70% H2O 
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Table A20, continued. 
Column #21 Sample 34 10543 27.7% 30% MeOH / 70% H2O 
Column #21 Sample 35 19302 50.8% 30% MeOH / 70% H2O 
Column #21 Sample 36 570 1.5% 30% MeOH / 70% H2O 
Column #21 Sample 37 14932 39.3% 30% MeOH / 70% H2O 
Column #21 Sample 38 21155 55.6% 30% MeOH / 70% H2O 
Column #21 Sample 39 14183 37.3% transition 
Column #21 Sample 40 10244 26.9% 40% MeOH / 60% H2O 
Column #21 Sample 41 23292 61.3% 40% MeOH / 60% H2O 
Column #21 Sample 42 16579 43.6% 40% MeOH / 60% H2O 
Column #21 Sample 43 18850 49.6% 40% MeOH / 60% H2O 
Column #21 Sample 44 20927 55.0% 40% MeOH / 60% H2O 
Column #21 Sample 45 21599 56.8% 40% MeOH / 60% H2O 
Column #21 Sample 46 17394 45.7% 40% MeOH / 60% H2O 
Column #21 Sample 47 22453 59.1% 40% MeOH / 60% H2O 
Column #21 Sample 48 13953 36.7% 40% MeOH / 60% H2O 
Column #21 Sample 49 21775 57.3% 40% MeOH / 60% H2O 
Column #21 Sample 50 12429 32.7% transition 
Column #21 Sample 51 20614 54.2% 50% MeOH / 50% H2O 
Column #21 Sample 52 24273 63.8% 50% MeOH / 50% H2O 
Column #21 Sample 53 17061 44.9% 50% MeOH / 50% H2O 
Column #21 Sample 54 17081 44.9% 50% MeOH / 50% H2O 
Column #21 Sample 55 16210 42.6% 50% MeOH / 50% H2O 
Column #21 Sample 56 5639 14.8% 50% MeOH / 50% H2O 
Column #21 Sample 57 22204 58.4% 50% MeOH / 50% H2O 
Column #21 Sample 58 14208 37.4% 50% MeOH / 50% H2O 
Column #21 Sample 59 19493 51.3% 50% MeOH / 50% H2O 
Column #21 Sample 60 24914 65.5% 50% MeOH / 50% H2O 
Column #21 Sample 61 626 1.6% transition 
Column #21 Sample 62 196 0.5% 60% MeOH / 40% H2O 
Column #21 Sample 63 2090 5.5% 60% MeOH / 40% H2O 
Column #21 Sample 64 80 0.2% 60% MeOH / 40% H2O 
Column #21 Sample 65 10509 27.6% 60% MeOH / 40% H2O 
Column #21 Sample 66 9665 25.4% 60% MeOH / 40% H2O 
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Table A20, continued. 
Column #21 Sample 67 5605 14.7% 60% MeOH / 40% H2O 
Column #21 Sample 68 3486 9.2% 60% MeOH / 40% H2O 
Column #21 Sample 69 1662 4.4% 60% MeOH / 40% H2O 
Column #21 Sample 70 5915 15.6% 60% MeOH / 40% H2O 
Column #21 Sample 71 13871 36.5% 60% MeOH / 40% H2O 
Column #21 Sample 72 79 0.2% transition 
Column #21 Sample 73 999 2.6% 70% MeOH / 30% H2O 
Column #21 Sample 74 5133 13.5% 70% MeOH / 30% H2O 
Column #21 Sample 75 196 0.5% 70% MeOH / 30% H2O 
Column #21 Sample 76 81 0.2% 70% MeOH / 30% H2O 
Column #21 Sample 77 3029 8.0% 70% MeOH / 30% H2O 
Column #21 Sample 78 130 0.3% 70% MeOH / 30% H2O 
Column #21 Sample 79 146 0.4% 70% MeOH / 30% H2O 
Column #21 Sample 80 85 0.2% 70% MeOH / 30% H2O 
Column #21 Sample 81 95 0.2% 70% MeOH / 30% H2O 
Column #21 Sample 82 172 0.5% transition 
Column #21 Sample 83 369 1.0% 80% MeOH / 20% H2O 
Column #21 Sample 84 3383 8.9% 80% MeOH / 20% H2O 
Column #21 Sample 85 58 0.2% 80% MeOH / 20% H2O 
Column #21 Sample 86 51 0.1% 80% MeOH / 20% H2O 
Column #21 Sample 87 2614 6.9% 80% MeOH / 20% H2O 
Column #21 Sample 88 83 0.2% 80% MeOH / 20% H2O 
Column #21 Sample 89 2305 6.1% 80% MeOH / 20% H2O 
Column #21 Sample 90 76 0.2% 80% MeOH / 20% H2O 
Column #21 Sample 91 57 0.1% 80% MeOH / 20% H2O 
Column #21 Sample 92 65 0.2% 80% MeOH / 20% H2O 
 
Table A21. Results for B16-F10 cell proliferation assay with Column #22 individual 
samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 26280 100.0% N/A 
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Table A21, continued. 
Average 10 mg/mL Elderberry 11073 42.1% N/A 
Column #22 Sample 1 91 0.3% 0% MeOH / 100% H2O 
Column #22 Sample 2 162 0.6% 0% MeOH / 100% H2O 
Column #22 Sample 3 118 0.4% 0% MeOH / 100% H2O 
Column #22 Sample 4 123 0.5% 0% MeOH / 100% H2O 
Column #22 Sample 5 197 0.7% 0% MeOH / 100% H2O 
Column #22 Sample 6 244 0.9% transition 
Column #22 Sample 7 68 0.3% 10% MeOH / 90% H2O 
Column #22 Sample 8 223 0.8% 10% MeOH / 90% H2O 
Column #22 Sample 9 14339 54.6% 10% MeOH / 90% H2O 
Column #22 Sample 10 101 0.4% 10% MeOH / 90% H2O 
Column #22 Sample 11 96 0.4% 10% MeOH / 90% H2O 
Column #22 Sample 12 170 0.6% 10% MeOH / 90% H2O 
Column #22 Sample 13 4395 16.7% 10% MeOH / 90% H2O 
Column #22 Sample 14 1864 7.1% 10% MeOH / 90% H2O 
Column #22 Sample 15 3552 13.5% 10% MeOH / 90% H2O 
Column #22 Sample 16 7632 29.0% 10% MeOH / 90% H2O 
Column #22 Sample 17 7916 30.1% transition 
Column #22 Sample 18 118 0.4% 20% MeOH / 80% H2O 
Column #22 Sample 19 1246 4.7% 20% MeOH / 80% H2O 
Column #22 Sample 20 8756 33.3% 20% MeOH / 80% H2O 
Column #22 Sample 21 82 0.3% 20% MeOH / 80% H2O 
Column #22 Sample 22 298 1.1% 20% MeOH / 80% H2O 
Column #22 Sample 23 155 0.6% 20% MeOH / 80% H2O 
Column #22 Sample 24 12266 46.7% 20% MeOH / 80% H2O 
Column #22 Sample 25 762 2.9% 20% MeOH / 80% H2O 
Column #22 Sample 26 73 0.3% 20% MeOH / 80% H2O 
Column #22 Sample 27 120 0.5% 20% MeOH / 80% H2O 
Column #22 Sample 28 4048 15.4% transition 
Column #22 Sample 29 112 0.4% 30% MeOH / 70% H2O 
Column #22 Sample 30 6927 26.4% 30% MeOH / 70% H2O 
Column #22 Sample 31 142 0.5% 30% MeOH / 70% H2O 
Column #22 Sample 32 10364 39.4% 30% MeOH / 70% H2O 
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Table A21, continued. 
Column #22 Sample 33 8728 33.2% 30% MeOH / 70% H2O 
Column #22 Sample 34 12275 46.7% 30% MeOH / 70% H2O 
Column #22 Sample 35 19625 74.7% 30% MeOH / 70% H2O 
Column #22 Sample 36 5911 22.5% 30% MeOH / 70% H2O 
Column #22 Sample 37 14361 54.6% 30% MeOH / 70% H2O 
Column #22 Sample 38 90 0.3% transition 
Column #22 Sample 39 68 0.3% 40% MeOH / 60% H2O 
Column #22 Sample 40 845 3.2% 40% MeOH / 60% H2O 
Column #22 Sample 41 83 0.3% 40% MeOH / 60% H2O 
Column #22 Sample 42 4916 18.7% 40% MeOH / 60% H2O 
Column #22 Sample 43 224 0.9% 40% MeOH / 60% H2O 
Column #22 Sample 44 90 0.3% 40% MeOH / 60% H2O 
Column #22 Sample 45 75 0.3% 40% MeOH / 60% H2O 
Column #22 Sample 46 55 0.2% 40% MeOH / 60% H2O 
Column #22 Sample 47 10024 38.1% 40% MeOH / 60% H2O 
Column #22 Sample 48 11836 45.0% transition 
Column #22 Sample 49 75 0.3% 50% MeOH / 50% H2O 
Column #22 Sample 50 59 0.2% 50% MeOH / 50% H2O 
Column #22 Sample 51 87 0.3% 50% MeOH / 50% H2O 
Column #22 Sample 52 74 0.3% 50% MeOH / 50% H2O 
Column #22 Sample 53 753 2.9% 50% MeOH / 50% H2O 
Column #22 Sample 54 1635 6.2% 50% MeOH / 50% H2O 
Column #22 Sample 55 5630 21.4% 50% MeOH / 50% H2O 
Column #22 Sample 56 169 0.6% 50% MeOH / 50% H2O 
Column #22 Sample 57 129 0.5% 50% MeOH / 50% H2O 
Column #22 Sample 58 85 0.3% transition 
Column #22 Sample 59 87 0.3% 60% MeOH / 40% H2O 
Column #22 Sample 60 102 0.4% 60% MeOH / 40% H2O 
Column #22 Sample 61 76 0.3% 60% MeOH / 40% H2O 
Column #22 Sample 62 83 0.3% 60% MeOH / 40% H2O 
Column #22 Sample 63 104 0.4% 60% MeOH / 40% H2O 
Column #22 Sample 64 1560 5.9% 60% MeOH / 40% H2O 
Column #22 Sample 65 388 1.5% 60% MeOH / 40% H2O 
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Table A21, continued. 
Column #22 Sample 66 780 3.0% 60% MeOH / 40% H2O 
Column #22 Sample 67 509 1.9% 60% MeOH / 40% H2O 
Column #22 Sample 68 48 0.2% 60% MeOH / 40% H2O 
Column #22 Sample 69 82 0.3% transition 
Column #22 Sample 70 2197 8.4% 70% MeOH / 30% H2O 
Column #22 Sample 71 600 2.3% 70% MeOH / 30% H2O 
Column #22 Sample 72 66 0.3% 70% MeOH / 30% H2O 
Column #22 Sample 73 58 0.2% 70% MeOH / 30% H2O 
Column #22 Sample 74 404 1.5% 70% MeOH / 30% H2O 
Column #22 Sample 75 230 0.9% 70% MeOH / 30% H2O 
Column #22 Sample 76 110 0.4% 70% MeOH / 30% H2O 
Column #22 Sample 77 91 0.3% 70% MeOH / 30% H2O 
Column #22 Sample 78 97 0.4% 70% MeOH / 30% H2O 
Column #22 Sample 79 85 0.3% transition 
Column #22 Sample 80 151 0.6% 80% MeOH / 20% H2O 
Column #22 Sample 81 3221 12.3% 80% MeOH / 20% H2O 
Column #22 Sample 82 8275 31.5% 80% MeOH / 20% H2O 
Column #22 Sample 83 4991 19.0% 80% MeOH / 20% H2O 
Column #22 Sample 84 89 0.3% 80% MeOH / 20% H2O 
Column #22 Sample 85 390 1.5% 80% MeOH / 20% H2O 
Column #22 Sample 86 133 0.5% 80% MeOH / 20% H2O 
Column #22 Sample 87 78 0.3% 80% MeOH / 20% H2O 
Column #22 Sample 88 303 1.2% 80% MeOH / 20% H2O 
 
Table A22. Results for B16-F10 cell proliferation assay with Column #23 individual 
samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 55949 100.0% N/A 
Average 10 mg/mL Elderberry 31371 56.1% N/A 
Column #23 Sample 45 8753 15.6% 40% MeOH / 60% H2O 
Column #23 Sample 46 9711 17.4% 40% MeOH / 60% H2O 
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Table A22, continued. 
Column #23 Sample 47 17184 30.7% 40% MeOH / 60% H2O 
Column #23 Sample 48 10781 19.3% transition 
Column #23 Sample 49 312 0.6% 50% MeOH / 50% H2O 
Column #23 Sample 50 188 0.3% 50% MeOH / 50% H2O 
Column #23 Sample 51 239 0.4% 50% MeOH / 50% H2O 
Column #23 Sample 52 9798 17.5% 50% MeOH / 50% H2O 
Column #23 Sample 53 117 0.2% 50% MeOH / 50% H2O 
Column #23 Sample 54 307 0.5% 50% MeOH / 50% H2O 
Column #23 Sample 55 94 0.2% 50% MeOH / 50% H2O 
Column #23 Sample 56 153 0.3% 50% MeOH / 50% H2O 
Column #23 Sample 57 8393 15.0% 50% MeOH / 50% H2O 
Column #23 Sample 58 4273 7.6% transition 
Column #23 Sample 59 4814 8.6% 60% MeOH / 40% H2O 
Column #23 Sample 60 9109 16.3% 60% MeOH / 40% H2O 
Column #23 Sample 61 12707 22.7% 60% MeOH / 40% H2O 
Column #23 Sample 62 107 0.2% 60% MeOH / 40% H2O 
Column #23 Sample 63 18676 33.4% 60% MeOH / 40% H2O 
Column #23 Sample 64 488 0.9% 60% MeOH / 40% H2O 
Column #23 Sample 65 12341 22.1% 60% MeOH / 40% H2O 
Column #23 Sample 66 84 0.2% 60% MeOH / 40% H2O 
Column #23 Sample 67 1162 2.1% 60% MeOH / 40% H2O 
Column #23 Sample 68 12622 22.6% transition 
Column #23 Sample 69 486 0.9% 70% MeOH / 30% H2O 
Column #23 Sample 70 660 1.2% 70% MeOH / 30% H2O 
Column #23 Sample 71 748 1.3% 70% MeOH / 30% H2O 
Column #23 Sample 72 79 0.1% 70% MeOH / 30% H2O 
Column #23 Sample 73 31 0.1% 70% MeOH / 30% H2O 
Column #23 Sample 74 42 0.1% 70% MeOH / 30% H2O 
Column #23 Sample 75 732 1.3% 70% MeOH / 30% H2O 
Column #23 Sample 76 1651 3.0% 70% MeOH / 30% H2O 
Column #23 Sample 77 7096 12.7% 70% MeOH / 30% H2O 
Column #23 Sample 78 2542 4.5% transition 
Column #23 Sample 79 6973 12.5% 80% MeOH / 20% H2O 
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Table A22, continued. 
Column #23 Sample 80 102 0.2% 80% MeOH / 20% H2O 
Column #23 Sample 81 703 1.3% 80% MeOH / 20% H2O 
Column #23 Sample 82 101 0.2% 80% MeOH / 20% H2O 
Column #23 Sample 83 64 0.1% 80% MeOH / 20% H2O 
Column #23 Sample 84 70 0.1% 80% MeOH / 20% H2O 
Column #23 Sample 85 101 0.2% 80% MeOH / 20% H2O 
Column #23 Sample 86 702 1.3% 80% MeOH / 20% H2O 
Column #23 Sample 87 252 0.5% 80% MeOH / 20% H2O 
 
Table A23. Results for B16-F10 cell proliferation assay with Column #24 individual 
samples. 
Sample Identity CPM % Proliferation (Control = 100%) Eluting Mobile Phase 
Average Control 39379 100.0% N/A 
Average 10 mg/mL Elderberry 24280 61.7% N/A 
Column #24 Sample 45 5982 15.2% 40% MeOH / 60% H2O 
Column #24 Sample 46 11549 29.3% 40% MeOH / 60% H2O 
Column #24 Sample 47 16942 43.0% 40% MeOH / 60% H2O 
Column #24 Sample 48 9937 25.2% 40% MeOH / 60% H2O 
Column #24 Sample 49 2804 7.1% transition 
Column #24 Sample 50 119 0.3% 50% MeOH / 50% H2O 
Column #24 Sample 51 77 0.2% 50% MeOH / 50% H2O 
Column #24 Sample 52 100 0.3% 50% MeOH / 50% H2O 
Column #24 Sample 53 1048 2.7% 50% MeOH / 50% H2O 
Column #24 Sample 54 8632 21.9% 50% MeOH / 50% H2O 
Column #24 Sample 55 575 1.5% 50% MeOH / 50% H2O 
Column #24 Sample 56 120 0.3% 50% MeOH / 50% H2O 
Column #24 Sample 57 14597 37.1% 50% MeOH / 50% H2O 
Column #24 Sample 58 459 1.2% transition 
Column #24 Sample 59 1962 5.0% 60% MeOH / 40% H2O 
Column #24 Sample 60 3589 9.1% 60% MeOH / 40% H2O 
Column #24 Sample 61 3247 8.2% 60% MeOH / 40% H2O 
Column #24 Sample 62 4944 12.6% 60% MeOH / 40% H2O 
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Table A23, continued. 
Column #24 Sample 63 127 0.3% 60% MeOH / 40% H2O 
Column #24 Sample 64 12695 32.2% 60% MeOH / 40% H2O 
Column #24 Sample 65 10965 27.8% 60% MeOH / 40% H2O 
Column #24 Sample 66 3546 9.0% 60% MeOH / 40% H2O 
Column #24 Sample 67 2963 7.5% 60% MeOH / 40% H2O 
Column #24 Sample 68 3617 9.2% 60% MeOH / 40% H2O 
Column #24 Sample 69 3196 8.1% transition 
Column #24 Sample 70 4102 10.4% 70% MeOH / 30% H2O 
Column #24 Sample 71 105 0.3% 70% MeOH / 30% H2O 
Column #24 Sample 72 124 0.3% 70% MeOH / 30% H2O 
Column #24 Sample 73 56 0.1% 70% MeOH / 30% H2O 
Column #24 Sample 74 76 0.2% 70% MeOH / 30% H2O 
Column #24 Sample 75 55 0.1% 70% MeOH / 30% H2O 
Column #24 Sample 76 478 1.2% 70% MeOH / 30% H2O 
Column #24 Sample 77 335 0.9% 70% MeOH / 30% H2O 
Column #24 Sample 78 14658 37.2% 70% MeOH / 30% H2O 
Column #24 Sample 79 9612 24.4% transition 
Column #24 Sample 80 2468 6.3% 80% MeOH / 20% H2O 
Column #24 Sample 81 63 0.2% 80% MeOH / 20% H2O 
Column #24 Sample 82 311 0.8% 80% MeOH / 20% H2O 
Column #24 Sample 83 88 0.2% 80% MeOH / 20% H2O 
Column #24 Sample 84 41 0.1% 80% MeOH / 20% H2O 
Column #24 Sample 85 59 0.1% 80% MeOH / 20% H2O 
Column #24 Sample 86 75 0.2% 80% MeOH / 20% H2O 
Column #24 Sample 87 87 0.2% 80% MeOH / 20% H2O 
Column #24 Sample 88 86 0.2% 80% MeOH / 20% H2O 
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Table A24. Pooling of Column #1 samples. 
Pool # Samples Pool # Samples 
1 1, 2, 3, 4 21 64 
2 5, 6, 7, 8 22 65, 66, 67, 68 
3 9, 10, 11 23 69, 70, 71, 72 
4 12, 13, 14, 15 24 73, 74 
5 16 25 75, 76, 77 
6 17, 18 26 78 
7 19, 20, 21 27 79, 80, 81 
8 22, 23, 24 28 82, 83 
9 25, 26, 27, 28, 29 29 84, 85, 86 
10 30, 31, 32, 33, 34 30 87, 88 
11 35, 36, 37, 38, 39 31 89, 90, 91 
12 40, 41, 42, 43, 44 32 92, 93, 94 
13 45, 46 33 95 
14 47, 48 34 96, 97, 98 
15 49, 50, 51 35 99, 100, 101, 102 
16 52, 53 36 103, 104 
17 54, 55 37 105, 106 
18 56, 57 38 107, 108, 109 
19 58, 59, 60, 61 39 110, 111 
20 62, 63   
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Table A25. Column #2-24 samples pooled to generate P16, P24, and P29. 
Column Samples pooled to make P16 
Samples pooled 
to make P24 
Samples pooled 
to make P29 
Column #2 49, 50, 51 73, 74, 75 85, 86, 87 
Column #3 53, 54 72, 73, 74 84 
Column #4 55, 56, 57 73, 74 85, 86 
Column #5 53, 54 72, 73, 74 85, 86, 87, 88 
Column #6 52, 53, 54 72, 73, 74 86, 87, 88, 89 
Column #7 52, 53, 54 71, 72, 73, 74 85, 86, 87, 88 
Column #8 52, 53, 54 73, 74 84, 85 
Column #9 53, 54 73, 74 86, 87 
Column #10 50, 51, 52, 53 73, 74 86, 87, 88, 89 
Column #11 50, 51, 52, 53 72, 73, 74 86, 87, 88, 89 
Column #12 51, 52, 53 71, 72, 73, 74 86, 87, 88 
Column #13 55, 56, 57, 58 74, 75, 76, 77 83, 84, 85, 86 
Column #14 54 72, 73, 74, 75 83, 84, 85 
Column #15 50, 51, 52, 53 71, 72, 73, 74 83, 84 
Column #16 50, 51, 52 73, 74 84, 85, 86 
Column #17 53, 54, 55 71, 72, 73, 74, 75 87, 88 
Column #18 51, 52, 53 72, 73, 74, 75 87, 88, 89, 90 
Column #19 53, 54 71, 72, 73 85, 86, 87, 88 
Column #20 49, 50, 51 73, 74, 75, 76 84, 85, 86, 87 
Column #21 56 72, 73 85, 86 
Column #22 49, 50, 51, 52, 53 72, 73, 74, 75 85, 86, 87, 88 
Column #23 53,54,55,56 72,73,74 82,83,84,85 
Column #24 50,51,52 71,72,73,74,75 84, 85, 86, 87 
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Appendix B: Figures 
 
 
Figure B1. Optimal concentration of trypsin addition before harvesting for tumor cell 
proliferation assays.  
 
 
Figure B2. Optimal concentration of Con A on spleen cell proliferation. 
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Figure B3. Standard IL-2 curve generated from the Quantikine murine IL-2 ELISA. 
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Appendix C: Solution Recipes 
The working solution of tritiated thymidine (3H-Thy) was prepared by adding 3.85 
mL of filter-sterilized deionized water, or 3.85 mL of filter-sterilized RPMI-1640 media to 
150 µL thymidine stock (Moravek Biochemicals, Brea, CA). 
Mobile phases for column chromatography were prepared by mixing varying 
concentrations of deionized water and methanol and a consistent amount of 0.01N HCl. 
Mobile phases were added to the column in order of decreasing polarity in 165 mL 
increments. 
 
Mobile Phase Volume of H2O (mL) 
Volume of 
MeOH (mL) 
Volume of 0.01N 
HCl (mL) 
0% MeOH / 100% H2O 150.0 0.0 15.0 
10% MeOH / 90% H2O 135.0 15.0 15.0 
20% MeOH / 80% H2O 12.0 30.0 15.0 
30% MeOH / 70% H2O 105.0 45.0 15.0 
40% MeOH / 60% H2O 90.0 60.0 15.0 
50% MeOH / 50% H2O 75.0 75.0 15.0 
60% MeOH / 40% H2O 60.0 90.0 15.0 
70% MeOH / 30% H2O 45.0 105.0 15.0 
80% MeOH / 20% H2O 30.0 120.0 15.0 
90% MeOH / 10% H2O 15.0 135.0 15.0 
100% MeOH / 0% H2O 0.0 150.0 15.0 
 
